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Abstract 
Shahrazad Ali Eteer  
The Physical Chemistry of Corticosteroid-cyclodextrin Complexes  
The Host-guest Chemistry of Corticosteroid and Cyclodextrin Systems 
Elucidated with NMR and Applied to Novel Surface-decorated Surface 
Enhanced Raman Spectroscopic Probes 
Keywords: Corticosteroids, HFA, complexation, cyclodextrins, inhalation, pMDI, 
NMR, SERS, nanoparticles. 
Inhaled corticosteroids (ICS) are used to address inflammatory illnesses 
including asthma and COPD, with delivery commonly achieved using 
pressurised metered dose inhalers (pMDI). Hydrofluoroalkanes (HFAs) have 
been introduced as an alternative propellant to chlorofluorocarbons (CFCs) to 
reduce their environmental impact. However, the thermodynamic properties of 
HFAs are poorly understood and are different to those of CFCs. It is essential, 
therefore, to characterise the drugs and excipients used in HFA inhalers in 
order to obtain a comprehensive understanding of the device performance and 
the therapeutic efficacy.  
This work has developed different analytical methods to study the complexation 
between ICS and CD which are added to enhance the solubility of inhaled drugs 
in pMDI propellant systems providing rational control of suspension vs. solution 
formulations and hence their dose uniformity and stability.  
The Nuclear Magnetic Resonance (NMR) method developed has shown weaker 
complexation between budesonide and the derivatised CDs DIMEB and 
TRIMEB in organic solvents compared to D2O with the strength of the complex 
formed being ranked as D2O > MeOD > CDCl3 > CD3CN. The derivatisation of 
the CD also shows a marked difference in complexation with budesonide with 
the strength of the association being ranked as DIMEB > βCD > TRIMEB. 
Studies of various ICS compounds with TRIMEB in the fluorinated propellant 
HPFP showed the association to be greatest in budesonide, followed by 
beclomethasone dipropionate, momestasone furoate and fluticasone 
propionate.  
Surface-enhanced Raman scattering (SERS) has been used for the detection of 
corticosteroids in water using thiol functionalised βCD as a complementary 
study to NMR. This has been utilised to evaluate the host-guest complexes 
formed and provides further insight into the complexation of the compounds by 
their inclusion into the CD cavity. 
The structural data obtained using the NMR and SERS approaches developed 
have provided a fundamental insight into the physical chemistry of these 
interactions at a molecular level. 
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1 Introduction 
1.1 Physiology of the lung, diseases and associated responses 
Administration of drugs via the pulmonary route was originally introduced 400 
years ago in the Middle East and India.1-3 Many drugs are favourably 
administered via the lung due to the advantages of having a large surface area 
and the existence of the epithelium with a thin membrane together with the low 
aqueous fluid available at the site of absorption. This enhances the drug 
absorption process resulting in quick uptake and fast onset of action compared 
to any other route of administration, with the exception of intravenous 
injection.4,5 Another advantage of this route is that the metabolism process 
decreases as a result of lower metabolising enzymes in the lung compared to 
the oral delivery route.4,6,7 Accordingly, the dose of the drug is reduced 
compared to the oral route, for example the salbutamol dose decreases to half 
when administered via the lung compared to oral administration3 and as a 
result, the systematic adverse effects are reduced.5 
Nowadays, different drugs are formulated to be administered by the pulmonary 
route to treat pulmonary diseases locally or to address some systematic 
diseases such as insulin for the treatment of diabetes mellitus and levodopa for 
Parkinson disease, which are not effective when given by oral administration.3,8 
It has been estimated that the around twenty Active Pharmaceutical Ingredients 
(APIs) in 65 different medications are administrated through the respiratory 
system.2,9 Research published by Ritchie in 2009 shows that 29 out of 81 
marketed pulmonary drugs are delivered directly to treat local pulmonary 
illnesses.10 Lower doses are administered via the pulmonary route to achieve 
the clinical effect without a reduction in the concentration at the action site such 
as inhaled corticosteroids and beta 2 agonists or a combination of the two 
groups which are administered in low doses that in turn reduce the adverse 
effects and produce rapid onset of action.3,11 Other examples are antibiotics, 
which are used to treat infectious diseases such as tuberculosis and cystic 
fibrosis (CF). In the case of CF, the dose is directly delivered to the infectious 
site which is the endobronchial space and therefore has the advantage of 
decreasing both the systemic adverse effects and the toxicity.12 
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Chronic Obstructive Pulmonary Disease (COPD) is a main cause of global 
mortality and morbidity where many people are affected and die from the 
disease itself or from the complications.13,14 It is considered the fourth leading 
cause of mortality, which is expected to be the third leading cause of mortality 
by 2020.14 It has been estimated that around 3 million UK people have COPD 
with 900,000 diagnosed as affected by COPD. Around 2 million are left without 
a definite diagnosis and most of these cases are diagnosed at the age of 50.15 
The World Health Organisation (WHO) estimated that the COPD burden is 
projected to increase and the number of cases affected is estimated to move 
from twelfth to fifth by 2020.16 Regarding asthma, around 300 million people are 
affected by asthma in the world17-19 with 250,000 mortalities per year.20 
Limited progress has been made in the development of therapeutic medications 
to treat COPD, however, a huge advancement in recent years has been 
achieved to develop medications with a variety of dosage forms to address the 
symptoms of asthma and this is due to a better understanding of the disease 
mechanism.16 The reason behind the difficulty in the development of COPD 
drugs is the lack of proper models to test COPD drugs which needs long term 
studies (not less than 3 years) and a high number of patients.16 Another reason 
is the unavailability of suitable animal models to test these drugs.21 Also, a 
difficulty in determining the suitable markers used to investigate the immediate 
efficacy of the new therapy. On the other hand, drug development in the 
treatment of COPD is ongoing with the existence of some drugs in preclinical 
and clinical stages of assessment.16  
The global initiative for asthma (GINA) defines asthma as a chronic 
inflammatory illness, which affects a number of cells and also cellular elements 
of the airways. It is accompanied by an increase in the hyperresponsiveness of 
the airways and as a result the patient suffers from recurrent symptoms of 
wheezing, breathlessness, chest tightness and coughing. It is also associated 
with obstruction in the air flow which is reversible spontaneously or after 
receiving therapy.19,22 Chronic inflammation causes the smooth muscle 
contraction of the lungs which leads to the narrowing of the airway. This change 
is associated with the increase in the easinophils and the thickening of the 
lamina reticularis. In addition, the size of the airway smooth muscle increases 
along with the number of the mucous glands by time. Other cells have also 
 3 
 
 
been included in the inflammation process such as neutrophils, T lymphocyte 
and macrophages, with the existence of other immune system compartments 
such as chemokines, histamine, cytokines and leukotrienes.23 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines 
COPD as a persistent airflow limitation accompanied by the chronic 
inflammatory response of the airways to harmful particles or gases. The airway 
limitation results from the damage to the parenchyma and the airways, in 
addition to that caused by smoking.15 Although it is progressive over time, it is 
still classified as a preventable and treatable illness. The main inflammatory 
cells included in COPD patients are neutrophils and macrophages which are 
estimated to be in higher number compared to patients with chronic bronchitis.22 
Although the two diseases are classified as chronic inflammatory illnesses 
causing bronchoconstriction, the main difference between them is the 
reversibility of the airway obstruction where it is reversible with or without 
therapy in the case of asthma but not so in COPD. Another difference is the 
aging of the population where the asthma affects people in their early childhood 
while COPD generally affects elderly people into and beyond their sixties.22,24 A 
study conducted by Keatings et al. shows that cytokines, tumor necrosis factor-
alpha (TNF-α) and interleukin-8 (IL-8) increases in the case of COPD and that 
might be responsible for the inflammation.25 
Current treatments are available to alleviate the episodes by reducing the 
inflammation and treat asthma, however, these are not effective in the case of 
COPD.26 Smoking cessation is a non-pharmacological intervention which is 
considered effective in the relieving the symptoms and preventing the 
development of COPD.27,28 Reducing the exposure to the risk factors could be 
considered as a part of treatment such as avoiding certain food, drugs (such as 
aspirin and beta blockers) or any additives that are known to cause episodes of 
the disease. Also, any triggers which might increase the incidence, such as viral 
infections and allergens or pollutants.19 Drug interventions can be used to 
address both diseases such as theophylline which is effective to treat 
asthma29,30 and COPD.31 Antibiotics have been found to have a beneficial effect 
in the case of acute exacerbation,27 however, some studies showed that they 
are not effective in the prophylaxis or in the treatment of both diseases.31 It has 
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been found that the viral infection such as influenza leads to exacerbation in 
asthmatic patients,32,33 and therefore, it is recommended to give influenza 
vaccines to patients who suffer from asthma including children33,34 or to those 
with COPD.35 This vaccine is safe and given to avoid pulmonary infection in the 
case of both diseases.35,36 Oligonucleotides are another class of drugs used to 
address many targets inside the lungs and it is a novel medicine used for the 
treatment of pulmonary illnesses.37,38 Recently, it has been reported that dietary 
antioxidants might be effective in the treatment of asthma and COPD.39,40 
Shaheen et al. demonstrated that higher intake of apples and also selenium 
may protect from asthma attack as a result of the flavonoid effect in the case of 
apple consumption.41 Another study suggests that low consumption of vitamin C 
(as a result of deficient in fruit intake) and manganese is associated with 
asthma.42 Other examples of antioxidants include thiol molecules such as 
glutathione and mucolytic drugs, these target the free radicals and oxidants 
involved in glutathione biosynthesis, which was further ending with the inhibition 
of gene expression in the inflammatory process.40 Tumor necrosis factor (TNF)-
α is a pleiotropic cytokine which is associated with many inflammatory diseases 
such as asthma.43,44 It is showed that TNF-α inhibitor therapy enhances the lung 
function and reduces the exacerbation of asthma44 and thus it is recommended 
to start controlled trials of this type of treatment to people with severe 
exacerbation of COPD.45 
1.2 Inhaled corticosteroids (ICS) 
Inhaled corticosteroids (ICS) are commonly used to address many inflammatory 
illnesses including asthma.46 It has been recommended to be used as first line 
therapy to treat persistent asthma in all ages47 and are effective in relieving the 
symptoms of asthma in all cases of different ages.48 Recent research showed 
that ICS is effective in the control of the inflammation in asthma, however, little 
response or sometimes non in case of COPD.49 This might be due to the 
differences in the inflammatory process between the two diseases in which a 
good response was achieved in asthma while very poor in COPD.48 Their 
mechanism of action is firstly by diffusing the cell membrane and binding to the 
cytoplasmic glucocorticoid receptors. This results in the activation of different 
processes that ends with the suppression of the inflammatory cells such as T-
lymphocytes, easinophils and mast cells.49 It has been found the administration 
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of systematic corticosteroids for acute asthma in emergency departments 
decreases patient admission to hospital.50 The most commonly used ICS are 
budesonide (BUD), beclomethasone dipropionate (BDP), beclomethasone 
(BCL), fluticasone propionate (FLU), mometasone furoate (MOM) (Figure 1.1), 
prednisolone and triamcinolone acetonide. This group of drugs have high 
molecular weight and are classified as lipophilic51 with low water solubility.52 
 
Figure 1.1: Chemical structure of budesonide (BUD), beclomethasone dipropionate (BDP), 
beclomethasone (BCL), fluticasone propionate (FLU) and mometasone furoate (MOM). 
1.3 Delivery Devices 
Three primary devices are commonly used to deliver APIs to the lungs; 
nebulisers, dry powder inhalers (DPIs) and pressurised metered dose inhalers 
(pMDIs). Nebulisers work by producing an inhalable aerosol of the API from a 
solution using compressed air. DPIs rely on the inhalation of a dry powdered 
blend of the API and a carrier particle (usually a sugar such as lactose). The 
particle size of the API is the key to the efficacy of the drug and needs to be 
controlled effectively. pMDIs are slightly different in their design, and produce 
the inhaled particles on actuation of the device. They consist of a pressurised 
canister containing the API and a propellant (volatile solvent) held as a liquid 
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under pressure. Once actuated, the liquid is delivered through the mouthpiece 
of the device producing the solid material in-situ, which is subsequently 
breathed in by the user. Depending on whether the API is held as a suspension 
in the canister, or is fully dissolved as a solution will play a key role in the 
products performance.53 
1.3.1 Nebuliser devices 
The nebulizer uses the compressed air to generate droplets from solutions or 
suspensions, which are then inhaled to the lung by normal breathing process.5 
There are two types of nebulisers namely pneumatic nebuliser and the 
ultrasonic nebuliser. In the first type, the compressed gas is forced through hole 
called venturi. Increase in the gas velocity leads to formation of a negative 
pressure that draws liquid up the tube. The liquid is then broken into small 
droplets by the effect of surface tension that in turn is inhaled by the patient via 
the mouthpiece during inspiration. The nebuliser system also continues to form 
droplets during expiration and is then exhaled outside body.54 In the ultrasonic 
nebuliser, high frequency sound waves are produced and then passed over the 
drug surface liquid which are then broken to form an aerosol.5 The most 
important point concerning the ultrasonic device is the size of the respirable 
droplets which is the range of 1-5 µm that is able to reach lower airways and 
better therapy. The other advantage of using the nebulizer is the simplicity of 
use55 and therefore, it can be used for young or very ill patients since no 
propellant is included in the formula so it is easy to use and it can be used to 
deliver large drug doses. In contrast, it is considered to be less portable 
compared to the DPI and pMDI as it needs compressed air for operation. Also, 
it takes longer time to achieve the therapy and is more expensive in terms of 
more equipment is needed compared to the DPI and pMDI.5,53 
1.3.2 Pressurised Metered Dose Inhaler (pMDI) devices 
Pressurised Metered Dose Inhaler (pMDI) is another device used to deliver 
COPD and asthmatic drugs. It was developed in the mid-20th century at Riker 
Laboratories56,57 and a new device introduced to the market was Medihaler Epi® 
in 1956.58 The device is formulated as a solution or suspension where the API is 
dissolved or suspended in the volatile propellant respectively. Some other 
additives are added in the case of suspension based formulation such as the 
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surfactant to increase the stability and the solvent to solubilise the API in the 
propellant.59 
The device has many advantages including the availability in a multi-dose unit, 
portability, ease of use, convenience and it is relatively inexpense.5,57,60 Also, it 
does not need high inspiratory flow, which is needed by DPI, to ensure good 
lung deposition; therefore, it is preferable to those with low lung efficiency. The 
main drawbacks of pMDI include; (i) the cold-Freon effect which results from the 
effect of a cold propellant that reaches the back of the throat, and (ii) higher 
drug deposition in the oropharynx resulting in the appearance of both local and 
systemic side effects. This latter issue has been addressed by recent re-
formulation of pMDI as discussed in Section 1.4.57 
1.3.3 Dry Powder Inhaler (DPI) devices 
Dry Powder Inhalers (DPIs) were introduced to the market in 196761 as an 
alternative to pMDIs to decrease the ozone-depleting effect of CFC which is a 
propellant that exists in pMDI and also to deliver molecules of high molecular 
weight.62 They consist of the drug mixed with a carrier powder commonly 
lactose preserved in separate gelatin capsule. Each capsule contains a single 
dose which is positioned in the inhaler at the administration time and punctured 
to release the drug. This protects the drug from moisture and thus the powder 
maintains its flowability to be perfectly deposited at the site of action.61 These 
devices needs strong inspiration to deliver the drug to the lung and therefore no 
coordination of actuation is needed and therefore better lung deposition.55,62 
The device has some disadvantages as it needs time to load the inhaler with 
the capsule every time and different brands of DPIs have different operation 
instructions.55 Some considerations are taken into account when dealing with 
the device as it needs to be kept dry as exposure to the air or exhalation 
through the mouthpiece results in clumping of the powder and restricts its 
flowability so it decreases the fine particles fraction on actuation.63,64 However, 
DPIs are still considered to be efficient in drug delivery to the lung and are easy 
to use.62 There are three types of DPI devices (i) unit dose where the inhaler is 
loaded by individual capsules before use,55 (ii) multi-unit dose by using sealed 
blisters of individual capsules that are loaded into the inhaler before actuation, 
and (iii) multi-dose reservoir which contains a bulky API and individual doses 
are released upon actuation.61,65 Examples of ADI of the three mentioned types 
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include; Rotahaler® (GSK), Diskus, also known as Accuhaler (GSK), and 
Turbuhaler (AstraZeneca) respectively.61 The DPI is principally designed by 
blending the drug with a carrier molecule, then by active or passive dispersion, 
the particles enter the body followed by separation of the drug particles from the 
carrier particles which are then ready for the deposition either in the oropharynx 
or deeply in the lung depending on their size.62 
1.4 Chlorofluorocarbons (CFC) and Hydrofluoroalkanes (HFA) – 
used in pMDIs 
All pMDIs prescribed before 1995 were mainly composed of CFC propellant. 
However, the Montreal Protocol banned the use of CFCs in 1987 as they 
caused damage to the ozone layer that was important to prevent the harmful 
sun ultraviolet radiation from reaching the earth. Therefore, the use of more 
environmentally friendly substances such as HFA propellants and alternative 
devices (DPI) could be considered a better solution to replace the CFC based 
formulations.5,56 The switching to HFAs was not a simple process, and the 
issues encountered during the formulation needed to be addressed; e.g. the 
surfactants in CFC formulations were insoluble and device seals were 
incompatible with HFAs. Also, because of the difference in the thermodynamic 
properties of HFAs, designing a special actuator is essential  to obtain the ideal 
particle size of APIs.66 In 1995, both 1,1,1,2-tetrafluoroethane (HFA 134a) and 
1,1,1,2,3,3,3-heptafluoropropane (HFA 227) propellants were officially approved 
by European Union to be efficient and safe for use in pMDIs.67,68 It appears to 
be generally accepted that the switching to HFA results in the production of 
more environmently friendly formulations of very fine particles that are 
deposited more successfully in the lung with reduced deposition in the 
oropharynx, and hence provide a more efficacious therapy with less 
local/systemic adverse effects compared to the CFC inhalers. Figure 1.2 shows 
the lung scintographic images of beclomethasone deposition from CFC and 
HFA pMDI devices which clearly indicates the increased lung deposition with an 
associated decrease in oropharyngeal deposition from HFA formulations 
compared to the CFC devices.69 
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Figure 1.2: Gamma scintographic images of lung (left side) and oropharynx (right side) of 
beclomethasone dipropionate MDI with a) HFA and b) CFC propellants.69 
The reformulation of pMDI products in HFA has led to an improvement in lung 
therapy due to lower initial spray velocity, initial droplet size and its evaporation 
which is different to those of CFC products.70 
1.5 Characteristics of HFA pMDIs formulations 
Many factors affect the performance of pMDI products such as (i) device design 
in terms of metering valve, nozzle diameter and (ii) the formulation namely; 
propellant volatility, vapour pressure, and its solubilising ability for the API in 
addition to the excipients.57 The propellant should be nontoxic and non-
flammable and compatible with other excipients. It should also have definite 
density and boiling point and its vapour pressure remains constant over 
product’s shelf-life.57 It is noted that the thermodynamic properties of both types 
of HFA (HFA 134a and HFA 227) were similar to CFC 12. However, no HFA 
propellant is comparable to trichlorofluoromethane and 
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dichlorotetrafluoroethane (CFC 11 and CFC 114), which were used to modify 
the vapour pressure in CFC system by reducing CFC 12 vapour pressure. The 
physical properties of each propellant (Table) can be related to its chemical 
structure and physicochemical behaviour71. Excipients are needed with lower 
volatility for modification of vapour pressure of the new type of HFA.57,72 The 
addition of non-volatile solvents such as polyethylene glycol and glycerol 
decreases the vapour pressure of propellant and thus modify its volatility.73 The 
addition of glycerol leads to production of larger particles with sizes similar to 
those of CFC particles so that the deposition and the absorption in the lung are 
comparable to those of CFC formulation. Examples of HFA formulation include 
the availability of BDP and budesonide as Modulite® which has characteristics 
that resemble the CFC based formulation.74,75 
Table 1.1: Physicochemical properties of pMDI propellants71 
Property CFC 11 CFC 12 CFC 114 HFA 134a HFA 227 
Boiling point (°C) 24 -30 4 -26 -16 
Vapor pressure (kPa) 89 566 182 572 390 
Enthalpy vap. (kJ/mol) 25.1 17.2 22.1 18.6 19.6 
Dielectric constant  2.3 2.1 2.2 9.5 4.1 
Dipole moment  0.45 0.51 0.58 2.1 1.2 
Induced polarisation 
 (m3 mol-2105) 
2.8 2.3 3.2 6.1 6.1 
Solubility parameter 
(Hildabrand units) 
7.5 6.1 6.4 6.6 6.2 
Kauri-Butanol value  60 18 12 9 13 
Log P (oct/water) 2.0 2.2 2.8 1.1 2.1 
Water solubility (ppm) 130 120 110 2200 610 
Density (g/cm3) 1.49 1.33 1.47 1.23 1.42 
Viscosity (mPa.s) 0.43 0.20 0.30 0.21 0.27 
Surface tension 
(mN/m2) 
18 9 11 8 7 
 
The main problem associated with the formulation of HFA preparations is the 
solubility of API and excipients in HFA. Therefore, it is considered a critical 
issue that should be taken into account during the design of new formulations. 
The solubility is the ability of a solute to dissolve in a solvent until the solution 
reaches saturation at which point no increase in the concentration of solute is 
observed and the solution is in equilibrium at specific temperature and 
pressure.76 It is predicted that around 70% of new drugs are poorly soluble in 
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water with nearly 40% of marketed oral drugs being practically insoluble in 
water (< 100 𝜇g/mL)77 and this is attributed to the chemistry of these drugs 
which are considered either weakly basic or acidic, so this contributes to give 
poor aqueous solubility properties.76 The solubility of drug compounds in HFAs 
is also poorly understood, and methods to determine these values are needed.  
1.5.1 Suspension formulations 
Preparing the drugs using excipients and/or co-solvents, forming salts / co-
crystals or using more advanced strategies such as delivering as pro-drugs can 
provide other possible mechanisms for improving solubility.78 Alternatively, the 
drug compounds can be prepared as suspensions in the case of pMDI 
products.79 A study conducted by Seville et al. prepared salbutamol as a pro-
drug with complete miscibility in HFA 134a compared to the lower solubility of 
salbutamol, which is released as a result from the metabolism of pro-drug by 
esterase to generate salbutamol.80 Drugs in pMDIs can be formulated as either 
suspension or solution preparations. Suspensions are generally prepared by 
micronising the particles of the APIs (commonly in a fluid or jet mill) to form 
smaller particles of 1-5 µm in size.57,76 The reformulation of APIs as a 
suspension is the common approach given the poor solubility of most inhaled 
drugs in HFAs.81 The advantages of this kind of formulation is its relative 
simplicity and minimal requirements for the inclusion of potentially toxic 
excipients in the product.82 
Many problems affect the stability of the suspension preparations which include: 
(i) creaming where the suspended drug is lighter in density than the HFA 
propellant so the particles separate and forms a layer on the surface of the 
propellant on standing,83 (ii) sedimentation where the drug particle is higher in 
density than the propellant and (iii) flocculation where there is difference in the 
hydrophobicity and hydrophilicity of the drug and propellant which causes the 
drug to deposit on the container wall. All these issues can lead to 
inhomogeneity in the dose emitted from the canister.82 
Ostwald ripening is another major influence on suspension stability; this 
phenomenon causes suspended particles to increases in size over time through 
mass transfer from the smaller particles in the suspension. This occurs through 
two principal mechanisms: (i) the smaller particles are deposited on the surface 
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of larger particles at the saturation point which leads to the increase the size of 
the suspended particles (ii) at high concentrations of suspended particles, the 
small particles tend to cluster and deposit on the surface of the bigger 
particles.84,85 This phenomenon causes formation of a supersaturated solution 
regarding the large particles that ends with crystallisation and the growth of the 
larger  particles.86 
Adequate use of the device with proper shaking before the actuation is 
important for dose uniformity.83,87 Many drug companies have offered some 
ways to tackle the problem of suspension instability by adding excipients such 
as surfactants. It has been reported that the conventional surfactants used in 
CFC (sorbitan trioleate, oleic acid and lecithin) are not soluble in HFA and 
therefore do not disperse appropriately to be adsorbed on the drug particles 
surface.88 Other substituted surfactants such as Span 85 and 
dipalmitoylphosphatidylcholine (DPPC) have been used to stabilise the HFA 
formulation of nanoparticles, although they have so far proved inadequate to 
confer suspension stability over the shelf-life. This is due to the different 
physico-chemical characteristics of HFAs as solvents, compared to CFC that 
influences properties critical to stabilisation of nanoparticle dispersion such as 
zeta potential and related surface characteristics.89 Some novel stabilisers 
based on essential oils such as cineole, cinnamaldehyde, and citral, have been 
studied and it is reported that citral and cineole have an advantage for 
stabilisation of insulin in HFA 134a propellant.90 Dickinson et al. found that 
lecithin based nanoparticles can form homogenous suspension by being 
dispersed in HFA propellant in the presence of 5% n-hexane,91 however, no 
long-term storage stability studies were reported. Research by Tan et al. 
showed that thymopentin nanoparticles formed a stable suspension in HFA 
134a using cineole and/or n-heptane as a stabiliser.89 Some products 
formulated as suspension formulations in HFA are available such as Ventolin® 
which is a combination of albuterol and HFA 134a. Other two component 
products are Advair®/Flovent®; suspensions of fluticasone propionate in HFA 
134a. 
1.5.2 Solution formulations 
In solution formulations, the drug is entirely dissolved in HFA propellant and this 
methodology produces preparations with the advantages of forming a 
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homogenous uniform product with efficient reproducible dose delivered to the 
lung compared to suspension formulation.82,92 Also, the formulation is 
considered to be stable and does not suffer from suspension associated issues 
described earlier (e.g. creaming, flocculation and sedimentation) and with 
deposition of the drug on the device’s surfaces. The solution preparation has 
some drawbacks such as the drug can be lost into the valve elastic 
components, and this is a considerable problem especially for low drug 
concentration. Also, when ethanol is added in excess amount as a co-solvent to 
increase the solute’s solubility, it is noticed that the vapour pressure might 
decrease below that required for efficient atomisation. In addition, toxicological 
studies are needed for alternative solvents to ethanol that can be used 
instead.82 Drugs should be soluble in the propellant to some extent to ensure 
good delivery and absorption to get better clinical efficacy.  
It is a difficult issue to formulate drugs with poor solubility since more adaption 
is needed, however several approaches to tackle the solubility problems have 
been explored.76 The addition of excipients is not only to enhance the solubility 
but also for better and more stable formulations during the storage period. 
Excipients are added to (i) control the bitter taste using flavouring agents, for 
example saccharin or menthol (ii) increase stability using antioxidants like 
ascorbic acid (iii) increase APIs solubility using co-solvents (the most common, 
ethanol) or surfactants in the propellant and (iv) modify aerosol size, stabilise 
the particles and also lubricate the valve using surfactants such as oleic acid.93  
Products of three components have also been marketed by using ethanol as a 
co-solvent to overcome the problem of solubility and enable their formulation as 
solution. Examples include; QVAR® / ALVESCO/ AEROSPAN® which is a 
solution of BDP, ciclesonide and flunisolide respectively in HFA 134a/ethanol 
mixture. Formulations with additional stabilising excipients include 
ATROVENT® which is ipratropium bromide in solution of HFA 134a with water, 
anhydrous citric acid and ethanol.93 Zhu et al. studied the effect of ethanol on 
the particle properties for this formulation and they found that the increase in 
ethanol concentration causes a decrease in the fine particle fraction and an 
increase in the mass median aerodynamic diameter and noted that the resulting 
particles could be classed within two morphologies.94 Evans et al. studied the 
possibility of forming a stable solution by using soya lecithin and water to form 
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micelles in CFC based formulation.95 Saleem and Smyth reported that the 
particle size increases with an increasing in co-solvent and surfactants 
concentration.96 However, the co-solvent caused a decrease in fine particles 
level. Recently, the water solubility and thus the dissolution of the compounds 
has been increased by addition of cyclodextrins (CDs).97 
1.5.3 Suspension vs solution formulations 
Generally, the main key difference between suspension and solution 
formulations is the dose actuated from the container (dose uniformity). 
Suspension preparation emitted particles are usually delivered in various sizes 
compared to the original particles in the formulation.98 The particle size 
generally depends on the initial actuated droplet size and the amount of non-
volatile materials in the preparation. The efficacy of the inhaler depends on the 
particle size distribution, the concentration of the drug in the inhaler, the number 
and the size of the delivered drug particles. These factors were studied by Stein 
who was trying to develop an equation for the determination the number of the 
particles in the MDI inhaler, concluding that the number is highly reliant on the 
mass median aerodynamic diameter (MMAD) of the particles and to a lesser 
extent on their mass in the entire inhaler. Also, it is found that solution 
preparation emitted a higher mass of drug particles as each actuated droplet 
has more drug compared to the suspension where many of the emitted droplets 
do not contain drug particles.99 Stein et al. developed a model for prediction of 
the aerodynamic particle size distribution from a suspension pMDI inhaler. They 
found good agreement in the results obtained with this model to those from a 
cascade impactor experiment which indicated the accurate estimation of particle 
size distribution acquired from suspension pMDI.100 Recently Ivey et al. 
developed an equation to determine the mass median aerodynamic diameter of 
the emitted aerosol from both HFA 134a and 227 solution MDIs, with various 
amounts of ethanol with a given propellant pressure and its surface tension. It is 
considered accurate in the determination of MMAD in comparison with results 
reported in the literature.101 
Stein and Myrdal studied the residual particle size distribution of solution MDIs 
on actuation by theoretical and experimental examination based on the 
determination of aerodynamic size distribution. Their residual size distribution is 
dependent on the propellant type and its pressure, ethanol and non-volatile 
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excipients (if present) concentrations, the diameter of actuator orifice and valve 
size.102 Solution pMDIs generate particles in the inhaler upon actuation, as soon 
as it is atomised. The droplets go through quick evaporation of propellant and 
other volatile excipients (if present) to form particles that are spherical and 
smaller in size containing the drug and any other non-volatile excipients present 
in the preparation. Their size is dependent on the initial size of the droplet, as 
the drug forms solubilised homogenous solutions and therefore, small droplets 
lead to a formation of small particles and vice versa. However, in the case of 
suspensions the droplets atomised have different diameters depending on the 
device and the formulation with some of them containing no drug and others 
with one, two or more drug particles which tend to diverge from the spherical 
shape compared to solution based formulations.100 
If we can develop additional strategies to formulate inhaled drugs as solutions in 
HFAs we can potentially obtain more stable and efficacious medications. In 
addition to the co-solvent approaches that have been used to good effect, 
excipients such as cyclodextrins (which have been commonly applied in oral 
dosage forms to increase the solubility of drugs) show promise in HFA based 
media to increase the solubility of inhaled drugs to a level where solutions are 
produced at a therapeutically relevant dose level. 
1.5.4 Cyclodextrins (CDs) as pMDI excipients 
Cyclodextrins (CDs) are molecules that consist of 6, 7 or 8 glucose units linked 
with α-1,4 bonds to form α, β or γ CD respectively to form condensed cone-like 
structure (Figure 1.3).103,104 
 
Figure 1.3: (a) Chemical structure of α, β and γ CDs (composed of 6, 7 and 8 glucose units 
respectively) and (b) the condensed cone. 
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When the glucose units are connected together, the structure is firm, while it still 
has some flexibility provided by α-1,4 bonds. This flexibility orientates the 
protons of methine group of both C3 and C5 and the two protons of methylene 
group of C6 in addition to the lone pairs of the oxygen atoms of the C4 (included 
in the α-1,4 bonds) towards the interior surface of the CD cavity (Figure 1.4, 
a).105 The ethereal oxygen of glucose residues and skeletal carbons that 
compose the inner CD cavity are responsible for giving it the hydrophobic 
character.106 This allows the CDs to form inclusion complexes with different 
hydrophobic molecules entirely or partially by hydrophobic interaction with van 
der Waals forces, compared to the external surface of CDs which are 
considered hydrophilic with the presence of hydroxyl group.104,107,108 The rim of 
the CD are knowns as primary and secondary rims, according to the number of 
the hydroxyl groups, where the primary rim has a single hydroxyl group of C6 
while the secondary one has two hydroxyl groups of C2 and C3. Accordingly, 
the primary rim becomes narrower while the secondary is wider and gives a 
truncated cone structure to the CD instead of cylinder, because of the natural 
arrangement of the glucose units.109 To improve the solubility, and increase the 
CD capacity to form inclusion complex, chemical modifications of the primary 
and secondary hydroxyl groups are made by substituting with ethyl, methyl, 
hydroxyethyl, sulfobutyl or hydroxypropyl groups. Methylated derivatives of CD 
include heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB) (Figure 1.4, b) and 
heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB) (Figure 1.4, c) where the 
hydroxyl groups at C6, C3 and C2 in  βCD are methylated to obtain TRIMEB 
whereas the methylation of hydroxyl groups at only C6 and C2 produces 
DIMEB. The physical and chemical properties of methylated derivatives are 
relatively altered compared to those of βCD. The water solubility of DIMEB and 
TRIMEB are 57 and 31 g/100 mL respectively which has been improved 
compared to 1.85 g/100 mL for the parent βCD.110 
 
Figure 1.4: Chemical structure of (a) βCD, (b) DIMEB and (c) TRIMEB 
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Recently, the use of CDs in the pharmaceutical industry has been adopted to 
overcome some solubility and dissolution problems. Different approaches have 
been taken in order to tackle the solubility issue which include the use of salt 
formation, surfactants, pH alteration of the medium or the use of co-solvents.106 
The use of CDs has been recently adopted to enhance the solubility, 
dissolution, bioavailability, physical and chemical stability and other applications 
in the pharmaceutical industry.111 The way of increasing the solubility by using 
CD is by forming the inclusion complex with incorporation of the hydrophobic 
part of the guest into the cavity, while the hydroxyl groups of the CD external 
surface gives the hydrophilicity of the resulting complex. The hiding of the 
hydrophobic part of the guest which is responsible for its poor solubility leads to 
an overall enhancement of its water solubility.112 Different range of the drugs 
have been prepared as inclusion complexes to enhance their water solubility, 
such as non-steroidal anti-inflammatory drugs (piroxicam113 and 
indomethacin114), griseofulvin,115 antidiabetic agents (gliclazide116 and 
tolbutamide117) and steroids.118 The CDs also can be added in order to 
decrease or even to avoid the irritation of eye and gastrointestinal tract 
(flufenamic acid,119 thalidomide120 and naproxen121) or to overcome the 
unpleasant taste or odour (naproxen, ibuprofen and bile acids).122 
The inclusion complex can be formed between the CDs and the guest 
molecules in water107 and also in many polar organic solvents.123,124 However, it 
has been reported that the formation of the inclusion complex in nonpolar 
solvent is difficult.125 Many studies were conducted to probe the effect of the 
addition of CDs on the solubility and stability of formulations in HFA propellants 
used in pMDI preparations. Williams et al. studied the stability of the HFA-
aspirin formulation by the addition of 2-Hydroxypropyl-β-cyclodextrin 
(HPβCD).126 Likewise, Steckel et al. studied the effect of HPβCD to stabilise 
HFA-budesonide formulations in the presence of ethanol and polyethylene 
glycol (PEG) 300. They found a formation of a stable suspension with no 
agglomeration over the storage period of 3 months. Importantly, without adding 
HPβCD, a supersaturated solution was formed and the material recrystallized 
on the inner surface of the container. However, they did not examine the effect 
of the co-solvent and CD on the solubility of budesonide and their effect on 
aerosol performance.127 
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The most significant feature of CDs is their capability to form the inclusion 
complex either in solution or in the solid state. In the case of solid state, the 
guest molecule can either be encapsulated or weakly interact with the surface 
of CD, while in solution state the equilibrium occurs between non-complexed 
and complexed molecule. Accordingly, the change in the physicochemical 
properties of both host and guest molecules occur and can be determined by 
various techniques.108,128 In aqueous solution, the apolar cavity of the 
cyclodextrin is occupied by the water molecules which can form a less favoured 
system in terms of energy because of the polar-apolar interaction. Therefore, 
the high enthalpy water can be readily displaced by suitable guest molecules 
(that have a lower polarity than water) to achieve apolar–apolar association; this 
is considered the driving force for the complex formation. This leads to a 
reduction of the ring strain of the CD as it is in the more favourable and stable 
low energy state.129 
1.5.4.1 Binding forces involved in complexation formation 
The equilibrium exists between the associated molecules (H.G) and their 
dissociated forms of CD (H) and guest (G) entities, and can be expressed by 
the stability constant, Ka.  
H+G  H∙G  Equation 1.1 
 
Ka= 
[H∙G]
[H][G]
 Equation 1.2 
 
It is used as an indicator to assess the stability of the inclusion complex 
between the guest and the host and its value is directly proportional to the 
stability of the formed complex. There are two main factors affecting the 
formation of the inclusion complex, the first one is the size of the CD and the 
guest molecule as well as the guest structure, as if the guest is not of suitable 
size; it will not enter the CD cavity. The second factor is the ability of the three 
components; guest, CD and solvent to thermodynamically interact to form a 
more favourable driving force that causes the guest to enter into the CD 
cavity.106 As the CD is a neutral molecule, therefore, the main forces involved in 
the complex formation are; hydrophobic interaction, hydrogen bonding and van 
der Waals interactions. 
 19 
 
 
Hydrophobic interactions arises from the repulsive force between the apolar CD 
cavity and the water inside the CD cavity which has a high enthalpy in one side, 
and between the apolar guest and the vehicle water on the other side.129 
Accordingly, the high enthalpy polar water molecules in the apolar CD cavity 
would be displaced by the hydrophobic guest, as well as the number of 
hydrogen bonds increases as the displaced water comes out to the external 
media. This leads to the decrease in the repulsive force between the guest and 
the bulk water on one hand, and an increase in the apolar–apolar (hydrophobic) 
interaction between the guest and the apolar CD cavity on the other hand. 
These interactions cause increase in free water molecules which ultimately 
leads to a positive change in entropy and to a lesser extent in the enthalpy.130 
Van der Waals interactions can occur due to the polarity of the molecules like 
dipole-dipole and dipole induced polar interaction. Conversely, this can also 
take place between apolar parts of the molecules and this is called London 
dispersion. The former interaction is weak with water and it is indirectly 
proportion to the permittivity of the medium and such interaction becomes 
stronger in presence of CD particularly in CD cavity and this is due to its small 
permittivity. Apolar interaction on the other hand happens when the molecules 
are near each other and are separated by a small distance and its affected by 
the steric hindrance of the molecules. Once again, van der Waals interaction 
also causes change in the thermodynamic state of the system and when it is 
minor compared to the hydrophobic interaction this leads to positive values of 
entropy and enthalpy. Conversely, if van der Waals forces are more 
predominant than hydrophobic interaction then this results in both entropy and 
enthalpy values are less than zero.131-133 
Hydrogen bonding can be formed between the primary and secondary hydroxyl 
groups of the CD with the guest molecule. Also, the bonding can be formed 
between the two hydroxyl groups of the CD.134 All the above bond act together 
to form the inclusion complex between the CD and the guest. 
The thermodynamic parameters such as the enthalpy change (ΔH°), the 
entropy change (ΔS°) and the free energy change (ΔG°) can be used to as a 
confirmation for the complexation driving forces. The van't Hoff equations are 
used to calculate ΔS° and ΔH° as follows: 
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ln K = - 
∆H°
RT
 + 
∆S°
R
 Equation 1.3 
 
ΔG° = -RT ln K             
 
Equation 1.4 
 
If the ΔH° and ΔS° are positive, this indicates that the interaction between the 
CD and the guest is an entropy-driven process and the hydrophobic interaction 
is the main force included in the complexation. However, if the ΔH° and ΔS° are 
negative, this implies an enthalpy-driven process and both hydrogen bonding 
and van der Waals interactions are the main forces for complexation.135 The 
positive entropy arises from the flexibility of guest molecule upon complexation, 
the liberation of water from the cavity and desolvation from the hydrophilic parts 
of both guest and the host. The negative enthalpy results from the suitable 
matching in term of shape and size between the CD and the guest whereas the 
negative entropy is attributable to the reduction in the conformational and 
translational freedoms of both guest and the CD after complexation.136 
1.5.4.2 Inclusion complex characterisation  
There are numerous techniques used for the characterisation of the inclusion 
complex. For example, high performance liquid chromatography (HPLC),137 
powder X-ray diffraction (PXRD),108 circular dichroism,138 thermogravimetric 
analysis (TGA),139 differential scanning calorimetry (DSC),140 FT-Raman 
spectroscopy,141 Fourier Transform Infrared Spectroscopy (FTIR),108 UV-Vis 
spectroscopy142 and Nuclear Magnetic Resonance (NMR).117 The two last 
instrumental techniques have been used in this thesis to study the complexation 
in solution form. 
The inclusion complex is characterised by measuring the stoichiometry and the 
stability constant of the systems under study. A continuous variation method or 
so-called Job’s plot is used to determine the stoichiometry of the complex where 
the change in the specific properties such as the chemical shift and absorbance 
is evaluated as an indication for the complexation.143 The setup of the method is 
based on the preparation of two equimolar solutions of both host and guest. 
Then different mixtures of both host and guest are made by taking different 
ratios from them and mixing to the standard volume with the total of the 
concentration of both components remaining constant.144 The stoichiometry is 
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then determined by measuring either the chemical shift in the case of NMR or 
the change in the absorbance at a certain wavelength by UV spectroscopy. The 
Hildebrand-Benesi method is a very common means to study the inclusion 
complex between the host and the guest,135 and depends on the measurements 
of the chemical shift changes as a function of concentration (NMR titration). The 
method is performed by adding a constant volume of the guest to different ratios 
from the CD solution to form different solutions which are then analysed by 
NMR. The CD concentrations are plotted versus the change in chemical shift, 
and the stability constant is calculated from the slope and the intercept of the 
obtained graphs using Hildebrand-Benesi Equation:  
1
∆δobs
= 
1
[CD]K ∆δmax
+ 
1
∆δmax
 Equation 1.5 
 
Where; ∆δobs is the change in the chemical shift of the proton of the complexed 
guest, ∆δmax is the chemical shift difference between the complex and free 
guest. The [CD] and K are the concentration of CD and association constant 
respectively.143 
Ultraviolet-Visible (UV-Vis) spectroscopy can also be used in the same manner 
by measuring the change in the absorbance of the guest as a function of 
concentration and the stability constant is measured using the following 
equation: 
1
ΔA
=
1
Δε [G]
0
K[CD]
+ 
1
Δε [G]
0
 Equation 1.6 
 
Where; ΔA and Δε are the absorbance and the molar absorptivity difference 
between the free and complexed guest. [G]0  is the initial guest concentration, K 
is the apparent formation and [CD] is the CD concentration.135 
1.5.4.3 Nuclear Magnetic Resonance (NMR) 
NMR is one of the techniques that has been used widely in this area of 
study.104,145-147 It is considered the most valuable technique for obtaining 
information on complex formation; the inclusion complex causes a change in 
the chemical shift of the protons of both the host and guest molecules. Due to 
the fact that the exchange between the free and complex guest or host is fast 
compared with the NMR time scale, it is expected that the peaks in the NMR 
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spectrum observed are a weighted average of the chemical shifts of both the 
free and the complexed molecule.148,149 The extent of the shift is related to the 
proton position in the molecule, cavity size of CD and also the ratio between the 
guest and CD.104,147 The chemical shift change of both the CD and the guest 
molecule has been attributed to the environment change from the polar 
aqueous medium to the apolar CD cavity and to the shielding effect arising from 
the cavity. The greater chemical shift change is an indication of the stronger 
interaction between the guest and the CD.150 NMR is therefore considered the 
most favourable technique to study complex formation since the 1H NMR 
titration experiments confirm the complex formation. The information about the 
mode, the deepness of guest penetration in the CD cavity, the stability and the 
stoichiometry of the complex can all be obtained from the NMR titration 
data.104,151 In addition, advanced two-dimensional techniques such as rotational 
overhauser effect spectroscopy (ROESY) can be used to assign the change in 
the shift of the protons of the complex structure.104 
1.5.4.4 Ultraviolet-Visible (UV-Vis) Spectroscopy 
Ultraviolet-Visible (UV-Vis) spectroscopy is one of the techniques used to 
identify the complexation by measuring the change in the absorption spectrum 
of the guest molecule which results from the change in the solvent environment 
before and after the addition of the host molecule.108,152 When the cyclodextrin 
is added, some changes are observed in terms of the intensity and position of 
the absorption spectrum of the molecule.153 As the molecule is inserted into the 
CD cavity, it is transferred from the aqueous environment to the apolar CD 
cavity. This results in the change of the molar extinction coefficient (Δε) of the 
chromophore of the molecule154 due to the perturbation of the chromophore 
electrons of the guest molecules.155 Also, the UV maximum is shifted and the 
fluorescence is enhanced for the fluorescence molecule as a result of the 
change in the surrounding medium.129 Another explanation of the change in the 
UV-Vis spectrum is replacement of the solvation shell around the guest 
completely or partially by the CD molecule which creates a new solute 
environment for the interactions.153 
1.5.4.5 Surface-enhanced Raman Scattering (SERS) 
Raman spectroscopy can be used as a fingerprint for the identification of a 
molecule; however, this technique has low sensitivity compared to fluorescence 
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or infrared absorption156 therefore, signal enhancement is sometimes necessary 
in order to detect low concentration molecules by this technique. It can be seen 
that (P) is the magnitude of the dipole moment resulting from the Raman 
scattering of the light, is directly proportional to the magnitude of the electric 
field (E) used for the excitement of the molecules. Their relation can be 
expressed in the equation P = αE, where α is the molecule polarizability. If the 
electric field is enhanced, it leads to the enhancement of the Raman scattering 
and the signal, this enhancement can result from the excitation of localised 
surface plasmon (LSP). This induces the enhancement of the electric field at 
the nanoparticle which enhances the Raman signal of the molecule located 
closer to the nanoparticle surface.157 The SERS effect results from the 
electromagnetic interaction between the metal nanoparticles and the adsorbate 
by involving of two processes as shown in Figure 1.5. The first process comes 
from the interaction between the incident beam and the nanoparticle which 
causes an enhancement of the local incident field E0 at a wavelength λ0. The 
second one (re-radiation of the Raman signal) is resulted from the interaction of 
the Raman signal scattered by adsorbate and the nanoparticle which then 
induces the Raman signal enhancement at a wavelength λR (Raman scattering 
enhancement).158  
 
Figure 1.5: Schematic diagram of SERS process. (1) metal nanoparticles surrounded by a solvent 
medium. (2) incident field E0 excites the nanoparticles at a wavelength λ0. (3) molecule is located 
near the nanoparticle surface. (4) the molecule is polarised by the local field that is then scattered 
Escat at Raman wavelength λR (5) the scattered field is then reacted with the nanoparticles 
producing field Erad through re-radiation process.158 
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The incident field, E0, causes the excitation to the metallic nanoparticle that 
leads to the enhancement of the local field at the particle vicinity. This local 
enhancement can be expressed by the following equation: 
ELoc = Mloc(λ0)E0 Equation 1.7 
 
The Mloc is local enhancement factor of the excited field at wavelength λ0. Then 
the enhanced local field excites the molecule near the nanoparticle, then, the 
excited molecule scatters a Raman signal in all directions at a shifted 
wavelength λR and this can be explained as:  
Escat = αELoc = α Mloc(λ0)E0 Equation 1.8 
                       
Where α is the molecule polarisability. The scattered field then interacts with the 
nanoparticle, which subsequently enhances the Raman scattering by the re-
radiation process which can be expressed by the following equation: 
Erad= Mrad(λR)Escat = Mrad(λR)αELoc= αMloc(λ0)Mrad(λR)E0 
 
Equation 1.9 
As a result of two enhancement processes, the Raman signal scattered by 
molecule has two enhancement factors at the excitation, λ0, and the Raman 
wavelengths, λR. Accordingly, The SERS intensity is then calculated as: 
ISERS = M2loc(λ0)M2rad(λR)I0 = GI0 Equation 1.10 
  
Where; I0 is the Raman signal intensity of the molecule without the nanoparticle. 
Without enhancement, the enhancement factor can be defined as: 
G(λ0, λR) M2loc(λ0)M2rad(λR) Equation 1.11 
 
Because of the Raman shift is low, it is found that the λ0 and λR are nearly close 
and consequently their factors are likely to be approximately equal as M2loc ≈ 
M2rad and then G ≈ M4loc. Accordingly, the SERS intensity can be estimated as: 
ISERS ≈ M4loc(λ0)·I0. Equation 1.12 
 
Thus the Raman enhancement is high as it is proportional to the fourth power of 
the electromagnetic field enhancement by the nanoparticle.158 The effect of the 
SERS is local, as the LSP decay length is about a few tens of nanometers 
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(between 15 and 20 nm).159,160 The decay length depends on the size and 
geometry of the nanostructure. For example, nanotriangles with height and 
width in the range of 30-35 and 70-100 nm respectively, the decay length is in 
the direct proportional to the nanotriangles width, whereas it inversely 
proportional to their height. On the other hand, as the Raman signal has been 
estimated as the fourth power of the electromagnetic field enhancement near 
the nanoparticle, the Raman enhancement length is more restricted than the 
field decay length. Dieringer et al. have estimated the relation between the 
SERS and the distance from the surface by the following equation: 
ISERS = (1 + r/a)−10 Equation 1.13 
  
Where; r, is the distance between the adsorbate and the surface of the particle 
and, a, is the mean size of the field enhancement at the particle surface.161 As a 
result, the SERS intensity decreases and is approximately nil in the range of 
nanometers distance from the nanoparticle surface. 
Lastly, it has been proved that the Raman enhancement depends on the 
position of the LSP resonance, that in turn can be modified by controlling the 
geometrical and optical properties of the nanoparticles.158 
SERS can be used in different fields such as biochemistry, polymer, material 
science and electrochemistry. It is used for the identification and also for 
structural prediction of the chemicals. Due to the fact that this technique is 
highly selective and sensitive, it can be used as a biosensor for the detection of 
diseases such as Alzheimer’s disease, cancers and Parkinson’s disease.162   
1.5.4.6 Solid state studies 
Different methods have been reported to prepare the inclusion complex in the 
solid state such as physical blending, kneading, co-precipitation, 
solution/solvent evaporation and co-grinding methods.163 The prepared system 
is then characterised by a range of techniques such as PXRD, Fourier 
transform-infrared (FT-IR) spectroscopy,108,140 Raman spectroscopy141 and 
differential scanning calorimetry (DSC).140 All these methods are important as 
additional tools to study the inclusion complex formation between the guest 
compounds and CDs in addition to the NMR and UV-Vis spectroscopy, which 
both can give information regarding the complexation in aqueous solution.  
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1.6 Study objectives 
It is essential to characterise and study the drugs and excipients in HFA 
inhalers in order to get a comprehensive understanding of the device 
performance and hence the therapy. Many studies have been conducted after 
the banning of CFCs and approval of HFA propellants (see Section 1.3), where 
both in vitro and in vivo studies have been undertaken to assess the 
effectiveness of HFA based therapies compared to CFC.69 As the driving force 
that is responsible for the formation of the inclusion complex is van der Waals or 
hydrophobic interactions between the host and the guest, the use of nonpolar 
solvents can act as strong competitors for the occupation of the CD cavity. Few 
studies have been carried out to probe the complexation and physical chemistry 
of host guest complexes in nonpolar solvents; a study by Menger and Dulany 
has assessed p-nitrophenol and heptakis (3-O-butyl-2,6-di-O-methyl)-β-
cyclodextrin in heptane and acetonitrile showing a complexation only in the 
former solvent.164 Another study performed by Uccello-Barretta on 1,1,1,3,3-
pentafluoro-2-(fluoromethoxy)-3-methoxypropane and heptakis(2,3-di-O-acetyl-
6-O-tert-butyldimethylsilyl)-β-cyclodextrin in deuterated cyclohexane showing 
the interaction between both compounds and in this case the derivatised 
cyclodextrin is used as a chiral selector for the enantiodiscrimination.165 
Notably, we are unaware of any other systematic studies of the physical 
chemistry of host guest complexes in the HFAs used in pMDI inhalers at this 
time.  
This work aims to develop methods using various analytical techniques to study 
the physicochemical properties of the active ingredients after the addition of the 
CDs and probe the host guest interactions. The drugs are studied in the 
presence of different types of CDs in a range of solvents of differing polarity; 
water, organic solvents and HFA. As stated in Section 1.5.4, the inclusion of the 
guest API into the CD cavity causes a change in the physicochemical properties 
of both the host and guest molecules. This is dependent on the strength of the 
interaction force between them in solution which is commonly expressed as the 
stability or equilibrium constant, Ka. UV-Vis and NMR studies will be carried out 
to investigate the complex formation in solution in terms of (i) stoichiometry and 
(ii) the stability constant. The ICS compound, budesonide will be used as a 
model to develop appropriate methods to investigate host guest complexes 
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established with beta cyclodextrin (βCD), and two derivatised βCDs, DIMEB 
and TRIMEB. The initial studies will be carried out in water (and D2O in the case 
of NMR) for ease of manipulation and to establish reliable methods. 
These methods will be developed further to allow the study of the budesonide 
complexes in the non-polar HFA solvents discussed earlier. The volatility of 
these systems makes analysis very challenging, and significant thought has to 
be given to their manipulation in the laboratory and within analytical 
instrumentation. Methods will be developed using HPFP (2H,3H-
decafluoropentane) as a model for HFA 134a and 227 based on work published 
by Rogueda166 that concludes the properties of HPFP were similar to those of 
HFA 134a and HFA 227 propellants. This assists the studies since HPFP is a 
volatile liquid at standard temperature and pressure (STP), whereas HFA 134 a 
and HFA 227 are both gases. It is, however, an objective of the development to 
produce methods that are easy to transfer to the study of the gaseous 
propellants using pressurised NMR. 
More conventional solid state studies will underpin the solution work to further 
our understanding of the complexation occurring, primarily using vibrational 
spectroscopy to characterise isolated host guest complexes. Solid mixtures of 
budesonide and βCD, DIMEB or TRIMEB will be prepared in a ratio depending 
on the stoichiometry results obtained from NMR and UV-Vis spectroscopy 
techniques. The prepared mixtures will be studied by Raman and FT-IR 
spectroscopy to give additional information about complexation by comparing 
the obtained spectra to the original of the guest and CDs.  
As the ICS are poorly soluble and weak Raman signals are obtained from 
solution, SERS techniques will be used to selectively enhance these signals. 
Silver and gold functionalised thiolated βCD will be used to attempt to exploit 
the SERS effect observed with multiple ICS compounds and further our 
understanding of the interactions with the CD systems. 
1.7 Aims 
The aim of this work is to develop novel analytical methods to interrogate the 
physical chemistry of HFA-based formulations. This requires development of 
structural analytical methods to study the product and characterise the interplay 
between the API and the formulation excipients. It covers both solution and 
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solid state studies to allow a better understanding of the behaviour and the 
stability of the ingredients in the device. The approach has been extended to 
investigate the interaction with solubilising excipients based on CDs. This will be 
a platform to help develop the formulation of inhaled drugs in HFA propellants, 
which in turn allows us to produce more effective systems in terms of better 
solubility and stability. The specific aims of this work can be summarised as 
follows: 
• Development of UV-Vis and NMR methods to study corticosteroids in the 
presence of βCD, TRIMEB and DIMEB in solvents of different polarity 
(including volatile HFAs) utilising budesonide as a model steroid 
compound. 
• Solid state studies to further investigate the complexation between 
budesonide and βCD, TRIMEB and DIMEB using vibrational 
spectroscopic techniques (Raman and FT-IR). 
• Assess the complexation of different ICS compounds including (i) 
budesonide (ii) beclomethasone dipropionate, (iii) beclomethasone, (iv) 
fluticasone propionate and (v) mometasone furoate in the presence of 
TRIMEB and DIMEB in HFA by NMR spectroscopy. 
• Development of SERS approaches to further interrogate the 
complexation between ICS and bespoke thiolated βCD. 
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2 Experimental 
2.1 Materials 
The materials were used as supplied and without further purification (Table 2.1.) 
Table 2.1: Supplier, purity and the batch information of the materials used in this study  
material supplier batch No. (purity) 
Beclomethasone Jai Radhe BMD-N-006-09 
Beclomethasone dipropionate Jai Radhe BMD-N-004-09 
Budesonide Sigma-Aldrich 100 % 
(22R)-Budesonide  Clearsynth 98.49 % 
Fluticasone propionate Jai Radhe 408901-FP 
Mometasone furoate Jai Radhe APL/72/C-09 
βCD SAFC STBB6461 
DIMEB Sigma-Aldrich 98 % 
TRIMEB Sigma-Aldrich 98 % 
Vanillin Sigma-Aldrich STBC7969V (99%) 
Deuterium oxide (D2O) Sigma-Aldrich 99.9 % 
Deuterated chloroform (CDCl3) CIL 99.8 % 
Deuterated  acetonitrile (CD3CN) CIL 99.8 % 
Deuterated methanol (MeOD) CIL 99.8 % 
EtOH (analytical grade) Fisher chemical  99.5 % 
CHCl3 (HPLC grade) Fisher chemical 99.8 % 
HPFP Apollo Scientific 98 % 
Triphenylphosphine Maybridge  21792 
Dimethylformamide  Sigma-Aldrich STBD6091V (99.8 %) 
Iodine Origin uncertain 
Sodium methoxide in methanol Sigma-Aldrich STBD7353V (25 %)  
Thiourea Sigma-Aldrich SZBE2950V (99 %) 
Sodium hydroxide Sigma-Aldrich SZBE1620V (98 %) 
Silver nitrate  ACROS A0341730 (99.8 %) 
Potassium chloride  AnalaR 1318220 (99.8 %) 
Sodium borohydride Sigma-Aldrich STBD3364V (98 %) 
Hydrogen tetrachloroaurate Sigma-Aldrich MKBS1011V 
Trisodium citrate  Sigma-Aldrich BCBL0853V (99 %) 
 
2.2 Methods 
2.2.1 Determination of host:guest stoichiometry by UV-Vis spectroscopy 
The solutions were prepared based on continuous variation method (Job’s plot) 
where an equal molar concentration of both compounds (guest) and 
cyclodextrin (host) were prepared, then different ratios of both components 
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were taken to form different solutions of equal volumes but the sum of the 
concentration of both components in each solution is constant and the solutions 
were then analysed by UV-Vis spectroscopy. The stoichiometry was determined 
by measuring the change in the absorbance at a certain wavelength by UV 
spectroscopy. 
2.2.1.1 Vanillin and βCD in H2O 
The solutions were prepared based on continuous variation method as shown in 
Table 2.2 where both vanillin and βCD are prepared in original concentration of 
5 mM in water. Then different ratios were taken from both solutions to form 
different solutions of constant concentration at 0.05 mM with constant volume at 
10 mL. All solutions were then analysed using Varian CARY 50 Probe UV-
Visible spectroscopy at λmax at 280 nm.  
Table 2.2: The preparetion of vanillin and βCD solutions based on continous variation method and 
analysed by UV–Vis spectroscopy. 
[βCD]*10-2 (mM) r 
Volume 
(mL) 
[van]*10-2 (mM) r 
Volume 
(mL) 
0 0 0 5 1 10 
0.5 0.1 1 4.5 0.9 9 
1 0.2 2 4 0.8 8 
1.5 0.3 3 3.5 0.7 7 
2 0.4 4 3 0.6 6 
2.5 0.5 5 2.5 0.5 5 
3 0.6 6 2 0.4 4 
3.5 0.7 7 1.5 0.3 3 
4 0.8 8 1 0.2 2 
4.5 0.9 9 0.5 0.1 1 
5 1 10 0 0 0 
 
2.2.1.2 BUD and βCD/TRIMEB in EtOH:H2O and H2O 
The solutions were prepared based on continuous variation method as shown in 
Table 2.3 where both budesonide and βCD/TRIMEB are prepared in original 
concentration of 0.04 mM in EtOH:H2O (50:50). Then different ratios were taken 
from both solutions to form different solutions of constant concentration at 0.04 
mM with constant volume at 10 mL. In the case of studying their complex in 
water, both components were prepared as stock solution of 0.05 mM in water. 
Then the same procedure was followed as in the case of using mixture of 
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EtOH:H2O (Table 2.4). All solutions were then analysed using Varian CARY 50 
Probe UV-Visible spectroscopy. 
Table 2.3: The preparetion of BUD and βCD/TRIMEB solutions in EtOH:H2O (50:50) based on 
continous variation method and analysed by UV-Vis spectroscopy. 
[βCD/TRIMEB]*10-2  
(mM) 
r 
Volume 
(mL) 
[BUD]*10-2 
(mM) 
r 
Volume 
(mL) 
0 0 0 4 1 10 
0.4 0.1 1 3.6 0.9 9 
0.8 0.2 2 3.2 0.8 8 
1.2 0.3 3 2.8 0.7 7 
1.6 0.4 4 2.4 0.6 6 
2 0.5 5 2 0.5 5 
2.4 0.6 6 1.6 0.4 4 
2.8 0.7 7 1.2 0.3 3 
3 0.8 8 0.8 0.2 2 
3.6 0.9 9 0.4 0.1 1 
4 1 10 0 0 0 
 
Table 2.4: The preparetion of BUD and βCD/TRIMEB solutions in H2O based on continous variation 
method and analysed by UV-Vis spectroscopy. 
[βCD/TRIMEB]*10-2  
(mM) 
r 
Volume 
(mL) 
[BUD]*10-2 
(mM) 
r 
Volume 
(mL) 
0 0 0 5 1 10 
0.5 0.1 1 4.5 0.9 9 
1 0.2 2 4 0.8 8 
1.5 0.3 3 3.5 0.7 7 
2 0.4 4 3 0.6 6 
2.5 0.5 5 2.5 0.5 5 
3 0.6 6 2 0.4 4 
3.5 0.7 7 1.5 0.3 3 
4 0.8 8 1 0.2 2 
4.5 0.9 9 0.5 0.1 1 
5 1 10 0 0 0 
 
2.2.2 Determination of host:guest association constants by UV-Vis 
spectroscopy 
The tested compound was held at constant concentration and different 
increasing concentrations of the CD were added to form different solutions 
which were then analysed by UV-Vis spectroscopy. The CD concentrations 
were plotted versus the change in the absorbance and the stability constant 
was calculated from the slope and the intercept of the obtained graphs. 
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2.2.2.1 Vanillin and βCD in H2O 
The vanillin solution was prepared at concentration of 1 mM in water. Then 
serial dilutions from βCD were then taken to form 2, 4, 6 and 8 mM solutions 
with the addition of fixed amount (0.5 mL) of vanillin from the stock solution and 
completed the volume with solvent to the 10 mL mark. All solutions were then 
taken for the analysis at λmax at 280 nm. 
2.2.2.2 BUD and βCD in EtOH:H2O and H2O 
The budesonide and βCD was studied in a 50:50 mixture of ethanol and water 
(EtOH:H2O), as the complex is not formed in the presence of only ethanol. The 
experiment was carried out by preparing a 0.4 mM budesonide and 10 mM βCD 
in ethanol/water solution. Then serial dilutions from βCD were then taken to 
form 2, 4, 6 and 8 mM solutions with the addition of fixed amount (1 mL) of 
budesonide from the stock solution and completed the volume with solvent to 
the 10 mL mark. The solutions were analysed with UV at λmax at 246 nm using a 
mixture of EtOH:H2O (50:50) as a blank. To study the complex formation in 
water, a solution of 0.05 mM of budesonide and solution of 10 mM βCD were 
prepared in water. Then serial dilutions from βCD were made to form 2, 3, 4, 5 
and 7 mM with the addition of fixed amount (1 mL) of budesonide from the stock 
solution (0.05 mM) and completed the volume with solvent to the 5 mL mark. All 
solutions were then measured with UV-Vis spectroscopy at 246 nm using water 
as a blank. 
2.2.2.3 BUD and TRIMEB in EtOH:H2O and H2O 
The experiment was done by preparation of 0.4 mM of budesonide and 2 mM 
TRIMEB in EtOH:H2O 50:50 solution. Then serial dilutions from TRIMEB were 
made to form 0.4, 0.6, 0.8, 1 and 1.4 mM with the addition of fixed amount (0.5 
mL) of budesonide from the stock solution and completed the volume with 
solvent to the 5 mL mark. All solutions were then measured with UV at 246 nm 
using a mixture of EtOH:H2O (50:50) as a blank. To study the complex 
formation in water, a solution of 0.05 mM of budesonide and solution of 2 mM 
TRIMEB were prepared in water. Then serial dilutions from TRIMEB were made 
to form 0.4, 0.6, 0.8, 1 and 1.4 mM with the addition of fixed amount (1 mL) of 
budesonide from the stock solution (0.05 mM) and completed the volume with 
solvent to the 5 mL mark. All solutions were then measured by UV-Vis 
spectroscopy at 246 nm using water as a blank. 
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2.2.3 Determination of host:guest stoichiometry by NMR spectroscopy 
An equal molar concentration of both compounds (guest) and cyclodextrin 
(host) were prepared, then different ratios of both components were taken to 
form different solutions of equal volumes but the sum of the concentration of 
both components in each solution is constant and the solutions were then 
analysed by NMR spectroscopy. The stoichiometry was determined by 
measuring the chemical shift differences of the guest molecule protons.  
2.2.3.1 Vanillin and βCD in D2O 
The solutions were prepared according to continuous variation methods where 
both vanillin and βCD original concentrations equal to 10 mM in D2O and 
different ratios were taken from both stock solutions to give different solutions of 
the same concentrations at 10 mM with constant volume at 1 mL (Table 2.5). 
The solution was then added to the standard NMR tube and then inserted into 
the Bruker 400 MHz NMR spectroscopy. 
Table 2.5: The preparetion of vanillin and βCD solutions based on continous variation method and 
analysed by 1H NMR. 
[βCD] (mM) r Volume (mL) [van] (mM) r Volume (mL) 
0 0 0 10 1 1 
1 0.1 0.1 9 0.9 0.9 
2 0.2 0.2 8 0.8 0.8 
3 0.3 0.3 7 0.7 0.7 
4 0.4 0.4 6 0.6 0.6 
5 0.5 0.5 5 0.5 0.5 
6 0.6 0.6 4 0.4 0.4 
7 0.7 0.7 3 0.3 0.3 
8 0.8 0.8 2 0.2 0.2 
9 0.9 0.9 1 0.1 0.1 
10 1 1 0 0 0 
 
2.2.3.2 BUD and βCD/DIMEB/TRIMEB in D2O 
The stoichiometry was studied by preparing equimolar concentration of both 
budesonide and either βCD, DIMEB or TRIMEB at 0.05 mM in D2O. Then, 
different ratios were taken from both solutions to form different solutions at 
constant concentration of 0.05 mM with constant volume at 1 mL (Table 2.6). 
The solution was added to the standard NMR tube while the reference solution 
(CHCl3 in CD3CN) was added to the inside capillary tube. The co-axial tube was 
then inserted into the JEOL 600 MHz NMR spectroscopy for analysis. 
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Table 2.6: The preparetion of BUD and βCD/DIMEB/TRIMEB solutions based on continous variation 
method and analysed by 1H NMR 
[βCD/DIMEB/TRIMEB]  
(mM) 
r 
Volume 
(mL) 
[BUD] 
(mM) 
r 
Volume 
(mL) 
0 0 0 0.05 1 1 
0.005 0.1 0.1 0.045 0.9 0.9 
0.01 0.2 0.2 0.04 0.8 0.8 
0.015 0.3 0.3 0.035 0.7 0.7 
0.02 0.4 0.4 0.03 0.6 0.6 
0.025 0.5 0.5 0.025 0.5 0.5 
0.03 0.6 0.6 0.02 0.4 0.4 
0.035 0.7 0.7 0.015 0.3 0.3 
0.04 0.8 0.8 0.01 0.2 0.2 
0.045 0.9 0.9 0.005 0.1 0.1 
0.05 1 1 0 0 0 
 
2.2.3.3 BUD and DIMEB/TRIMEB in HPFP 
The stoichiometry was studied by preparing equimolar concentration of both 
budesonide and either of DIMEB or TRIMEB at 0.175 mM in HPFP. Then, 
different ratios were taken from both solutions to form different solutions at 
constant concentration of 0.175 mM with constant volume at 0.5 mL (Table 2.7). 
The solution was added to the standard NMR tube while the reference solution 
(CHCl3 in CD3CN) was added to the inside capillary tube. The co-axial tube was 
then inserted into the JEOL 600 MHz NMR spectroscopy for analysis. 
Table 2.7: The preparetion of BUD and DIMEB/TRIMEB solutions based on continous variation 
method and analysed by 1H NMR. 
[DIMEB/TRIMEB] 
(mM) 
r 
Volume 
(mL) 
[BUD] 
(mM) 
r 
Volume 
(mL) 
0 0 0 0.175 1 0.5 
0.0175 0.1 0.05 0.1575 0.9 0.45 
0.035 0.2 0.1 0.14 0.8 0.4 
0.0525 0.3 0.15 0.1225 0.7 0.35 
0.07 0.4 0.2 0.105 0.6 0.3 
0.0875 0.5 0.25 0.0875 0.5 0.25 
0.105 0.6 0.3 0.07 0.4 0.2 
0.1225 0.7 0.35 0.0525 0.3 0.15 
0.14 0.8 0.4 0.035 0.2 0.1 
0.1575 0.9 0.45 0.0175 0.1 0.05 
0.175 1 0.5 0 0 0 
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2.2.4 Determination of host:guest association constants by NMR 
spectroscopy 
The tested compound was held at constant concentration and different 
increasing concentrations of the CD were added to form different solutions 
which were then analysed by NMR spectroscopy. The CD concentrations were 
plotted versus the change in the chemical shift and the stability constant was 
calculated from the slope and the intercept of the obtained graphs. 
2.2.4.1 Vanillin and βCD in D2O 
The vanillin concentration was held at 8 mM in D2O with adding βCD at 0, 12, 
14, 15 and 16 mM in D2O. The solution was then placed in the standard NMR 
tube and then inserted into the Bruker 400 MHz NMR spectroscopy. 
2.2.4.2 BUD and DIMEB/TRIMEB in CD3CN, CDCl3 and MeOD 
This is done by preparing 10 mM budesonide solution and 10 mM of DIMEB 
separately in CD3CN, Then fixed volume of budesonide was taken, which was 
equal to 2 mM and added to the DIMEB in increasing amount at (1, 2, 4, 6 and 
8 mM) to form different solutions of fixed budesonide concentration. The 
solution was placed in the standard NMR and then inserted into the JEOL 600 
MHz NMR spectroscopy for analysis. The same experiment was repeated using 
CDCl3 and MeOD as solvent. The same procedure was followed using TRIMEB 
instead of DIMEB. 
2.2.4.3 BUD and βCD/DIMEB/TRIMEB in D2O 
The calculation of stability constant was carried out by preparing 0.05 mM 
budesonide solution and 10 mM solution of either βCD, DIMEB or TRIMEB in 
D2O. Then 0.8 mL of budesonide was taken (equivalent to 0.04 mM) with 
adding different volumes of either; βCD, DIMEB or TRIMEB solution to give 
concentration of 0.2, 0.4, 1, 1.4 and 2 mM. All the solutions were made up to 1 
mL with D2O. The solution was then added to the standard NMR tube while the 
reference solution (CHCl3 in CD3CN) was added to the inside capillary tube. 
The co-axial tube was then inserted into the JEOL 600 MHz NMR spectroscopy 
for analysis. 
2.2.4.4  (BUD/BDP/MOM/FLU) and TRIMEB/DIMEB in HPFP 
The calculation of stability constant was carried out by preparing 0.175, 0.4, 
0.04 and 0.04 mM solutions of BUD, BDP, MOM and FLU respectively and 1 
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mM and 0.75 mM solution of TRIMEB and DIMEB in HPFP respectively. Then 
0.5 mL of either; BUD, BDP, MOM or FLU was taken (equivalent to 0.0875, 0.2, 
0.02 and 0.02 mM respectively) with adding different volumes of TRIMEB 
solution to give concentration of 0.1, 0.2, 0.3, 0.4 and 0.5 mM. For the 
experiments using the high concentration of TRIMEB, the same procedure 
followed with the addition of different volumes of TRIMEB solution (4 mM) to 
give concentration of 0.4, 0.8, 1.2, 1.6 and 2 mM. A 0.5 mL of either BUD or 
BDP was added to the DIMEB solution with adding different volumes to give 
concentration of 0.075, 0.15, 0.225, 0.3 and 0.375 mM. All the solutions were 
made up to 1 mL with HPFP. The solution was then added to the standard NMR 
tube while the reference solution (CHCl3 in CD3CN) was added to the inside 
capillary tube. The co-axial tube was then inserted into the JEOL 600 MHz NMR 
spectroscopy for analysis. 
2.2.5 Preparation of physical mixtures of budesonide and cyclodextrins 
A physical mixture of budesonide and CDs are prepared by mixing them by 
trituration using a mortar and pestle and the solid mixtures are then stored in a 
closed vial.163 
2.2.6 Preparation of inclusion complexes using evaporation methods 
The complex is prepared by dissolving 1 mole of CD in water (1 mL) and 1 mole 
of budesonide in ethanol (1 mL). Then, the aqueous solution of CD is added to 
the ethanolic solution of budesonide. The resultant solution is then stirred for 24 
hours followed by vacuum evaporation and the dried mass is stored in a closed 
vial.163 
2.2.7 SERS study 
2.2.7.1 Synthesis of thiol functionalised βCD (SCD) 
The compound was initially synthesised by dissolving triphenylphosphine (10.10 
g, 38.5 mmol) in dry dimethylformamide (DMF, 40 mL) followed by careful 
addition of iodine (10.15 g, 39.85 mmol) with vigorous stirring. Then oven dried 
βCD (2.70 g, 2.35 mmol) was added to the resulted dark brown solution and left 
overnight with stirring at 70 °C under nitrogen. The DMF was then removed 
under reduced pressure to leave a brown oil. Sodium methoxide in methanol (3 
M) was added to alter the pH from 1 to 9 and the solution was then allowed to 
stand at room temperature for 30 minutes. Then, the mixture was poured into 
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methanol (200 mL) to form a precipitate which was then filtered and washed 
thoroughly with methanol and finally purified by Soxhlet extraction with 
methanol. The product (per-6-iodo-βCD) was then dried in the oven to reach a 
constant weight; yield 2.80 g (61.8%).167 
Per-6-iodo-βCD (0.97 g, 0.5 mmol) was dissolved in dry DMF (10 mL) followed 
by the slow addition of thiourea (0.30 g, 4.0 mmol). The resulted mixture was 
left overnight with stirring at 70 °C under nitrogen. The DMF was then removed 
under reduced pressure to produce a yellow oil. Water (50 mL) and sodium 
hydroxide (0.26 g) were then added and the mixture was heated to a gentle 
reflux under nitrogen for 1 hour. The formed suspension was then acidified with 
HCl (2 M, 2 mL) and the resulting precipitate was then collected by vacuum 
filtration and washed thoroughly with water. The product (per-6-thio-βCD) was 
then was dried in the oven to reach a constant weight; yield 0.497 g (51 %). 
Per-6-thio-βCD (0.10 g) was suspended in 10 mL water and 0.23 g of sodium 
hydroxide was added and stirred for 30 min. The excess NaOH was then 
neutralized with 1 M HCl by measuring the pH of the solution. The sodium salt 
of per-thio-βCD was then recovered by freeze-drying.167 
 per-6-iodo-βCD 
NMR δ/ppm: 3.3 (21H, H2, H4, H6a, m), 3.6 (14H, H3, H5, m), 3.8 (14H, H7, 
H6b, d), 5 (7H, Ha, s), 5.9 (7H, OH-3, s), 6.1 (7H, OH-2, d). 
IR ῡ/cm-1: 585 (C-I, ms), 1036 (C-O, vs), 1326/1368/1413 (CH2 bend, mw), 
2913 (C-H stretch, w), 3325 (OH hydrogen bonded, m br). 
per-6-thio-βCD  
NMR δ/ppm: 2.1 (7H, SH, t), 2.5 (solvent, s), 3.2 (14H, H7, H6b, m), 3.7 (14H, 
H3, H5, m), 5 (7H, H1, s), 5.9 (14H, H3, OH-2, m). 
IR ῡ/cm-1: 1012 (C-O, vs), 1363 (CH2 bend, m br.), 2554 (S-H, w), 2916 (CH 
stretch, m), 3317 (O-H hydrogen bonded, m br). 
2.2.7.2 Silver nanoparticles preparation (Ag NPs) 
Silver nitrate (10 mL, 1 mM) was added dropwise to chilled sodium borohydride 
(30 mL, 2 mM). The mixture was stirred vigorously with the addition of silver 
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nitrate, the stirring was then stopped and potassium chloride (20 µL) was then 
added. The yellowish resulting solution was then wrapped with foil and kept 
away from the natural light.168 
2.2.7.3 Gold nanoparticles preparation (Au NPs) 
Small seed Au-NPs were synthesised by citrate reduction. 1% solution of 
trisodium citrate was prepared by dissolving 50 mg in 5 mL of distilled water 
which was then added to a refluxing solution of hydrogen tetrachloroaurate 
(HAuCl4 (20 mg) in distilled water (50 mL). The colour of the resulting solution 
was changed through the reaction to deep red colour. The heat was removed 
after the solution was refluxed for 30 minutes.169 Final Au-NPs were 
synthesised from the seed solution with citrate reduction. Hydrogen 
tetrachloroaurate (0.5 mL, 11 mM) was added to distilled water (32 mL) and the 
solution brought to reflux. The prepared seed Au-NPs solution (0.3 mL) was 
added followed closely by 1% solution of trisodium citrate (0.17 mL). The heat 
was removed after 10 minutes and the solution was allowed to cool with 
stirring.169  
2.2.7.4 Corticosteroids (CSs) solution  
Aqueous solution of each of corticosteroids (BUD, BDP, FLU and MOM) was 
prepared in the concentration near their solubility in water (0.05, 0.003, 0.001 
and 0.0015 mM respectively). 1 mL of each solution was then mixed with 0.5 
mL of the prepared Ag or Au-NPs and 0.5 mL of water (S1). Another solution 
prepared by mixing 0.5 mL of the prepared Ag or Au-NPs with 0.5 mL of SCD 
solution (0.125 mM) and the resulting solution was added to 1 mL of 
corticosteroid solution (S2). Both prepared solutions had the same Ag or Au 
NPs concentration and the same corticosteroid concentration with the second 
contains SCD. Blank solution was prepared by mixing 1 mL of corticosteroid 
solution with 1 mL of water to produce the same concentration of the compound 
as the above prepared solutions (S3). All the prepared solutions are presented 
in Table 2.8. 
Table 2.8: Different corticosteroids solutions prepared by mixing with Ag or Au NPs and SCD. 
S1 S2 S3 
1 mL of CS solution 1 mL of CS solution 1 mL of CS solution 
0.5 mL of Ag or Au-NPs 0.5 mL of Ag or Au-NPs 1 mL of water 
0.5 mL of water 0.5 mL of SCD /// 
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The prepared Ag-NPs were centrifuged by placing in a 1.5 mL centrifuged tube 
for 30 min at 3000 g, 1.25 mL of supernatant was removed and the NPs were 
resuspended in water to 1.5 mL 170. The Au-NPs were centrifuged by placing in 
a 1.5 mL centrifuged tube for 20 min at 7000 g, 1.25 mL of supernatant was 
removed and the NPs were resuspended in water to 1.5 mL 171. Then both 
centrifuged solutions of Ag and Au-NPs were mixed with the corticosteroid 
solution and the same procedure was followed as in the case of uncentrifuged 
solutions. All the solutions were analysed by Raman spectroscopy. 
2.3 Instrumentation  
2.3.1 UV-Vis spectroscopy 
2.3.1.1 UV-Vis analysis of the complexation 
The samples are analysed in a glass cuvette and positioned in the Varian 
CARY 50 Probe UV-Visible spectroscopy using Cary WinUv software. The 
blank was also run between samples, which was the solvent being used for the 
preparation.  
2.3.1.2 UV-Vis analysis of Ag/Au NPs 
The Au and Ag NPs solutions were analysed in a glass cuvette and positioned 
in the Varian CARY 50 Probe UV-Visible spectroscopy using Cary WinUv 
software. The blank was also run which was the solvent being used for the 
preparation (water). The absorption spectra for both Au and Ag-NPs solutions 
were recorded in the range of 300-900 nm.   
2.3.2 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-
OES) analysis of Ag/Au NPs 
The Ag and Au-NPs were prepared according to the method specified in the 
section 2.2.7.2 and 2.2.7.3. Equal volumes of the uncentrifuged Ag-NPs 
solution and nitric acid (69 %) were mixed. Similarly, equal volumes of the 
centrifuged Ag-NPs solution and nitric acid (69 %) were mixed and then both 
uncentrifuged and centrifuged solutions were taken for the analysis. The 
addition of the nitric acid is to dissolve the Ag-NPs and convert them back to the 
silver nitrate.172 Both uncentrifuged and centrifuged Au-NPs solutions were 
taken directly for the analysis. The test samples were prepared for analysis by 
ICP-OES (Thermo Fisher iCAP 6500 Duo ICP-OES) by diluting 0.1 mL in 2 mL 
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of nitric acid with 25 µL of Rhodium (internal standard). The samples were then 
made up to the volume 25 mL with deionised water. Clear solutions, free from 
particulates were generated that were taken for the analysis. 
2.3.3 Dynamic Light Scattering (DLS) analysis of Ag/Au NPs 
DLS measurements were performed at 25° C using a Malvern ZS ZEN 3600 
system (Malvern instruments GmbH, UK) equipped with a red laser (633 nm). 
The Au and Ag-NPs solutions were put in the cuvette that was then positioned 
in the instrument where the laser light was directed and focused on the cuvette. 
The measurements were performed with 3 runs of 10 measurements. The 
signals were collected by a photodiode detector and processed by Malvern 
Zetasizer nanoapplication software.  
2.3.4 Transmission Electron Microscopy (TEM) analysis of Ag/Au NPs 
Transmission electron microscopy (TEM) measurements were performed at an 
acceleration voltage of 80 kV. A drop of Au and Ag-NPs solutions were placed 
onto carbon coated 200 mesh copper grids and allowed to dry overnight prior to 
the measurements. Mean particle sizes were determined on the basis of the 
TEM images taken by measuring 100 particles per sample. 
2.3.5 NMR spectroscopy 
For studying the complex formation in different solvents, the prepared solution 
of the molecule and CD in the desired solvent is transferred to a 5 mm NMR 
tube which was then inserted into the JEOL 600 MHz NMR spectroscopy. A co-
axial NMR tube setup (Wilmad Labglass, NJ, USA) was prepared by inserting a 
co-axial capillary tube within the standard 5 mm NMR tube for the purpose of 
adding a physically isolated reference material. The studied solution was added 
to the standard NMR tube while the reference solution (CHCl3 in CD3CN) was 
added to the inside capillary tube. The co-axial tube was then inserted into the 
JEOL 600 MHz NMR spectroscopy. The sample was locked and shimmed 
using PFGs (D2O) and a standard 1H NMR spectrum collected. Further 1H 
experiment was performed using a presaturation method by suppressed solvent 
at 4.67 ppm (D2O) and at 2.80 ppm (CH3CN residual) using different attenuation 
at (30,40), (40,40), (50,40), (30,50), (40,50), (50,50), (60,50), (44,50), (46,50), 
(45,50) dB. The experiment was repeated with an attenuation value of (45,50) 
dB at 4.67 ppm (D2O) and at 2.80 ppm (CH3CN residual) respectively and the 
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spectra were obtained using 2048 scans. The study of the complexation in 
HPFP was performed by suppression of HPFP signal at 4.38 ppm and residual 
CH3CN signal at 2.15 ppm using a power of 45 and 50 dB respectively with long 
acquisition times (2048 scans). The study of the pure R-enantiomer of BUD was 
performed on 400 MHz NMR using the same pre-saturation suppression 
parameters used for the racemic mixture and the spectra were collected with 
equivalent acquisition times (2048 scans). NMR spectra were acquired over a 
10 ppm spectral width using 65 K data points, giving a spectral resolution of 
0.00015 ppm. These acquisition parameters allowed us to extract chemical shift 
values for the titration experiments with accuracy to the 4th decimal place and 
track the small displacements observed in the experiments. 
2.3.6 FT-IR spectroscopy 
Samples of physical mixtures and complexes of budesonide and (βCD, TRIMEB 
and DIMEB) were prepared as potassium bromide (KBr) discs by taking about 2 
mg of sample in an agate mortar and pestle and about 350 mg of KBr and grind 
them into a fine powder. The resultant powder was then pressed to form KBr 
disc using a SpecAc hydraulic press and die set under 10 tonne pressure. The 
disc was then transferred to be analysed by the Digilab UMA 400 FT-IR using a 
transmission mode with 64 scans and 2 cm-1 spectral resolution in the range of 
400-4000 cm-1 with an acquisition of a background spectrum that was 
subtracted from the sample spectra using the Digilab software. 
2.3.7 Raman spectroscopy 
Samples of physical mixtures and complexes of budesonide and (βCD, TRIMEB 
and DIMEB) were put on aluminium slides for Raman analysis using 50x 
objective lens of the Renishaw InVia Raman microscope which was calibrated 
prior starting work using the internal silicon reference for wavenumber shift with 
manual adjustment to 520.0 cm-1. Spectra were collected over the range 100-
3200 cm-1 using 785 nm high powered diode laser at 100% power with 10 
seconds exposure time and 10 accumulations. 
SERS studies were performed using foil covered glass slides, placing a drop of 
the sample on the slide and using the 20x lens to collect the spectrum. The 
analysis was performed using 100 % laser power and 10 s exposure time with 1 
accumulation. Raw data were pre-processed with Bruker OPUS 7.5 before 
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plotting with Origin 2018. Baselines were corrected with concave rubber band 
method over 64 baseline points and 10 iterations; spectra were normalised in 
the range 3200-300 cm-1 before plotting.  
3 Development of UV-Vis and NMR methods for the study of 
host:guest complexes using vanillin and βCD 
NMR spectroscopy is one of the techniques that has been extensively used for 
this purpose, as part of method development, it is valuable to repeat some 
published work to ensure the reproducibility of the methods and results obtained 
from the analytical instrumentation. Also, to understand the determination of the 
stoichiometry and the apparent stability, as they both depend on the chemical 
shift differences between the pure and the complex compound with CD. Vanillin 
has been studied by NMR for complexation with CD and was chosen as a 
representative model for the method development.173 It has a simple structure 
(Figure 3.1) and has a large chemical shift difference between its free and 
complexed forms so that it is easier to understand the determination of the 
stability constant. Vanillin was also examined by UV-Vis spectroscopy as 
another method to study the complexation. 
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H H
O
OH
CH3
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Figure 3.1: Structure of vanillin 
 
3.1 Complexation study of vanillin and βCD in D2O by NMR  
The stoichiometry was determined using continuous variation method as 
described in Section 2.2.3.1. The results are presented in Table 3.1 where the 
chemical shift was recorded in Hz (very small shift were observed in the case of 
taking shift at ppm) taking 4.75 ppm for the residual water as reference. The 
calculation was based on the shift occurred at H5 proton of βCD (the same 
proton was taken in the literature) which had a considerable shift compared to 
the other hydrogens (Figure 3.2). The chemical shift difference between pure 
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vanillin and complex vanillin (∆δobs) was calculated by taking the difference 
between pure vanillin (in the absence of βCD, δfree) and complex vanillin (in the 
presence of βCD, δcomplex). 
Table 3.1: Results of 1H NMR analysis for the determination of stoichiometry between vanillin and 
βCD  
[βCD] (mM) R δcomplex (Hz) ∆δobs (δfree - δcomplex) Hz ∆δ[βCD] 
0 0 0 0 0 
1 0.1 1495.9 42.4 42.4 
2 0.2 1501 37.3 74.6 
3 0.3 1505.5 32.8 98.4 
4 0.4 1509.5 28.8 115.2 
5 0.5 1513.6 24.7 123.5 
6 0.6 1519.1 19.2 115.2 
7 0.7 1526.2 12.1 84.7 
8 0.8 1530.8 7.5 60 
9 0.9 1534.3 4 36 
10 1 1538.3 0 0 
δfree = 1538.3 Hz    
 
 
Figure 3.2: Partial 1H NMR spectrum of (a) βCD (10 mM), (b) 5 mM of βCD and 5 mM of vanillin. 
The stoichiometry was determined by plotting r which was the ratio of 
[βCD]/[van]+[βCD] versus ∆δ * [βCD] (Figure 3.3) which clearly showed that the 
highest value of r was at 0.5, indicating the stoichiometry ratio of the complex 
was 1:1 and was consistent with those reported by Pirnau et al.173 
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Figure 3.3: Determination of  the stoichiometry of the complex between vanillin and βCD by 1H 
NMR based on H5 proton of βCD 
The stability constant was determined by keeping the vanillin concentration 
constant while increasing the concentration of βCD to form different solutions of 
constant vanillin concentration with different concentrations of βCD (Section 
2.2.4.1). The stability constant of the complex was calculated according to 
Hildebrand-Benesi Equation:174 
1
∆δobs
= 
1
[CD]K ∆δmax
+ 
1
∆δmax
 Equation 3.1 
 
Where Δδobs is the difference in the chemical shift between free vanillin and the 
observed value for a given ratio, and Δδmax is the chemical shift difference 
between free vanillin and the pure complex. The [CD] and K are the 
concentration of βCD and association constant respectively. The stability 
constant was determined depending on the shift at Hb proton of vanillin (Figure 
3.4). The results are presented in Table 3.2. 
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Figure 3.4: Structure of vanillin 
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Table 3.2: Results of the determination of the association constant between vanillin and βCD using 
1H NMR 
βCD  
(mM)  
1/βCD 
 (mM-1) 
Exp. 1 (δfree = 2805.5 Hz) Exp. 2 (δfree = 2809.1 Hz) 
δcomplex ∆δobs 1/∆δobs δcomplex ∆δobs 1/∆δobs 
12 0.083 2818.2 12.7 0.079 2820.2 11.1 0.090 
14 0.071 2821.0 15.5 0.065 2822.8 13.7 0.073 
15 0.067 2822.7 17.2 0.058 2824.7 15.6 0.064 
16 0.063 2824.9 19.4 0.052 2826.3 17.2 0.058 
∆δobs (δcomplex - δfree) 
The stability constant can be calculated from the slope and the intercept of the 
straight line equation of the NMR titration (Figures 3.5).  
 
Figure 3.5: Reciprocal plot for the determination of association constant between vanillin and βCD 
by 1H NMR.  
A good linear relationship was obtained from the two experiments which 
indicated the stoichiometry of the complex was 1:1 and the mean stability 
constant was 24 M-1.  
3.2 Complexation study of vanillin and βCD in water by UV-Vis 
spectroscopy 
The vanillin solution without the βCD (at 0.05 mM) was first run in the scan 
range of 200-350 nm to determine the λmax of vanillin in the presence of water 
as a solvent and peaks were found at 230, 280 and 310 nm. The λmax at 280 nm 
was chosen for the analysis of vanillin in this study. The solutions were 
prepared based on continuous variation method (Section 2.2.1.1) and their 
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absorbance were measured at 280 nm. The absorbance (A) was calculated by 
taking the differences in the absorbance between free vanillin (without βCD) A0, 
and absorbance of each solution of βCD-complexed vanillin (Ameasured), and the 
results are presented in Table 3.3. 
Table 3.3: Results of the determination of the stoichiometry between vanillin and βCD using UV-Vis 
spectroscopy. 
Vanillin [van]*10-2  
(mM) 
r Ameasured A A[van] 
5 1 0.52 0 0 
4.5 0.9 0.449 0.071 0.320 
4 0.8 0.39 0.13 0.520 
3.5 0.7 0.335 0.185 0.648 
3 0.6 0.284 0.236 0.708 
2.5 0.5 0.228 0.292 0.730 
2 0.4 0.189 0.331 0.662 
1.5 0.3 0.147 0.373 0.560 
1 0.2 0.09 0.43 0.430 
0.5 0.1 0.051 0.469 0.235 
0 0 0 0 0 
A0 = 0.520     
 
The stoichiometry was determined by plotting r which was the ratio of 
[van]/[van]+[βCD] versus A* [van] ( Figure 3.6) and it has been found that the 
maximum r was 0.5 which revealed 1:1 stoichiometry ratio of the complexation. 
 
Figure 3.6: Determination of  the stoichiometry of the complex between vanillin and βCD based on 
the absorbance at 280 nm using UV-Vis spectroscopy. 
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To determine the association constant, the vanillin concentration was kept 
constant at 0.05 mM and βCD was added at 2, 4, 6 and 8 mM as described in 
Section 2.2.2.1. The experiment was repeated three times and the results are 
presented in the Table 3.4. 
Table 3.4: Results of the determination of the association constant between vanillin and  βCD 
added at 0, 2, 4, 6 and 8 mM in H2O using UV-Vis spectroscopy. 
βCD (mM) 
Absorbance at 280 nm 
Mean SD % CV 
1 2 3 
0 0.477 0.476 0.480 0.478 0.002 0.436 
2 0.500 0.504 0.508 0.504 0.004 0.794 
4 0.513 0.520 0.524 0.519 0.006 1.073 
6 0.521 0.530 0.534 0.528 0.007 1.260 
8 0.529 0.538 0.543 0.537 0.007 1.322 
 
The stability constant of the complex formed between vanillin and βCD was 
determined by plotting 1/ [βCD] versus 1/A according to Hildebrand-Benesi 
Equation 175:  
1
ΔA
=
1
Δε [G]
0
K[CD]
+ 
1
Δε [G]
0
 Equation 3.2 
 
Where; ΔA is the absorbance difference between the absorbance of free vanillin 
A0 and complex vanillin (Ameasured). [G]0 and K are the initial vanillin 
concentration and stability constant while Δε is the molar absorptivity difference 
between the free and complex vanillin and [CD] is the βCD concentration. It can 
be seen clearly the absorbance of vanillin was increased as the concentration of 
βCD was increased (hyperchromic effect) with small hypsochromic shift to the 
maximum at 280 nm (Figure 3.7).  
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Figure 3.7: UV spectra of vanillin with βCD concentration at 1) 0, 2) 2, 3) 4, 4) 6 and 5) 8 mM 
The results for the three experiments are shown in Table 3.5 and the reciprocal 
plot to determine the stability constant is shown in Figure 3.8. 
Table 3.5: Results of the determination of the association constant between vanillin and βCD added 
at 2, 4, 6 and 8 mM in H2O using UV-Vis spectroscopy. 
1/CD  
mM-1 
Exp. 1 (A0 = 0.477) Exp. 2 (A0 = 0.476) Exp. 3 (A0 = 0.480) 
Mean 
A* A 1/A A* A 1/A A*  A 1/A 
0.5 0.5 0.023 43.5 0.504 0.028 35.7 0.508 0.028 35.7 38.3 
0.25 0.513 0.036 27.8 0.52 0.044 22.7 0.524 0.044 22.7 24.4 
0.17 0.521 0.044 22.7 0.53 0.054 18.5 0.534 0.054 18.5 19.9 
0.13 0.529 0.052 19.2 0.538 0.062 16.1 0.543 0.063 15.9 17.1 
A*= Ameasured, A = A* - A0        
 
 
Figure 3.8: Reciprocal plot for the association constant determination between vanillin and βCD by 
UV-Vis spectroscopy (Mean ± SD, n=3). 
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A good linear relationship was obtained which demonstrated that the 
stoichiometry of the complex formed between vanillin and βCD is 1:1. The mean 
K value was calculated from the slope and the intercept as mentioned above 
and was found to be 184 M-1.  
3.3 Discussion 
The method of continuous variation applied to study the stoichiometry and the 
titration method to calculate the stability constant based on Hildebrand-Benesi 
equation showed good results from both techniques used. This indicated that 
both methods can be applied as an additional approach to study the inclusion 
complex between budesonide and other corticosteroids with cyclodextrins. 
  
 50 
 
 
4 Host:guest Interactions in conventional solvents using UV-
Vis and NMR spectroscopy 
The main aim of this work is to study complexation of corticosteroids and CDs in 
HFA based solvent systems. Our first step, has been to study the complexation 
of BUD (as a representative model to the other corticosteroids) in conventional 
solvents using UV-Vis methods and in deuterated solvents using NMR methods 
to obtain comprehensive data on the complexation of BUD in three derivatised 
CDs in a range of different solvent systems. The three solvents were chosen to 
investigate the effect of differing solvent polarity on the complexation. CDCl3 is 
used as a relatively non-polar solvent, with CD3CN and MeOD being polar 
aprotic and protic solvents respectively. The complexation of BUD was also 
studied in D2O to investigate the behaviour in polar solvents, though significant 
challenges with this system were encountered with the limited solubility of BUD 
in D2O, and these method development challenges are also discussed in this 
Chapter. 
4.1 Complexation study of BUD and βCD/TRIMEB by UV-Vis 
spectroscopy  
The complexation of BUD and βCD/TRIMEB was investigated in a mixture of 
EtOH/H2O and in water alone. BUD solution in water was prepared at a 
concentration near the previously determined solubility (23.5 µg/mL).52 The 
study relies on the addition of different concentrations of cyclodextrins to a fixed 
concentration of budesonide followed by the determination of the absorbances 
of each solution (at a fixed wavelength) and compared to that of the original 
budesonide solution (without the addition of cyclodextrins). The complex 
formation was confirmed by the existence of either a hyperchromic or 
bathochromic shift at λmax of budesonide.  
4.1.1 Complexation of BUD and βCD in EtOH: H2O and H2O 
The complexation between BUD and βCD was investigated in 50:50 mixture of 
EtOH/H2O and in water by preparing different solutions as described in Section 
2.2.2.2. The BUD solution without βCD (at 0.04 mM) was first run in the scan 
range 200-350 nm to determine its λmax which was found at 246 nm in 
EtOH/H2O and in water. All solutions were measured at 246 nm.  
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The results showed that BUD had a hyperchromic shift as its absorbance was 
increased with the increasing βCD concentration. No significant appearance of 
either hypsochromic or bathochromic shifts to the maximum at 246 nm (Figure 
4.1). The change in the absorption spectrum of the guest molecule as its 
chromophore was transferred from a polar medium (EtOH/H2O) to a non-polar 
CD cavity is a result of the inclusion complex forming in solution. This caused 
disconcertion of guest electronic energy levels as a result of the interaction of 
guest with the host molecule directly or by elimination of water molecules or 
both together.128 
 
Figure 4.1: UV spectra of budesonide with βCD concentration at 1) 0, 2) 2, 3) 4, 4) 6 and 5) 8 mM in 
EtOH/H2O (50:50) solvent. 
The results and the calculation of the stability constant of the complexation in 
(EtOH:H2O) and in water are presented in Tables 4.1/4.2 and 4.3/4.4 
respectively with the reciprocal plots are shown in Figure 4.2. 
Table 4.1: Results of the complexation between budesonide and βCD added at  0, 2, 4, 6 and 8 mM 
in EtOH/H2O (50:50) using UV-Vis spectroscopy. 
CD (mM) 
Absorbance at 246 nm 
Mean SD % CV 
1 2 3 
0 0.573 0.568 0.575 0.572 0.004 0.630 
2 0.583 0.579 0.586 0.583 0.004 0.603 
4 0.597 0.600 0.603 0.600 0.003 0.5 
6 0.618 0.625 0.627 0.623 0.005 0.758 
8 0.64 0.635 0.655 0.643 0.01 1.618 
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Table 4.2: Results of the stability constant determination between budesonide and βCD added at  2, 
4, 6 and 8 mM in EtOH/H2O (50:50) using UV-Vis spectroscopy. 
1/CD 
mM-1  
Exp. 1 (A0 = 0.573) Exp. 2 (A0 = 0.568) Exp. 3 (A0 = 0.575) 
Mean 
A* A 1/A A* A 1/A A*  A 1/A 
0.5 0.583 0.01 100 0.579 0.011 90.9 0.586 0.011 90.9 93.9 
0.25 0.597 0.024 41.8 0.600 0.032 31.3 0.603 0.028 35.7 36.2 
0.17 0.618 0.045 22.2 0.625 0.057 17.5 0.627 0.052 19.2 19.7 
0.13 0.64 0.067 14.9 0.635 0.067 14.9 0.655 0.08 12.5 14.1 
A* = Ameasured, A = A* - A0       
 
Table 4.3: Results of the complexation between budesonide and βCD added at  0, 2, 3, 4, 5 and 7 
mM in H2O using UV-Vis spectroscopy. 
CD (mM) 
Absorbance at 246 nm 
Mean SD % CV 
1 2 3 
0 0.141 0.146 0.138 0.142 0.004 2.853 
2 0.147 0.152 0.144 0.148 0.004 2.737 
3 0.151 0.156 0.148 0.152 0.004 2.665 
4 0.156 0.162 0.154 0.157 0.004 2.646 
5 0.165 0.17 0.163 0.166 0.004 2.172 
7 0.192 0.197 0.187 0.192 0.005 2.604 
 
Table 4.4: Results of the stability constant determination between budesonide and βCD added at  2, 
3, 4, 5 and 7 mM in H2O using UV-Vis spectroscopy. 
1/CD  
mM-1 
Exp. 1 (A0 = 0.141) Exp. 2 (A0 = 0.146) Exp. 3 (A0 = 0.138) 
Mean 
A* A 1/A A* A 1/A A*  A 1/A 
0.50 0.147 0.006 167 0.152 0.006 167 0.144 0.006 167 167 
0.33 0.151 0.01 100 0.156 0.01 100 0.148 0.01 100 100 
0.25 0.156 0.015 66.7 0.162 0.016 62.5 0.154 0.016 62.5 63.9 
0.20 0.165 0.024 41.7 0.17 0.024 41.7 0.163 0.025 40 41.1 
0.14 0.192 0.051 19.6 0.197 0.051 19.6 0.187 0.049 20.4 19.9 
A* = Ameasured, A = A* - A0 
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Figure 4.2: Reciprocal plot for the determination of association constant between budesonide and 
βCD in EtOH/H2O (50:50) and H2O by UV-Vis spectroscopy (Mean ± SD, n=3). 
It can be seen from the plots that a good linear relationship was obtained which 
indicated that the stoichiometry of the complex formed between budesonide and 
βCD was 1:1. The mean K values of the complexation in EtOH/H2O and in 
water were calculated from the slope and the intercept and they were found to 
be 72 and 94 M-1 respectively. The stoichiometry of the complex in EtOH/H2O 
and in water was confirmed by the continuous variation method where both 
BUD and βCD are prepared as stock solutions. Then different ratios were taken 
from both solutions to form different solutions of constant concentration with 
constant volume (see Section 2.2.1.2). The results are presented in Tables 4.5 
and 4.6. 
Table 4.5: Results of the determination of the stoichiometry between budesonide and βCD in 
EtOH/H2O (50:50) using UV-Vis spectroscopy. 
[BUD]*10-2  (mM)  r Ameasured A (Ameasured - A0) A[BUD] 
4 1 0.586 0 0 
3.6 0.9 0.517 0.069 0.248 
3.2 0.8 0.46 0.126 0.403 
2.8 0.7 0.403 0.183 0.512 
2.4 0.6 0.341 0.245 0.588 
2 0.5 0.287 0.299 0.598 
1.6 0.4 0.232 0.354 0.566 
1.2 0.3 0.174 0.412 0.494 
0.8 0.2 0.117 0.469 0.375 
0.4 0.1 0.067 0.519 0.208 
0 0 0 0 0 
A0 = 0.586     
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Table 4.6: Results of the determination of the stoichiometry between budesonide and βCD in H2O 
using UV-Vis spectroscopy. 
[BUD]*10-2  (mM) r Ameasured A (Ameasured - A0) A[BUD] 
5 1 0.901 0 0 
4.5 0.9 0.772 0.129 0.581 
4 0.8 0.67 0.231 0.924 
3.5 0.7 0.575 0.326 1.141 
3 0.6 0.48 0.421 1.263 
2.5 0.5 0.37 0.531 1.328 
2 0.4 0.302 0.599 1.198 
1.5 0.3 0.243 0.658 0.987 
1 0.2 0.158 0.743 0.743 
0.5 0.1 0.076 0.825 0.413 
0 0 0 0 0 
A0 = 0.901     
 
The stoichiometry was determined by plotting r which is the ratio of 
[BUD]/[BUD]+[βCD] versus A* [BUD] (Figure 4.3), and it has been found that 
the highest r value was 0.5 which corresponds to 1:1 stoichiometric ratio of the 
complex in both co-solvent system and in water. 
 
Figure 4.3: Determination of  the stoichiometry of the complex between budesonide and βCD in 
EtOH/H2O (50:50) and H2O based on the absorbance at 246 nm using UV-Vis spectroscopy. 
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4.1.2 Complexation of BUD and TRIMEB in EtOH: H2O and H2O 
The complexation between BUD and TRIMEB was studied in 50:50 (EtOH:H2O) 
and in water where the prepared solutions (see Section 2.2.2.3) were measured 
at 246 nm. The results of the triplicate experiments and the calculation of the 
stability constant in (EtOH:H2O) and in water are presented in Tables 4.7/4.8 
and 4.9/4.10 respectively with the reciprocal plots being shown in Figure 4.4. 
Table 4.7: Results of the complexation and the stability constant determination between 
budesonide and TRIMEB added at 0, 0.4, 0.6, 0.8, 1 and 1.4 mM in EtOH/H2O (50:50) using UV-Vis 
spectroscopy. 
CD (mM) 
Absorbance at 246 nm 
Mean SD % CV 
1 2 3 
0 0.577 0.571 0.576 0.575 0.003 0.559 
0.4 0.589 0.584 0.587 0.587 0.003 0.429 
0.6 0.595 0.59 0.591 0.592 0.003 0.447 
0.8 0.601 0.596 0.595 0.597 0.003 0.538 
1 0.606 0.601 0.6 0.602 0.003 0.534 
1.4 0.613 0.613 0.612 0.613 0.001 0.094 
 
Table 4.8: Results of the stability constant determination between budesonide and TRIMEB added 
at 0.4, 0.6, 0.8, 1 and 1.4 mM in EtOH/H2O (50:50) using UV-Vis spectroscopy. 
1/CD  
mM-1 
Exp. 1 (A0 = 0.577) Exp. 2 (A0 = 0.571) Exp. 3 (A0 = 0.576) 
Mean 
A* A 1/A A* A 1/A A*  A 1/A 
2.5 0.589 0.012 83.3 0.584 0.013 76.9 0.587 0.011 90.9 83.7 
1.7 0.595 0.018 55.6 0.59 0.019 52.6 0.591 0.015 66.7 58.3 
1.3 0.601 0.024 41.7 0.596 0.025 40.0 0.595 0.019 52.6 44.8 
1 0.606 0.029 34.5 0.601 0.03 33.3 0.6 0.024 41.7 36.5 
0.7 0.613 0.036 27.8 0.613 0.042 23.8 0.612 0.036 27.8 26.5 
A* = Ameasured, A = A* - A0        
 
Table 4.9: Results of the complexation and the stability constant determination between 
budesonide and TRIMEB added at 0, 0.4, 0.6, 0.8, 1 and 1.4 mM in H2O using UV-Vis spectroscopy. 
CD (mM) 
Absorbance at 246 nm 
Mean SD % CV 
1 2 3 
0 0.178 0.172 0.169 0.173 0.005 2.649 
0.4 0.2 0.194 0.191 0.195 0.005 2.350 
0.6 0.213 0.208 0.204 0.208 0.005 2.164 
0.8 0.226 0.221 0.218 0.222 0.004 1.823 
1 0.241 0.235 0.233 0.236 0.004 1.762 
1.4 0.278 0.27 0.266 0.271 0.006 2.252 
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Table 4.10: Results of the stability constant determination between budesonide and TRIMEB added 
at 0.4, 0.6, 0.8, 1 and 1.4 mM in H2O using UV-Vis spectroscopy. 
1/CD  
mM-1 
Exp. 1 (A0 = 0.178) Exp. 2 (A0 = 0.172) Exp. 3 (A0 = 0.169) 
Mean 
A* A 1/A A* A 1/A A*  A 1/A 
2.5 0.2 0.022 45.5 0.194 0.022 45.5 0.191 0.022 45.5 45.5 
1.7 0.213 0.035 28.6 0.208 0.036 27.8 0.204 0.035 28.6 28.3 
1.3 0.226 0.048 20.8 0.221 0.049 20.4 0.218 0.049 20.4 20.6 
1 0.241 0.063 15.9 0.235 0.063 15.9 0.233 0.064 15.6 15.8 
0.7 0.278 0.1 10 0.27 0.098 10.2 0.266 0.097 10.3 10.2 
A* = Ameasured, A = A* - A0        
 
 
Figure 4.4: Reciprocal plot for the determination of association constant between budesonide and 
TRIMEB in EtOH/H2O (50:50) and H2O by UV-Vis spectroscopy (Mean ± SD, n=3). 
 
The reciprocal plots showed a good linear relationship indicating that the 
inclusion complex formed had a stoichiometry of 1:1 in both solvent systems. 
The mean K values were calculated from the slope and the intercept and they 
were found to be 138 and 205 M-1 in EtOH/H2O and in water respectively. The 
stoichiometry of the complex in EtOH/H2O and in water was verified by Job’s 
plot of continuous variation method (Section 2.2.1.2) as shown in Tables 4.11 
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Table 4.11: Results of the determination of the stoichiometry between budesonide and TRIMEB in 
EtOH/H2O (50:50) using UV-Vis spectroscopy. 
[BUD]*10-2  (mM)  r Ameasured A (Ameasured - A0) A[BUD] 
4 1 0.568 0 0 
3.6 0.9 0.527 0.041 0.148 
3.2 0.8 0.467 0.101 0.323 
2.8 0.7 0.402 0.166 0.465 
2.4 0.6 0.337 0.231 0.554 
2 0.5 0.27 0.298 0.596 
1.6 0.4 0.227 0.341 0.546 
1.2 0.3 0.183 0.385 0.462 
0.8 0.2 0.129 0.439 0.351 
0.4 0.1 0.07 0.498 0.199 
0 0 0 0 0 
A0 = 0.568 
    
 
Table 4.12: Results of the determination of the stoichiometry between budesonide and TRIMEB in 
H2O using UV-Vis spectroscopy. 
[BUD]*10-2  (mM) r Ameasured A (Ameasured - A0) A[BUD] 
5 1 0.835 0 0 
4.5 0.9 0.74 0.095 0.428 
4 0.8 0.657 0.178 0.712 
3.5 0.7 0.585 0.25 0.875 
3 0.6 0.506 0.329 0.987 
2.5 0.5 0.415 0.42 1.050 
2 0.4 0.345 0.49 0.980 
1.5 0.3 0.253 0.582 0.873 
1 0.2 0.166 0.669 0.669 
0.5 0.1 0.092 0.743 0.372 
0 0 0 0 0 
A0 = 0.835     
 
The Job’s plots showed the maximum value of r was 0.5 which indicated the 
inclusion complex had stoichiometric ratio of 1:1 in both in water and in 
EtOH/H2O solvent system (Figure 4.5). 
 58 
 
 
 
Figure 4.5: Determination of  the stoichiometry of the complex between budesonide and TRIMEB in 
EtOH/H2O (50:50) and H2O based on the absorbance at 246 nm using UV-Vis spectroscopy. 
 
4.2 Complexation study of BUD and DIMEB/TRIMEB by NMR 
The complexation between BUD and DIMEB/TRIMEB was investigated in the 
three solvents; CD3CN, CDCl3 and MeOD using 600 MHz NMR (Section 
2.2.4.2). The studies of the complexation with βCD in organic solvents were not 
assessed because of its insolubility in many organic solvents.  
4.2.1 Complexation of BUD and DIMEB/TRIMEB in CD3CN 
It was found that there was no chemical shift differences observed for BUD 
(Figure 4.6) with TRIMEB and DIMEB using CD3CN as solvent indicating no 
complex formed (Tables 4.13 and 4.14).  
 
Figure 4.6: Chemical structure of budesonide 
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Table 4.13: Results of the chemical shift of budesonide and TRIMEB added at 0, 1, 2, 4, 6, and 8 mM 
in CD3CN using 1H NMR. 
Proton 
position 
TRIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.8848 0.8852 0.8848 0.8848 0.8847 0.8843 
H-C19 1.3898 1.3902 1.3898 1.3898 1.3992 1.3894 
H-C4 5.8968 5.8961 5.8957 5.8963 5.8962 5.8964 
H-C2 6.1491 6.1509 6.1505 6.1505 6.1510 6.1512 
H-C1 7.2695 7.2709 7.2700 7.2700 7.2705 7.2695 
 
Table 4.14: Results of the chemical shift of budesonide and DIMEB added at 0, 1, 2, 4, 6, and 8 mM 
in CD3CN using 1H NMR. 
Proton 
position 
DIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.8848 0.8854 0.8859 0.8861 0.8870 0.8871 
H-C19 1.3898 1.3909 1.3911 1.3921 1.3927 1.3935 
H-C4 5.8968 5.8962 5.897 5.8997 5.9014 5.9015 
H-C2 6.1491 6.1499 6.1496 6.1499 6.1499 6.1494 
H-C1 7.2695 7.2700 7.2702 7.2705 7.2705 7.2717 
 
4.2.2 Complexation of BUD and DIMEB/TRIMEB in CDCl3 
The same experiments were repeated for BUD with both DIMEB and TRIMEB 
in CDCl3. The results showed fewer chemical shift differences for BUD (Figure 
4.6) with TRIMEB (Table 4.15) compared to that with DIMEB (Table 4.16).  
Table 4.15: Results of the chemical shift of budesonide and TRIMEB added at 0, 1, 2, 4, 6, and 8 mM 
in CDCl3 using 1H NMR. 
Proton 
position 
TRIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.9808 0.9804 0.9799 0.9784 0.9773 0.9766 
H-C19 1.4338 1.4334 1.4328 1.4315 1.4307 1.4295 
H-C4 6.0220 6.0217 6.0213 6.0204 6.0196 6.0179 
H-C2 6.2833 6.2851 6.2846 6.2833 6.2824 6.2813 
H-C1 7.2304 7.2271 7.2260 7.2258 7.2249 7.2238 
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Table 4.16: Results of the chemical shift of budesonide and DIMEB added at 0, 1, 2, 4, 6, and 8 mM 
in CDCl3 using 1H NMR. 
Proton 
position 
DIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.9808 0.9804 0.9799 0.9787 0.9770 0.975 
H-C19 1.4338 1.4334 1.4328 1.4316 1.4305 1.4285 
H-C4 6.0220 6.0217 6.0214 6.0203 6.0186 6.0167 
H-C2 6.2833 6.2847 6.2840 6.2828 6.2811 6.2796 
H-C1 7.2304 7.2267 7.2265 7.2265 7.2248 7.2249 
 
The K values were determined from the reciprocal plots between BUD and 
TRIMEB/DIMEB as shown in Figures 4.7 and 4.8 respectively based on the 
chemical shift differences of protons (H-C19 and H-C4). The values were found 
to be 64 and 73 M-1 with TRIMEB and DIMEB respectively (Table 4.17).  
 
Figure 4.7: Reciprocal plot for the determination of association constant between budesonide and 
TRIMEB in CDCl3 by 1H NMR based on the chemical shift of H-C4 and H-C19 at 6.022 and 1.4338 ppm 
respectively. 
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Figure 4.8: Reciprocal plot for the determination of association constant between budesonide and 
DIMEB in CDCl3 by 1H NMR based on the chemical shift of H-C4 and H-C19 at 6.022 and 1.4338 ppm 
respectively. 
 
Table 4.17: The calculated K for the complex formed between budesonide and (TRIMEB, DIMEB) in 
CDCl3 
Host 
Stability constant, K (M-1) 
H-C19 H-C4 
TRIMEB 63 64 
DIMEB 70 75 
 
4.2.3 Complexation of BUD and DIMEB/TRIMEB in MeOD 
The complexation between BUD and TRIMEB/DIMEB was also investigated in 
MeOD and the results showed fewer chemical shifts differences for BUD 
(Figure 4.6) with TRIMEB (Table 4.18) compared to that with DIMEB (Table 
4.19). 
Table 4.18: results of the chemical shift of budesonide and TRIMEB added at 0, 1, 2, 4, 6, and 8 mM 
in MeOD using 1H NMR. 
Proton 
position 
TRIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.9493 0.9499 0.9508 0.9536 0.9558 0.9564 
H-C19 1.4600 1.4621 1.4637 1.4670 1.4687 1.4706 
H-C4 5.9860 5.9885 5.9908 5.9940 5.9963 5.9988 
H-C2 6.2408 6.2410 6.2416 6.2454 6.2471 6.2496 
H-C1 7.4204 7.4206 7.4218 7.4238 7.4255 7.4263 
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Table 4.19: results of the chemical shift of budesonide and DIMEB added at 0, 1, 2, 4, 6, and 8 Mm 
in MeOD using 1H NMR. 
Proton 
position 
DIMEB concentration (mM) 
0 1 2 4 6 8 
Chemical shift (ppm) 
H-C18 0.9493 0.9523 0.9550 0.9573 0.9615 0.9643 
H-C19 1.4600 1.4645 1.4689 1.4733 1.4775 1.4802 
H-C4 5.9860 5.9899 5.9925 5.9969 6.0020 6.0067 
H-C2 6.2408 6.2415 6.2414 6.2420 6.2439 6.2455 
H-C1 7.4204 7.4223 7.4244 7.4256 7.4281 7.4302 
 
The K values were determined from the reciprocal plots between BUD and 
TRIMEB/DIMEB as shown in Figures 4.9 and 4.10 respectively based on the 
chemical shift differences at H-C19 and H-C4 protons which were found to be 91 
and 116 M-1 with TRIMEB and DIMEB respectively (Table 4.20). 
 
Figure 4.9: Reciprocal plot for the determination of association constant between budesonide and 
TRIMEB in MeOD by NMR depending on the chemical shift of H-C4 and H-C19 at 5.9860 and 1.4600 
ppm respectively. 
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Figure 4.10: Reciprocal plot for the determination of association constant between budesonide and 
DIMEB in MeOD by NMR depending on the chemical shift of H-C4 and H-C19 at 5.9860 and 1.4600 
ppm respectively. 
Table 4.20: The calculated K for the complex formed between budesonide and (TRIMEB, DIMEB) in 
MeOD 
Host 
Stability constant, K (M-1) 
H-C19 H-C4 
TRIMEB 92 90 
DIMEB 118 114 
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4.2.4 Complexation of BUD and βCD/DIMEB/TRIMEB in D2O 
The study of the complexation between BUD and the three types of CD; βCD, 
TRIMEB and DIMEB was investigated in D2O. First, BUD was prepared at a 
concentration near the previously determined solubility in D2O (23.5 µg/mL) 52. 
The solution was prepared at 21.5 µg/mL, which is equivalent to 0.05 mM. The 
solution was analysed by 600 MHz NMR and the spectrum showed that BUD 
signals were masked by a large signal of D2O (Figure 4.11, a) which was ca. 
three orders of magnitude larger than the BUD signals. This difference in 
resonance intensity hindered the detection of BUD signals. During acquisition of 
the Free Induction Decay (FID) signal, the analogue-to-digital converter (ADC) 
limits the dynamic range of both the spectral width and the amplitude of the 
measured resonances. This process is responsible for translating the electrical 
signals of NMR into a dual number which is proportional to the signal magnitude 
in terms of bits. The ratio between the largest and smallest bits is defined as the 
dynamic range of ADC i.e. it is the ability for the NMR to detect small signals in 
the presence of largest ones.176,177 In the case of detecting BUD in D2O, the 
receiver gain is restricted by the D2O signal because the ADC limits exceed by 
D2O signal as the receiver gain increases. Most instruments use 16-bit ADC 
which gives a dynamic range of 65536 to 1 and in this case if it is assumed that 
the D2O signal fills the ADC, then the smallest signal that can be detected takes 
a value of 1. Therefore, any signal less than 1 is not detected. Multiple methods 
are used in order to decrease the D2O signal intensity and consequently the 
dynamic range of NMR signals will be within the dynamic range of ADC and 
receiver. One such method is presaturation of the solvent resonance, which 
serves to decrease its magnitude before the NMR signals reach the receiver. 
This is carried out by giving irradiation with low power at the solvent frequency 
for the purpose of saturating the solvent protons. Then, a pulse with high power 
is applied for the excitation of the sample nuclei to get the FID. At the time of 
applying the high power pulse, there is no difference in the population of the 
solvent protons (i.e. no magnetisation), hence no FID signal is produced.177 In 
this study, the suppression method was applied by presaturating the D2O signal 
at 4.67 ppm, using a power of 40 dB with scan numbers of 128, 256 and 2048 
scans. It has been shown that suppression of the D2O signal with 2048 scans 
produced a spectrum with BUD peaks of acceptable S:N (Figure 4.11, b).  
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Figure 4.11: 1H NMR spectra of budesonide in D2O (a) without and (b) with solvent suppression at 
4.67 ppm. 
Increasing the acquisition times is a process in the NMR spectrometer which 
can be used to increase the signal to noise ratio by repeating acquisition and 
collecting the recorded FID. The signal intensity adds coherently as the number 
of scans increase. However, the noise is likely to cancel as it adds according to 
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the square root of the scan number (√SN). Thus, the signal to noise ratio (S/N) 
is proportional to the scan number divided by the square root as follows: 
S
N
∝
SN
√SN
=√SN Equation 4.1 
 
The effect of the acquisition times on budesonide system (D2O) was 
investigated by increasing the scan number and calculating the S/N of the peak 
H-C18 (Figure 4.12) and H-C4 (Figure 4.13) at 0.75 and 5.97 ppm respectively. 
As anticipated, increasing the scan number led to the increase in the S/N values 
observed following the √𝑆𝑁 relationship (Equation 4.1).  
 
Figure 4.12: Calculation of the S/N of budesonide spectra in D2O for the H-C18 peak at 0.75 ppm 
collected with different scan number at 128, 256 and 2048 scan. 
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Figure 4.13: Calculation of the S/N of budesonide spectra in D2O for the H-C4 peak at 5.97 ppm 
collected with different scan number at 128, 256 and 2048 scan. 
It is important to reference the chemical shift of all the peaks in the NMR 
spectrum by relating them to an internal reference (tetramethylsilane, TMS (0 
ppm) or residual solvent resonance). In this case, the HOD signal (residual 
solvent) at 4.67 ppm was altered too dramatically by the applied suppression 
and therefore it cannot be used for this purpose.  Alternatively, the addition of 
the internal standard can be used for this referencing purpose, but addition to 
the analytical solution needed to be avoided so as not to change the solvent 
properties of the complexation medium. It should therefore be physically 
separated from the other components. A co-axial NMR tube set up (Figure 4.14) 
is commonly used for this purpose, where a small NMR tube with the capillary 
end (co-axial insert) is inserted in the standard NMR tube. The sample solution 
is added to the standard tube while the internal standard is added to the co-
axial tube so that it would be physically separated from the sample solution by a 
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glass capillary. The advantage of this system is allowing the addition of a 
reference NMR material in a sensible way for a calibration purpose. 
 
Figure 4.14: A co-axial NMR tube set up consists of inner tube (upper) inserted in the standard 
NMR tube (lower) with the addition of sample solution and the reference material added to the inner 
tube.178 
 
The internal standard used in this work was a mixture of (CHCl3 / CD3CN) 
based on the previous study conducted by Telford179 where CHCl3 was chosen 
because it has singlet sharp peak and its chemical shift position is away from 
the other budesonide and cyclodextrin signals so that it can be used as a 
reference for chemical shift referencing and quantitative work as necessary. 
The experiment was set up by preparing solutions of budesonide and βCD in 
D2O and adding to the standard NMR tube of the co-axial tube system as 
mentioned above with the addition of (CHCl3 / CD3CN) in the concentration of 
10 mg/mL in the inner tube. It was found that a large peak at 8.24 ppm (Figure 
4.15, a) was different to the normal CHCl3 resonance which was usually located 
at 7.24 ppm. In order to investigate the relation of this peak to CHCl3, the 
concentration was reduced to 100 µg/mL. It was found that the peak was 
reduced in intensity proportionally to the decrease in the concentration (Figure 
4.15, b) which suggested the relation of this peak to the CHCl3.  
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Figure 4.15: 1H NMR spectra of budesonide and βCD in D2O using CHCl3/CD3CN at (a) 10 mg/mL 
and (b) 100 µg/mL as reference showing that the peak at 8.24 ppm decreased in intensity when the 
concentration of CHCl3 decreased. 
Then, the sample solution of budesonide and βCD in D2O (in NMR tube) was 
run without a co-axial insert tube and the result showed the absence of the peak 
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at 8.24 ppm which confirmed the relation of this peak to the CHCl3 and not to 
the sample components (Figure 4.16).  
 
Figure 4.16: 1H NMR spectrum of budesonide in D2O run without co-axial insert with solvent 
suppression at 4.67 ppm showing that the absence of the peak at 8.24 ppm. 
Finally, the spectrum of D2O solvent (positioned in NMR tube of the co-axial 
system) with the co-axial inner tube containing only CHCl3 was compared to the 
spectrum of D2O with (CHCl3 / CD3CN) in the co-axial tube. It has been shown 
that one peak appeared at 7.07 ppm in the first spectrum (Figure 4.17, a) and 
was shifted to 8.24 ppm in the second spectrum with the presence of CD3CN 
(Figure 4.17, b). It has been reported that the residual peaks of both solvents in 
the co-solvent system have different chemical shifts compared to either of these 
two alone.177 Accordingly, the peak at 7.07 ppm for the CHCl3 was shifted to 
8.24 ppm because of the presence CD3CN in the system. This CHCl3 
resonance at 8.24 ppm is used as a reference in the further experiments for the 
assignment of both host and the guest peaks in the same solvent system. 
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Figure 4.17: 1H NMR spectra of D2O with the addition of only CHCl3 (a) and CHCl3/CD3CN (b) in the 
co-axial insert with solvent suppression at 4.67 ppm showing that the peak of CHCl3 is shifted from 
7.07 to 8.24 ppm. 
It has been found another intense peak was appeared in the spectrum at 2.80 
ppm which was related to the CH3CN residual. Suppression of this peak 
alongside with D2O peak might enhance the BUD spectrum. Therefore, the 
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method was developed using two suppressions at 4.67 ppm (D2O) and at 2.80 
ppm (CH3CN residual) with different attenuations at (30,40), (40,40), (50,40), 
(30,50), (40,50), (50,50), (60,50), (44,50),(46,50), (45,50) dB. The suppression 
with 45 dB at 4.67 ppm and 50 dB at 2.8 ppm was the best and chosen for the 
further experiments. To enhance the sensitivity, different parameters are used 
for this purpose. It is clearly that the sensitivity can be improved by increasing 
the magnetic field (B0) which increases the difference in the population between 
α and β states and therefore, the sample magnetisation at the equilibrium 
increases with an increase in the FID signal. The largest NMR magnetic field 
available at the University of Bradford is 600 MHz and it is used in this work for 
a better sensitivity. The method has been further developed by using different 
concentrations of BUD (0.01, 0.02, 0.03 and 0.04 mM). The S/N ratio was 
calculated for H-C1, H-C2 and H-C4 resonances and the spectrum with 0.04 mM 
produced a better S/N ratio with a reasonable intensity of the BUD signals 
together with the decrease in the noise intensity (Figure 4.18). 
 
 
Figure 4.18: Budesonide spectra in D2O collected at 2048 scan showing the calculation of the S/N 
using different concentrations at 0.02, 0.03 and 0.04 mM.  
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The study of the inclusion formation between BUD and βCD was performed with 
the solvent suppressions at 4.67 ppm (45 dB) and 2.80 ppm (50 dB) with the 
internal standard of CHCl3 in CD3CN (100 µg/mL) and long acquisition times 
(2048 scans). 
The assignment of BUD in D2O was made based on its assignment in CDCl3 
(Figure 4.19), where small shift occurs for all the peaks in two different solvents 
(CDCl3 and D2O). BUD was analysed in CDCl3 by NMR and its assignment are 
shown in Table 4.21.180,181 Figures 4.20 and 4.21 showed spectral expansion of 
the budesonide spectrum in the high and low field regions respectively. 
 
Figure 4.19: 1H NMR spectrum of budesonide in CDCl3 
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Figure 4.20: 1H NMR spectrum of budesonide in CDCl3 in high field region (0.5-4 ppm) 
 
 
Figure 4.21: 1H NMR spectrum of budesonide in CDCl3 in low field region (4-8 ppm) 
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Table 4.21: 1H NMR spectral assignment of the budesonide in CDCl3.180,181 
Proton position Chemical shift (ppm) Spin-Spin Coupling Data 
C1 7.23 (dd, J=10.3, 2.7 Hz) 
C2 6.27 (ddd, J=10, 4.8, 1.7 Hz) 
C4 6.01 (m) 
C6 2.34 (m) 
C7 1.15 (m) 
C8 2.16 (m) 
C9 1.12 (dd, J=3.0, 4.5 Hz) 
C11 4.49 (m) 
C16 4.88 
5.16 
(R) (d, J=4.8 Hz) 
(S) (m) 
C18 0.98 (s) 
C19 1.44 (d, J=1.4 Hz) 
C21 4.49 
4.60 
4.25 
4.22 
(R) (m), 
(S) (dd, J=19.9, 4.8 Hz), 
(R) (dd, J=10, 5.2 Hz) 
(S) (dd, J=10, 5.2 Hz) 
C22 4.55 
5.15 
(R) (t, J=4.2 Hz) 
(S) (t, J=4.6 Hz) 
C25 0.91 (t, J=7.3 Hz) 
Budesonide spectrum is assigned relative to residual chloroform at 7.25 ppm. Multiplicity given 
with the abbreviations: s (singlet), d (doublet), t (triplet), dd (doublet of doublets), ddd (doublet of 
doublets of doublets), m (multiplet).(R) and (S) are epimers of budesonide 
The peaks at 4-5 ppm in the NMR spectrum of BUD were affected by 
presaturation of D2O at 4.67 ppm and hence, were difficult to assign. The other 
peaks were assigned as shown in Table 4.22 where a consistent upfield shift 
occurred for the peaks in D2O when compared to those in CDCl3 as shown in 
Figures 4.22 and 4.23. 
Table 4.22: Chemical shift of budesonide in D2O and compared to those in CDCl3  
Carbon 
number 
Chemical shift (ppm)  Chemical shift 
difference CDCl3 D2O 
1 7.22 7.39 0.17 
2 6.27 6.18 0.09 
4 6.02 5.96 0.06 
18 0.99 0.75 0.24 
19 1.45 1.24 0.21 
25 0.91 0.69 0.22 
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Figure 4.22: Budesonide chemical shift in CDCl3 (lower) and D2O (upper) in high field region (0.6-
1.7 ppm) showing a little shift when using different solvents. 
 
 
Figure 4.23: Budesonide chemical shift in CDCl3 (lower) and D2O (upper) in low field region (5.5-8 
ppm) showing a little shift when using different solvents. 
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4.2.4.1 Budesonide and βCD 
The complexation of BUD and βCD in D2O was investigated by recording the 
chemical shift values of BUD peaks (referenced to CHCl3 from the co-axial 
insert) for the all five different solutions prepared with increasing CD 
concentration (Section 2.2.4.3) relative to BUD peaks from a pure BUD solution 
without βCD addition.  
It has been noticed two peaks were observed at approximately 0.72 and 0.77 
ppm at 0.2 mM βCD concentration. Both peaks were then slightly downfield 
shifted with the increasing βCD concentration which both could be assigned to 
the H-C18 peak of R- and S-enantiomers of BUD. However, no observable 
change was noted for H-C25 peak although its multiplicity changed as the βCD 
concentration was increased. The H-C19 proton of BUD at 1.25 ppm had 
remarkable downfield shift and was split into two distinctive peaks as the 
concentration of βCD was increased which both of them could be related to the 
both enantiomers of BUD. However, it was difficult to assign and match both 
shifted peaks of the H-C18 and H-C19 protons to the R- and S-enantiomers of 
BUD unless performing an additional experiment with the pure enantiomer and 
comparing to those of the racemic mixture. The spectra of the complexed BUD 
in the high field region are shown in Figure 4.24. 
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Figure 4.24: Budesonide (0.04 mM) chemical shift in high field region (0.6-1.6 ppm) with the 
addition of βCD at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O.  
In the low field region, small downfield shift was observed with H-C1 proton of 
the quinone ring, whereas upfield shift was noted for the other protons of the 
quinone ring (H-C2 and H-C4). The doublet H-C2 peak was split into three peaks 
with increasing CD concentration. The H-C4 singlet peak was split into two 
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distinctive peaks with increasing the βCD concentration, and both peaks could 
be assigned to the both R- and S-enantiomers of BUD (Figure 4.25).  
 
Figure 4.25: Budesonide (0.04 mM) chemical shift in low field region (5.9-7.6 ppm) with the addition 
of βCD at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O. 
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The chemical shift differences of H-C19 proton at 1.2570 ppm (Table 4.23) were 
used to determine the K as shown in Table 4.24, with the Hildebrand-Benesi 
plot being shown in Figure 4.26. 
Table 4.23: Results of the chemical shift of budesonide and βCD added at 0, 0.2, 0.4, 1, 1.4 and 2 
mM in D2O using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
βCD concentration (mM) 
0 0.2 0.4 1 1.4 2 
Chemical shift (ppm) 
1 
H-C19 1.2570 
1.2905 1.3150 1.3530 1.3660 1.3853 
2 1.2903 1.3139 1.3542 1.3686 1.3793 
3 1.2906 1.3170 1.3558 1.3678 1.3790 
Mean 1.2905 1.3153 1.3543 1.3675 1.3812 
SD 0.0002 0.0016 0.0014 0.0013 0.0036 
% CV 0.0118 0.1195 0.1037 0.0974 0.2573 
 
Table 4.24: Results of the complexation between budesonide and βCD added at 0.2, 0.4, 1, 1.4 and 
2 mM in D2O using 1H NMR based on the chemical shift of H-C19 at 1.2570 ppm. 
βCD 
(mM) 
1/βCD 
(mM-1) 
1/∆δobs (1.2570 ppm) 
1 2 3 Mean 
0.2 5 29.9 30 29.8 29.9 
0.4 2.5 17.2 17.6 16.7 17.2 
1 1 10.4 10.3 10.1 10.3 
1.4 0.7 9.2 8.9 9 9.1 
2 0.5 7.8 8.2 8.2 8.1 
 
 
Figure 4.26: Reciprocal plot for the determination of the association constant between budesonide 
and βCD in D2O by 1H NMR based on the chemical shift of H-C19 at 1.2570 ppm (Mean ± SD, n=3). 
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The reciprocal plots of 1/∆δobs versus 1/[βCD] showed a good linearity which 
indicated a stoichiometry of the complexation was 1:1. The mean K value was 
found to be 1129 M-1 according to the chemical shift changes of H-C19 proton 
(Table 4.25).  
Table.4.25: Results of the stability constant between budesonide and βCD added at 0.2, 0.4, 1, 1.4 
and 2 mM in D2O using 1H NMR. 
Proton 
NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C19 1.2570 1129 1127 1129 1129 2.5 0.2 
 
The stoichiometry 1:1 of the complex was verified by continuous variation 
method (Section 2.2.3.2). The calculation was based on the chemical shift 
differences of the H-C2 proton of BUD at (6.1931 and 6.1744 ppm). The 
chemical shift difference between free and complexed budesonide (∆δobs) was 
calculated by taking the difference between chemical shift of free budesonide 
(in the absence of βCD, δfree) and chemical shift of complexed budesonide (in 
the presence of βCD, δcomplex). The stoichiometry was then determined as shown 
in Tables 4.26 and 4.27. 
Table 4.26: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and βCD in D2O based on the chemical shift of H-C2 proton of budesonide at 6.1931 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 6.1931 0 0 0 
0.045 0.9 6.1906 0.0025 11.3 x 10-5 1.13 
0.04 0.8 6.1889 0.0042 16.8 x 10-5 1.68 
0.035 0.7 6.1874 0.0057 19.9 x 10-5 1.99 
0.03 0.6 6.1854 0.0077 23.1 x 10-5 2.31 
0.025 0.5 6.1834 0.0097 24.3 x 10-5 2.43 
0.02 0.4 6.1824 0.0107 21.4 x 10-5 2.14 
0.015 0.3 6.1809 0.0122 18.3 x 10-5 1.83 
0.01 0.2 6.1789 0.0142 14.2 x 10-5 1.42 
0 0 0 0 0 0 
δfree = 6.1931 ppm    
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Table 4.27: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and βCD in D2O based on the chemical shift of H-C2 proton of budesonide at 6.1744 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 6.1744 0 0 0 
0.045 0.9 6.1715 0.0029 13.1 x 10-5 1.31 
0.04 0.8 6.1695 0.0049 19.6 x 10-5 1.96 
0.035 0.7 6.1675 0.0069 24.2 x 10-5 2.42 
0.03 0.6 6.165 0.0094 28.2 x 10-5 2.82 
0.025 0.5 6.1625 0.0119 29.8 x 10-5 2.98 
0.02 0.4 6.1611 0.0133 26.6 x 10-5 2.66 
0.015 0.3 6.1596 0.0148 22.2 x 10-5 2.22 
0.01 0.2 6.1568 0.0176 17.6 x 10-5 1.76 
0 0 0 0 0 0 
δfree = 6.1744 ppm     
 
The stoichiometry was determined by plotting r, which was the ratio of 
[BUD]/[BUD]+[βCD] versus ∆δ[BUD] (Figure 4.27). The results showed the 
maximum value of r was 0.5 which demonstrated that the stoichiometry was 1:1 
for the complex. 
 
Figure 4.27: Determination of the stoichiometry of the complex between budesonide and βCD  in 
D2O by 1H NMR based on the chemical shift of H-C2 proton of budesonide. 
 
4.2.4.2 Budesonide and TRIMEB 
The complexation between BUD and TRIMEB was investigated in D2O as 
described in Section 2.2.4.3. The results showed downfield changes occurred 
for the H-C19 peak at 1.2570 ppm with a partial split at higher TRIMEB 
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concentration (1.6 and 2 mM). No shift was observed for both H-C18 and H-C25 
protons (Figure 4.28). 
 
Figure 4.28: Budesonide (0.04 mM) chemical shift in high field region (0.6-1.6 ppm) with the 
addition of TRIMEB at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O. 
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The H-C4 proton of the quinone ring at 5.9645 ppm was observed as a singlet 
peak with slight upfield shift, and minor shift was noted for the H-C1 proton of 
the quinone ring. However, small shift was observed for the doublet H-C2 proton 
which was then split into three peaks with increasing TRIMEB concentration 
(Figure 4.29). 
 
Figure 4.29: Budesonide (0.04 mM) chemical shift in low field region (5.9-7.54 ppm) with the 
addition of TRIMEB at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O. 
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The stability constant was calculated based on the chemical shift differences of 
H-C19 and H-C4 at 1.2570 and 5.9645 ppm respectively. The results are 
presented in Table 4.28. 
Table 4.28: Results of the chemical shift of budesonide and TRIMEB added at 0, 0.2, 0.4, 1, 1.4 and 
2 mM in D2O using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
TRIMEB concentration (mM) 
0 0.2 0.4 1 1.4 2 
Chemical shift (ppm) 
1 
H-C19 1.2570 
1.2588 1.2613 1.2752 1.2836 1.2941 
2 1.2589 1.2614 1.2784 1.2838 1.2961 
3 1.2589 1.2615 1.2769 1.2851 1.2954 
Mean 1.2589 1.2614 1.2768 1.2842 1.2952 
SD 0.0001 0.0001 0.0016 0.0008 0.0010 
% CV 0.0046 0.0079 0.1254 0.0634 0.0784 
1 
H-C4 5.9645 
5.9636 5.9625 5.9555 5.9500 5.9415 
2 5.9637 5.9626 5.9574 5.9512 5.9439 
3 5.9637 5.9626 5.9573 5.9508 5.9440 
Mean 5.9637 5.9626 5.9569 5.9504 5.9437 
SD 0.0001 0.0001 0.0009 0.0012 0.0010 
% CV 0.0010 0.0010 0.0150 0.0204 0.0175 
 
The data and the reciprocal plots used to determine the stability constant are 
shown in Table 4.29 and Figure 4.30. 
Table 4.29: Results of the complexation between budesonide and TRIMEB added at 0.2, 0.4, 1, 1.4 
and 2 mM in D2O using 1H NMR based on the chemical shift differences of H-C19 and H-C4 at 1.2570 
and 5.9645 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (1.2570 ppm) 1/∆δobs (5.9645 ppm) 
1 2 3 Mean 1 2 3 Mean 
0.2 5 555 526 526 536 1111 1250 1250 1204 
0.4 2.5 233 227 222 227 500 526.3 526.3 517.5 
1 1 54.9 46.7 50.3 50.6 1111 140.9 138.9 130.3 
1.4 0.7 37.6 37.3 35.6 36.8 68.9 75.2 73 72.4 
2 0.5 26.9 25.6 26 26.2 43 48.5 48.8 46.9 
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Figure 4.30: Reciprocal plot for the determination of the association constant between budesonide 
and TRIMEB in D2O by 1H NMR based on the chemical shift differences of H-C19 and H-C4 at 1.2570 
and 5.9645 ppm (Mean ± SD, n=3). 
The reciprocal plot showed a linear relationship which suggested 1:1 
stoichiometric ratio of the complex. The mean K values were 429 M-1 for the 
values obtained from two H-C19 and H-C4 protons (Table 4.30).  
Table 4.30: Results of the stability constant between budesonide and TRIMEB added at 0.2, 0.4, 1, 
1.4 and 2 mM in D2O using 1H NMR. 
Proton 
NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C19 1.257 425 426 426 426 0.6 0.1 
H-C4 5.9645 427 432 437 432 5 1.2 
 
The stoichiometry was confirmed by continuous variation method as described 
in Section 2.2.3.2 and the calculation was based on the chemical shift changes 
of the H-C2 proton of BUD at 6.1931 and 6.1744 ppm. The results are 
presented in Tables 4.31 and 4.32. 
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Table 4.31: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and TRIMEB in D2O based on the chemical shift of H-C2 proton of budesonide at 6.1931 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 6.1931 0 0 0 
0.045 0.9 6.1912 0.0019 8.6 x 10-5 0.86 
0.04 0.8 6.1901 0.003 12 x 10-5 1.2 
0.035 0.7 6.189 0.0041 14.4 x 10-5 1.44 
0.03 0.6 6.1874 0.0057 17.1 x 10-5 1.71 
0.025 0.5 6.1855 0.0076 19 x 10-5 1.9 
0.02 0.4 6.1846 0.0085 17 x 10-5 1.7 
0.015 0.3 6.1834 0.0097 14.6 x 10-5 1.46 
0.01 0.2 6.1829 0.0102 10.2 x 10-5 1.02 
0 0 0 0 0 0 
δfree = 6.1931 ppm    
 
Table 4.32: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and TRIMEB in D2O based on the chemical shift of H-C2 proton of budesonide at 6.1744 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 6.1744 0 0 0 
0.045 0.9 6.1722 0.0022 9.9 x 10-5 0.99 
0.04 0.8 6.171 0.0034 13.6 x 10-5 1.36 
0.035 0.7 6.1695 0.0049 17.2 x 10-5 1.72 
0.03 0.6 6.1675 0.0069 20.7 x 10-5 2.07 
0.025 0.5 6.1657 0.0087 21.8 x 10-5 2.18 
0.02 0.4 6.1648 0.0096 19.2 x 10-5 1.92 
0.015 0.3 6.1636 0.0108 16.2 x 10-5 1.62 
0.01 0.2 6.1629 0.0115 11.5 x 10-5 1.15 
0 0 0 0 0 0 
δfree = 6.1744 ppm    
 
The plot shown in Figure 4.31 demonstrated that the inclusion complex had 1:1 
stoichiometry since the highest value of r was at 0.5. 
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Figure 4.31: Determination of the stoichiometry of the complex between budesonide and TRIMEB 
in D2O by 1H NMR based on the chemical shift differences of H-C2 proton of budesonide. 
 
4.2.4.3 Budesonide and DIMEB 
The inclusion complex between BUD and DIMEB was investigated in D2O 
according to method specified in Section 2.2.4.3. The results showed two peaks 
were observed at approximately 0.72 and 0.77 ppm at 0.2 mM DIMEB 
concentration which were then slightly downfield shifted with the increasing 
DIMEB concentration. Both peaks could be assigned to the H-C18 peak of R- 
and S-enantiomers of BUD. However, no change was observed for H-C25 proton 
although its multiplicity changed as the DIMEB concentration was increased. 
The H-C19 resonance was observed with downfield shift that showed a fully split 
initially into two distinctive peaks and were then partially split at 1.4 and 2 mM 
DIMEB concentration. These two peaks could be assigned to the R- and S-
enantiomers of BUD. However, it was hard to assign and relate both shifted 
peaks for each of the H-C18 and H-C19 protons to the R- and S-enantiomers of 
BUD without performing an additional experiment with the pure enantiomer and 
comparing to those of the racemic mixture. The spectra of the complexed BUD 
in the high field region are shown in (Figure 4.32). 
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Figure 4.32: Budesonide (0.04 mM) chemical shift in high field region (0.6-1.6 ppm) with the 
addition of DIMEB at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O. 
In the low field region, upfield shifts were observed for all of the quinone ring 
protons. The H-C4 singlet peak was split into two distinctive peaks with 
increasing the DIMEB concentration, and both peaks could be assigned to the 
both R- and S-enantiomers of BUD. The doublet H-C2 peak was split into four 
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peaks whereas the distinct multiplicity change was observed for H-C1 proton (J-
coupling constants increase with increasing DIMEB concentration. The spectra 
of the complexed BUD in the low field region are shown in Figure 4.33. 
 
Figure 4.33: Budesonide (0.04 mM) chemical shift in low field region (5.8-7.6 ppm) with the addition 
of DIMEB at 0, 0.2, 0.4, 1, 1.4 and 2 mM in D2O. 
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The K value was calculated based on the chemical shift displacements of H-C19 
and H-C4 protons at 1.257 and 5.9645 ppm respectively. The results are 
presented in Table 4.33. 
Table 4.33: Results of the chemical shift of budesonide and DIMEB added at 0, 0.2, 0.4, 1, 1.4 and 2 
mM in D2O using 1H NMR. 
Exp. 
number 
Proton 
position 
(ppm) 
DIMEB concentration (mM) 
0 0.2 0.4 1 1.4 2 
Chemical shift (ppm) 
1 
H-C19 1.2570 
1.3124 1.3356 1.3536 1.3576 1.3635 
2 1.3121 1.3333 1.3515 1.3539 1.3674 
3 1.3129 1.3346 1.3501 1.3577 1.3693 
Mean 1.3125 1.3345 1.3517 1.3564 1.3667 
SD 0.0004 0.0012 0.0018 0.0022 0.0030 
% CV 0.0308 0.0864 0.1303 0.1597 0.2163 
1 
H-C4 5.9645 
5.9422 5.9352 5.9276 5.9231 5.9209 
2 5.9413 5.9340 5.9264 5.9210 5.9193 
3 5.9409 5.9330 5.9247 5.9220 5.9177 
Mean 5.9415 5.9341 5.9262 5.9220 5.9193 
SD 0.0007 0.0011 0.0015 0.0011 0.0016 
% CV 0.0112 0.0186 0.0246 0.0177 0.0270 
 
The data and the reciprocal plot used to calculate the stability constant are 
presented in Table 4.34 and shown in Figure 4.34. 
Table 4.34: Results of the complexation between budesonide and DIMEB added at 0.2, 0.4, 1, 1.4 
and 2 mM in D2O using 1H NMR based on the chemical shift of H-C19 and H-C4 at 1.257 and 5.9645 
ppm.  
DIMEB 
(mM) 
DIMEB 
(mM-1) 
1/∆δobs (1.2570 ppm) 1/∆δobs (5.9645 ppm) 
1 2 3 Mean 1 2 3 Mean 
0.2 5 18.1 18.2 17.9 18.1 44.8 43.1 42.4 43.4 
0.4 2.5 12.7 13.1 12.9 12.9 34.1 32.8 31.8 32.9 
1 1 10.4 10.6 10.7 10.6 27.1 26.3 25.1 26.2 
1.4 0.7 9.9 10.3 9.9 10.1 24.2 22.9 23.5 23.6 
2 0.5 9.4 9.1 8.9 9.1 22.9 22.1 21.4 22.1 
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Figure 4.34: Reciprocal plot for the determination of the association constant between budesonide 
and DIMEB in D2O by 1H NMR based on the chemical shift of H-C19 and H-C4 at 1.2570 and 5.9645 
ppm (Mean ± SD, n=3). 
The reciprocal plot showed a linear relationship indicating that the ratio of the 
stoichiometry of the complex was 1:1. The mean K value was found to be 4446 
M-1 based on the H-C19 and H-C4 protons (Table 4.35).  
Table 4.35: Results of the stability constant between budesonide and DIMEB added at 0.2, 0.4, 1, 
1.4 and 2 mM in D2O using 1H NMR. 
Proton 
NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C19 1.2570 4444 4440 4449 4444 4.5 0.1 
H-C4 5.9645 4446 4449 4445 4447 2.1 0.05 
 
The stoichiometry of 1:1 was verified by continuous variation method and the 
solutions were prepared according to the method specified in Section 2.2.3.2. 
The calculation was based on the chemical shift changes observed at H-C19 
and H-C4 protons of budesonide at 1.2570 and 5.9645 ppm respectively. The 
stoichiometry was then determined as shown in Tables 4.36 and 4.37. 
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Table 4.36: Results of 1H NMR analysis for the determination of the stoichiometry between 
budesonide and DIMEB in D2O based on the chemical shift of H-C19 proton of budesonide at 1.2570 
ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 1.2570 0 0 0 
0.045 0.9 1.2655 0.0085 38.3 x 10-5 3.83 
0.04 0.8 1.2760 0.0190 76 x 10-5 7.6 
0.035 0.7 1.2840 0.0270 94.5 x 10-5 9.45 
0.03 0.6 1.2919 0.0349 104.7 x 10-5 10.47 
0.025 0.5 1.3007 0.0437 109.3 x 10-5 10.93 
0.02 0.4 1.3076 0.0506 101.2 x 10-5 10.12 
0.015 0.3 1.3134 0.0564 84.6 x 10-5 8.46 
0.01 0.2 1.3243 0.0673 67.3 x 10-5 6.73 
0 0 0 0 0 0 
δfree = 1.2570 ppm    
 
Table 4.37: Results of 1H NMR analysis for the determination of the stoichiometry between 
budesonide and TRIMEB in D2O based on the chemical shift of H-C4 proton of budesonide at 5.9645 
ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.05 1 5.9645 0 0 0 
0.045 0.9 5.9585 0.006 27 x 10-5 2.7 
0.04 0.8 5.9534 0.0111 44.4 x 10-5 4.44 
0.035 0.7 5.9482 0.0163 57.1 x 10-5 5.71 
0.03 0.6 5.9422 0.0223 66.9 x 10-5 6.69 
0.025 0.5 5.936 0.0285 71.3 x 10-5 7.13 
0.02 0.4 5.9329 0.0316 63.2 x 10-5 6.32 
0.015 0.3 5.9307 0.0338 50.7 x 10-5 5.07 
0.01 0.2 5.9299 0.0346 34.6 x 10-5 3.46 
0 0 0 0 0 0 
δfree = 5.9645 ppm    
 
The Job’s plot showed the highest value of r was at 0.5 demonstrating the 
stoichiometry of the complex was 1:1 (Figure 4.35). 
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Figure 4.35: Determination of  the stoichiometry of the complex between budesonide and DIMEB in 
D2O by 1H NMR based on the chemical shift change of H-C19 and H-C4 protons of budesonide. 
 
4.3 Analysis of solid complexes of BUD and βCD/TRIMEB/DIMEB 
using vibrational spectroscopy 
4.3.1 FTIR 
4.3.1.1 BUD and βCD complex 
The physical mixture and co-evaporation complex prepared from BUD and βCD 
were analysed by IR. The assignment of IR peaks of BUD was consistent to 
those reported by Raval et al.182 and Gangurde et al.183 The peak at 3480 cm-1 
was related to the stretching of the OH group. The band at 1721 cm-1 was due 
to the stretching of the C=O ketone group whereas the bands at 1603 cm-1 was 
ascribed to the stretching of C=O ring. The bands at 1667 and 1441 cm-1 were 
related to the stretching of C=C and C-C ring respectively. The stretching of C-
O was observed at 1092 cm-1 whereas the stretching of C-C was observed at 
937 cm-1. The assignment of IR spectrum of BUD is presented in Table 4.38. 
Table 4.38: IR bands of budesonide.182,183 
Wavenumbers (cm-1) Assignment 
3480 OH  
2957 aliphatic C-H 
1721 stretching of C=O  ketone 
1667 stretching of C=C 
1603 stretching of  C=O ring 
1441 stretching of  C-C ring 
1092 stretching of C-O group 
937 stretching of C-C 
0
2
4
6
8
10
12
0 0.2 0.4 0.6 0.8 1
∆
δ
[B
U
D
]*
1
0
4
r
H-C4 (5.9645 ppm)
H-C19 (1.2570 ppm)
 95 
 
 
The assignment of βCD IR peaks is illustrated in Table 4.39 and is consistent to 
those reported by Roik and Belyakova184 and Rabadiya et al.185 
Table 4.39: IR bands of βCD.184,185 
Wavenumbers (cm-1) Functional group 
3399 stretching of OH  
2924 stretching of C-H in (CH/CH2 groups) 
1260-1000 stretching of C-O 
1158 stretching of C-C 
1030 bending vibration of OH 
 
It has been noticed that the OH bands of both BUD and βCD in the complex 
spectrum were broader compared to the BUD and βCD alone. The band at 
1667 cm-1 which was related to stretching of C=C was slightly shifted to 1666 
cm-1 and split in the case of physical mixture, while the other band at 1603 cm-1 
was considerably decreased in intensity. Also, there was a shift in the band at 
1721 cm-1 that was related to frequency of the C=O ketone and became 
broader in the case of co-evaporation complex (Figures 4.36 and 4.37). These 
changes in the bands of the quinone ring suggested that this part was 
responsible for the complex by entering into the βCD cavity. The main bands 
shift for BUD, βCD and their complexes are illustrated in Table 4.40.  
Table 4.40: Main bands of pure budesonide, pure βCD and their complexes (physical mixture and 
co-evaporation) 
Wavenumbers (cm-1) 
BUD βCD Physical mixture Co-evaporation 
3480 − 
(3407) Broad band (3430) Broad band 
− 3399 
− 2924 2932 2925 
1721 − 1720 1717 
1667 − 1666 1666 
1603 − 1603 (Decreased in intensity) 
− 1158 1157 1158 
− 1030 1029 1030 
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Figure 4.36: IR spectra of pure budesonide, βCD, physical mixture and co-evaporation complex 
showing a broad band of OH group in the range or 3300-3500 cm-1 and other shifts related to the 
quinone ring of budesonide. 
 
Figure 4.37: IR spectra of pure budesonide, βCD, physical mixture and co-evaporation complex 
showing shifts of the quinone ring of budesonide. 
 
4.3.1.2 BUD and TRIMEB complex 
The physical mixture and co-evaporation complex prepared from BUD and 
TRIMEB were analysed by IR spectroscopy. The same results were obtained 
with TRIMEB as with βCD, where the main changes were with the OH group 
(Figure 4.38) and quinone ring (Figure 4.39). The main bands shift for BUD, 
TRIMEB and their complexes are presented in Table 4.41. 
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Table 4.41: Main bands of pure budesonide, pure TRIMEB and their complexes (physical mixture 
and co-evaporation) 
Wavenumbers (cm-1) 
BUD TRIMEB Physical mixture Co-evaporation 
3480 − 
(3468) Broad peak (3430) Broad peak 
− 3445 
− 2930 2928 2929 
1721 − 1718 1717 
1667 − 1667 1666 
1603 − 1603 (Decreased in intensity) 
− 1162 1163 1163 
− 1041 1038 1038 
 
 
Figure 4.38: IR spectra of pure budesonide, TRIMEB, physical mixture and co-evaporation complex 
showing a broad band of OH group in the range or 3300-3500 cm-1 and other shifts related to the 
quinone ring of budesonide. 
 
Figure 4.39: IR spectra of pure budesonide, TRIMEB, physical mixture and co-evaporation complex 
showing shifts of the quinone ring of budesonide. 
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4.3.1.3 BUD and DIMEB complex 
The main band affected in the complexation with DIMEB were the OH group 
(Figure 4.40) and quinone ring (Figure 4.41). The main bands shift for BUD, 
DIMEB and their complexes are presented in Table 4.42. 
Table 4.42: Main bands of pure budesonide, pure DIMEB and their complexes (physical mixture and 
co-evaporation) 
Wavenumbers (cm-1) 
BUD DIMEB Physical mixture Co-evaporation 
3480 − 
(3408) Broad peak (3402) Broad peak 
− 3404 
− 2926 2929 2927 
1721 − 1719 1717 
1667 − 1667 1661 
1603 − 1603 (Decreased in intensity) 
− 1156 1156 1154 
− 1045 1047 1043 
 
 
Figure 4.40: IR spectra of pure budesonide, DIMEB, physical mixture and co-evaporation complex 
showing a broad band of OH group in the range or 3300-3500 cm-1 and other shifts related to the 
quinone ring of budesonide. 
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Figure 4.41: IR spectra of pure budesonide, DIMEB, physical mixture and co-evaporation complex 
showing shifts of the quinone ring of budesonide. 
 
4.3.2 Raman spectroscopy 
4.3.2.1 BUD and βCD complex 
The Raman spectrum of budesonide has been assigned with refer to the 
literature, the main peaks at 1714 cm-1 and 1657 cm-1 were corresponded to the 
frequency of C=O and C=C of quinone ring respectively.186 The other two peaks 
at 1627 cm-1 and 1603 cm-1 correspond to the frequency of C=C stretching of 
the ring.186 It has been noticed that there was no obvious shift at 1657 cm-1 of 
both complexes prepared between budesonide and βCD (physical mixture and 
co-evaporation complex). However, the band at 1603 cm-1 became broader and 
decreased in intensity in the physical mixture compared to the budesonide 
spectrum with a considerable reduction in the case of co-evaporation of 
budesonide and βCD. On the other hand, considerable reduction in the intensity 
of the band at 1627 cm-1 was observed for the two complexes prepared. There 
was also a change in the shape and also a reduction in intensity of band at 
1714 cm-1. Generally, these bands mentioned earlier were related to the 
quinone ring and these changes suggested that this part of budesonide formed 
the complex with βCD (Figure 4.42).  
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Figure 4.42: Raman spectra of pure budesonide, pure βCD and 1:1 complex of physical mixture and 
co-evaporation complex showing shifts in the quinone ring bands. 
 
4.3.2.2 BUD and TRIMEB complex 
The results showed that the band at 1657 cm-1 was observed at a higher 
wavenumber at 1665 cm-1 with the co-evaporation of BUD and TRIMEB. For the 
other bands at 1714, 1627 and 1603 cm-1, the same results were obtained as 
those with βCD which suggests that the quinone ring is engaged in a more 
significant interaction with the host (TRIMEB) (Figure 4.43). 
 
Figure 4.43: Raman spectra of pure budesonide, pure TRIMEB and 1:1 complex of physical mixture 
and co-evaporation complex showing shifts in the quinone ring bands. 
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4.3.2.3 BUD and DIMEB complex 
In the case of DIMEB, the band at 1657 cm-1 was observed at higher frequency 
shift at 1660 cm-1 in the complex of co-evaporation method and at 1665 cm-1 in 
the complex of physical mixture. The same results obtained with other bands at 
1714, 1627 and 1603 cm-1 as those with βCD and TRIMEB which suggests that 
the quinone ring is involved in the interaction with the DIMEB (Figure 4.44). 
 
Figure 4.44: Raman spectra of pure budesonide, pure DIMEB and 1:1 complex of physical mixture 
and co-evaporation complex showing shifts in the quinone ring bands. 
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4.4 Discussion 
4.4.1 Complexation studies by UV-Vis spectroscopy  
The results obtained from UV technique showed a higher complexation in H2O 
compared to co-solvent of EtOH/H2O mixture with both βCD and TRIMEB 
where the obtained K values were found to be 94 and 72 M-1 in the case βCD 
compared to 205 and 138 M-1 for TRIMEB in H2O and EtOH/H2O mixture 
respectively. This might be related to the BUD solubility as it is soluble in 
ethanol and insoluble in water, since generally as the solubility of the guest 
molecule in the solvent increases, less complexation occurs with the host 
making BUD complexation higher in H2O compared to the EtOH/H2O mixture. 
The reciprocal plot of the titration experiments of BUD with both βCD and 
TRIMEB in H2O and EtOH/H2O mixture showed a good linearity indicating that 
the stoichiometry of the complex was 1:1. The stoichiometry was further 
confirmed by Job’s plot of continuous variation method.  
The influence of co-solvent on the complexation between CD and the guest is a 
controversial topic. It has been found that the co-solvent has an ability to 
dissolve the guest molecule, before entering the CD’s cavity and thus facilitates 
the complex formation. Also, the co-solvent system can dissolve the excess 
guest molecules that do not enter into the CD’s cavity.187 In contrast, some 
reports showed that the co-solvent system has a destabilisation effect on the 
CD involved complexation.188 This was explained by two mechanisms; firstly, 
the co-solvent can affect the bulk solvent polarity where it can reduce the 
polarity of the system at a particular co-solvent concentration to an extent which 
favours the desolvation of the guest molecule.189 Secondly, the co-solvent may 
compete with the guest molecule by entering and occupying the CDs cavity.190-
192 Okubo et al. studied the effect of a mixed solvent of ethanol and water on the 
complexation between the surfactant hexadecyl trimethyl ammonium bromide 
(C16TAB) and βCD. They found that the value of K decreases as the proportion 
of ethanol increases, with the reported K values of 2000 and 450 M-1 for 1 M 
and 4 M ethanol concentrations respectively. The obtained results were 
attributed to the stabilisation of the surfactant tail by the organic solvent, which 
subsequently led to weakening of the hydrophobic interaction between 
surfactant and the CD.193 A similar finding was reported on the effect of 
isopropanol and water mixtures on the complexation between dodecyl trimethyl 
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ammonium bromide (C12TAB) and βCD.194 The greater complexation observed 
with water in this work compared to the co-solvent with ethanol is attributed to 
the fact that the co-solvent system reduces the water solvation (reduces the 
polarity outside the CD cavity) and thus allows the ethanol to access the BUD 
molecule. This results in the preference for BUD to be located partially outside 
the CD cavity and thus a weak complexation occurs. By contrast, in aqueous 
solution, water inside the CD cavity has a reduced polarity compared to the bulk 
solvent i.e. outside of the CD cavity. Hence, the non-polar BUD is driven to 
associate with the cavity of the CD molecule and complexation occurs.  
4.4.2 Complexation studies by NMR  
4.4.2.1 Effect of solvent 
The influence of the solvent type on the complex formation between BUD and 
three different types of CDs (βCD, DIMEB and TRIMEB) was investigated in this 
work using the NMR titration method. The obtained results showed weaker 
inclusion complex between BUD and βCD, DIMEB/TRIMEB in the organic 
solvents (CD3CN, MeOD and CDCl3) compared to D2O as illustrated in Table 
4.43. The reciprocal plot of the titration experiments used to study the 
complexation of BUD with βCD, DIMEB and TRIMEB in D2O showed good 
linearity demonstrating that the complex had a stoichiometry of 1:1. The 
continuous variation method confirmed the stoichiometry to be 1:1 of the 
inclusion complex since the plot showed a maximum at r = 0.5. 
Table 4.43: Complex formation of budesonide with βCD, DIMEB and TRIMEB in three solvent 
system; D2O, MeOD and CDCl3. 
CD type 
Association constant, Ka (M-1) 
D2O CD3CN MeOD CDCl3 
βCD 1129 not assessed due to insolubility 
DIMEB 4446 No complex formed 116 73 
TRIMEB 429 No complex formed  91 64 
 
The strength of the complex formed among the solvents assessed can be 
ranked as follows:  D2O > MeOD > CDCl3 > CD3CN. The results showed that no 
complexation occurred with CD3CN and this was consistent with results   
obtained by Menger and Dulany where no binding was formed between p-
nitrophenol (guest) and peralkylated CD (host) in acetonitrile.164 They stated 
that the acetonitrile displays a polarity similar to that of the CD cavity; hence 
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there is no drive for complexation.164 The complexation observed in water was 
the strongest of all the solvents assessed, and these results are in agreement 
with those from other studies. For example, Siegel and Breslow reported that 
the binding constant between anisole and βCD in water is two orders of 
magnitude bigger than that in DMSO.123 Similarly, Smithrud and Diederich 
studied the binding affinity of a cyclophane receptor for pyrene in different 
solvents. They found that the binding constant was decreased in the following 
order: water > ethanol > acetone > carbon disulphide.195 Despite the fact that 
D2O showed stronger complexation in comparison to the organic solvents in this 
work and also with some other studies, however, this cannot be obeyed as a 
general rule since on the other hand, some studies showed stronger 
complexation with organic solvents than water. For instance, Menger and 
Dulany found the binding of p-nitrophenol with peralkylated CD is stronger in 
heptane compared to that in water with both βCD and αCD.164 Nakai et al. 
found that p-nitrophenol transferred from the aqueous phase to the CDCl3 
phase by addition of methyl βCD to the organic solvent.196 The contradictory 
results were explained based on the polarity of the host, guest, and solvent 
rather than anticipating that complex formation was based on the solvent type 
solely. It has been found that when both guest and host are nonpolar, the 
binding is controlled by the dispersion forces between guest and host as well as 
the desolvation of cohesive and polar solvent molecules.197 It was concluded 
that binding occurs when there is a difference in the polarity of the cavity and 
the solvent system outside the cavity.164 The binding of a nonpolar guest is 
preferred in a polar solvent such as water195 while a polar guest is most 
favourable in a less polar solvent.198 The previous examples of anisole and 
cyclophane (non-polar guests) formed stronger complexation in the presence of 
water because the CD cavity is less polar than the medium. However, p-
nitrophenol (has some hydrophilic character) formed stronger complexation in 
the organic solvent (heptane) as the CD cavity is more polar compared to the 
medium. 
In this study, BUD as a nonpolar guest preferred the CD cavity of less polarity in 
the presence of water, which is as a result a stronger complexation in the 
aqueous solvent formed compared to MeOD and CDCl3. In the latter two 
solvents, BUD cannot form strong complexation as in water because the CD 
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cavity is more polar than the organic solvents in which it is soluble,199 which 
provides the ideal environment for BUD to favour solvation, hence reducing the 
driving force of BUD to enter the DIMEB and TRIMEB cavity. Also, such 
solvents might compete with BUD for occupying the DIMEB and TRIMEB cavity, 
which ultimately decreases its binding and the complexation. This might explain 
the higher complexation between BUD and CDs in water compared to the 
utilised organic solvents. 
4.4.2.2 CD type and its effect on complexation 
The effect of CDs type on the complexation with BUD was studied utilising three 
different types of CDs; (i) βCD, (ii) DIMEB and (iii) TRIMEB and the results were 
summarised in Table 4.44 and Figures 4.45 and 4.46. 
Table 4.44: Chemical shift displacements of BUD with 2 mM βCD, DIMEB and TRIMEB in D2O 
related to the chemical shift of free BUD. 
CD type 
Chemical shift displacements (ppm) 
H-C1 H-C2 H-C4 H-C18 H-C19 
βCD D* (0.01) U** (0.07) U** (0.03) D* (0.05) D** (0.12, 0.16) 
DIMEB U** (0.06) U** (0.11) U** (0.06) D* (0.03) D** (0.11) 
TRIMEB NS D* (0.01) U* (0.02) NS D* (0.04) 
D* = small downfield, D** = large downfield, U* = small upfield, U** = large upfield, NS = no 
significant shift 
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Figure 4.45: BUD chemical shift differences in the high field region complexed with 2 mM βCD, 
DIMEB and TRIMEB. 
 
Figure 4.46: BUD chemical shift differences in the low field region complexed with 2 mM βCD, 
DIMEB and TRIMEB. 
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Veiga et al. studied the complexation between tolbutamide and βCD which they 
found a pronounced shift difference for the aromatic protons. They suggested 
that the positive sign for one proton was an indication for its closeness to 
oxygen atom in the CD cavity, while the negative sign for the another proton 
suggested that it is located at a large distance from the oxygen compared to the 
hydrogen atom.200 Ribeiro et al. also studied the complexation between 
vinpocetine and βCD and sulfobutyl ether βCD. They found upfield shifts for the 
aromatic protons and suggested that this part is involved in the complexation 
with the CD.201 Another study was carried out on chloramphenicol and DIMEB 
which showed both upfield and downfield shifts occurred for the phenyl moiety 
suggested that this part entered into the DIMEB cavity.155 The results obtained 
were in agreement to those obtained by Larsen et al. who studied the complex 
formation between βCD and prednisolone (Figure 4.47, b) whose structure is 
related to budesonide (Figure 4.47, a). They found that the prednisolone forms 
a complex by entering into βCD cavity from the wider rim with the quinone ring 
being considered the main site responsible for the complex formation through 
accessing deeply into the cavity.202 Also, another study conducted by Uekama 
et al. showed that the quinone ring of the hydrocortisone (Figure 4.47, c) was 
able to enter further into the βCD and γCD cavities and thus it was responsible 
for the complex formation.203   
 
Figure 4.47: Chemical structure of (a) budesonide, (b) prednisolone and (c) hydrocortisone 
It has been reported that the intramolecular bonds between the secondary 
hydroxyl groups of the C2 and C3 of βCD at the wider rim are responsible for  
its rigid structure.105 The methylation of the OH group of βCD at C2 and C6 
leads to the improvement of the complexation efficiency of DIMEB.204 Green 
and Guillory found strong complexation occurred between chlorambucil and 
DIMEB compared to that obtained with βCD, indicating that the main driving 
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force for the complexation was not related to the formation of the hydrogen 
bonds between chlorambucil and DIMEB as fewer free hydroxyl groups 
(compared to βCD) are available to form new hydrogen bonds. They suggested 
that the methylation of the hydroxyl groups led to the expanding of the DIMEB 
cavity which enhanced the guest binding by hydrophobic interaction.205 On the 
other hand, in the case of TRIMEB, the secondary hydroxyl groups of C2 and 
C3 are replaced by methyl groups making them unable to form hydrogen bonds. 
This resulted in the enlargement of the surface area inside the cavity as well as 
increasing its height by 2 Å, which in turn makes it suitable for accommodation 
of a large molecule. The DIMEB showed a stronger complex compared to 
TRIMEB, which might be due to the rounded shape of DIMEB resulting from the 
formation of the intramolecular hydrogen bonds between C2 and C3, which 
affords more space in the cavity for the guest to enter deeply compared to that 
of the TRIMEB.206 Also, it has been shown that the methylation of the primary 
OH groups leads to the improvement in the binding constant whereas the 
secondary OH group methylation decreases the binding. On the other hand, 
substitution at the primary position does not decrease the rigidity of the cavity 
and this the reason behind increasing of the binding constant when the 
substitution happens at the primary position.207 The substitution of the 
secondary OH groups (at C2 and C3) by methyl groups results in TRIMEB 
unable to form hydrogen bonds which resulted in the flexibility and loss of the 
conformational stabilisation of the cavity that leads to a weak complex 
formation. The methylation of one secondary OH group at C2 in DIMEB and the 
presence of a free OH group at C3 gives rigidity to the DIMEB by forming 
intramolecular hydrogen bonds, which can form a stronger complex with the 
guest compared to TRIMEB. However, the substituted methyl groups cause a 
steric hindrance in the cavity which lead to weaker complex.208 Bardelang et al. 
found that the stability constant of the complex between nitroxide derivative 
compound and DIMEB is 150 times greater than that with TRIMEB, they 
explained that the free hydroxyl group at C3 in the DIMEB led to the easy 
access to its cavity by the guest compared to TRIMEB.209  
The K values obtained for BUD with CDs can be ordered as following DIMEB > 
βCD > TRIMEB where the values were 4446, 1129, and 429 M-1 respectively, 
which supported the NMR results, where larger chemical shift differences were 
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observed with both DIMEB and βCD compared to TRIMEB. These results were 
consistent to those obtained by Iijima and Karube who investigated the 
interaction of the acid azo dyes with βCD, DIMEB and TRIMEB by UV 
spectroscopy. They found the K values at 25°C were 1000, 4350 and 600 M-1 
and at 35°C were 740, 3980 and 450 M-1 for βCD, DIMEB and TRIMEB 
respectively i.e DIMEB > βCD > TRIMEB. They assumed that the binding 
constant was increased with dimethyl derivatised CD compared to the parent 
CD due to hydrophobic interaction. By contrast, the additional substitution of the 
methyl group (TRIMEB) decreases the binding constant due to steric hindrance 
of the dye molecule (guest).210 Another study performed by Letort et al. showed 
that the parent βCD had less hydrolysis inhibition effect on fenitrothion 
(organophosphorus pesticide) compared to the methylated βCDs (TRIMEB and 
DIMEB). The methyl groups can cause the extension of the cavity size of 
TRIMEB and DIMEB which in turn allows fenitrothion to enter deeply into the 
cavity. In addition, the phosphate moiety of the fenitrothion can be protected 
from external nucleophilic attack by the methyl groups of the methylated βCDs 
which prevented the entry of hydroxide ions.211 The results performed by 
Uekama et al. on hydrocortisone showed that it forms a more loosely held 
complex with γCD compared to βCD,203 this is due to the structure of both CDs, 
where the γCD has a cavity volume of 427 Å with an external and internal 
diameter of 17.5 and 7.5-8.3 Å respectively, compared to βCD with the cavity 
size of 262 Å and with an external and internal diameter 15.4 and 6-6.5 Å 
respectively.212 Therefore, the hydrocortisone forms a strong complex with βCD 
compared to a weaker complex with γCD with a larger cavity. Also, another 
study performed on prednisolone found a higher association constant with βCD 
compared to γCD whereas 6α-methyl prednisolone forms a higher association 
constant with γCD compared to βCD. It was suggested that the bulky molecule 
of 6α-methyl prednisolone with the addition of methyl group required a large 
cavity to form complex and γCD is more favourable for the complexation than 
βCD (methyl group prevents it from penetrating further inside the cavity). On the 
other hand, prednisolone alone prefers βCD to form a strong complex than γCD 
since the βCD cavity is suitable in size to form an inclusion complex with 
prednisolone compared to the larger cavity size of γCD.203 Accordingly, the 
enlargement of the CD cavity is not always associated with strong complexation 
and the two mentioned examples support this statement, where the 6α-methyl 
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prednisolone with the bulky structure prefers the larger cavity of γCD whereas 
prednisolone prefers βCD with smaller cavity for the complex formation.202  
In this study, the chemical shift differences of the complexed BUD protons with 
the three types of CDs (βCD, DIMEB and TRIMEB), was related to the change 
in the microenvironment of the BUD protons in the presence of CDs. All of the 
three CD types caused chemical shift changes for the quinone ring protons and 
H-C19 which confirmed the entrance of the BUD to their cavities with the 
quinone ring part. By contrast, the chemical shift change of H-C18 of BUD was 
observed with both βCD and DIMEB but not TRIMEB, indicating the deeper 
entrance of BUD into βCD and DIMEB cavities compared to TRIMEB. The 
upfield shifts of the quinone ring protons of BUD (H-C1, H-C2 and H-C4) with 
βCD and DIMEB, with the exception of H-C1 proton with βCD could be ascribed 
to the conformational changes resulting from the complexation and from the 
shielding effect of the CD hydrophobic cavity. This effect was induced by the 
oxygen atoms located on the inner surface of the CD cavity and thus could 
suggest that these protons were located closer to the oxygen atom in the CD 
cavity.155,201,213 This indicated that this part of BUD (quinone ring) was involved 
in the complexation with the βCD and DIMEB by entering into their cavities. By 
contrast, Both H-C18 and H-C19 protons of BUD with both types of CDs (βCD 
and DIMEB) and H-C1 proton with βCD were observed with downfield shift, and 
different explanations had been given to clarify this shift difference. One of the 
reasons behind this change was the structure rearrangement and 
conformational changes of guest (BUD) molecule after the complexation.200 
Also, it could be related to the change in the local polarity214 or a deshielding 
effect resulting from van der Waals interaction with the carbohydrate chains.213 
Another explanation was owing to the interaction of theses protons (H-C18 and 
H-C19) with the hydrophilic external part of the βCD and DIMED.201 Alternatively, 
it could be suggested that these protons were located at large distance from the 
oxygen compared to the hydrogen atom.  
According to these views, it could be suggested that H-C18 and H-C19 protons 
interacted with the outside surface of βCD and DIMED, but near their wider rim 
in which they were situated, far from the oxygen atom located inside the CDs 
cavities. The extent of the chemical shift difference was largely observed with 
H-C19 than H-C18 suggested the closer of the former proton to the wider rim of 
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the both CDs cavities whereas the later was situated away from the rim but still 
be affected by the CD environment. The downfield shift of H-C1 proton with βCD 
suggested the presence of this proton near the cavity rim compared to DIMEB, 
where this proton was observed with upfield shift that in turn indicated its 
entrance into the DIMEB cavity. This explained the high K value of DIMEB 
compared with βCD as BUD was more deeply entered into the DIMEB cavity. 
The complexation with TRIMEB showed an upfield shift for only H-C4 of the 
quinone ring whereas a small downfield shift of the H-C2 proton. Also, the H-C19 
proton was observed with a small downfield shift and no change was noted for 
H-C18 proton. This suggested that the quinone ring entered the TRIMEB cavity 
partially where the H-C4 proton was situated at a distance not closer to the 
oxygen atoms inside the cavity. This explained the small shift changes for this 
proton compared to the complexation with βCD and DIMED where the H-C4 
proton was located closer to the oxygen atom inside the CD cavity and hence a 
larger shift change was observed. The other protons with downfield shifts (H-C2 
and H-C19) were located outside the cavity and the shift differences could be 
attributed to their interaction with the hydrophilic external part of the TRIMEB. 
However, no shift was observed for H-C18 suggesting that this proton was far 
from the TRIMEB cavity.  
To summarise, BUD interacted with DIMEB, where the quinone ring totally 
entered into its cavity whereas it partially entered into the βCD cavity (H-C1 of 
BUD observed with downfield shift), leaving both H-C19 and H-C18 (with 
downfield shift) outside with the former located near the wider rim whereas the 
later was situated a large distance from both CDs cavities. Concerning the 
complexation with TRIMEB, BUD was situated in a position where only H-C4 
proton of the quinone ring (experienced upfield shift) entered the TRIMEB cavity 
leaving the other H-C1 and H-C2 protons of the quinone ring altogether with H-
C19 proton (with downfield shift) outside the cavity. The chemical shift difference 
of H-C2 proton was larger due to its closeness to the methoxyl oxygen atoms of 
TRIMEB (at C2 and C3) compared to the H-C19 proton. As the quinone ring 
partially entered the cavity, therefore, the BUD molecule would be situated 
outside the cavity and hence the H-C18 was located at a larger distance from the 
cavity compared to the same proton in the complexation with βCD and DIMED. 
The cavity dimensions of βCD and DIMED are suitable for BUD to enter deeply 
 112 
 
 
compared to a larger cavity of TRIMEB. In addition, intramolecular hydrogen 
bonds are responsible for giving a rigid structure for βCD and DIMEB cavities 
that formed a higher binding constant and a firm complex compared to the 
flexible TRIMEB cavity.  
One can conclude that, the extent of the chemical shift difference was 
dependent on the strength of the interaction between the quinone protons and 
the CD cavity. The closer distance between the CD and the guest (BUD), a 
stronger host-guest complex formed and hence a larger chemical shift 
differences was observed. Consequently, the BUD fitted the cavity size of 
DIMEB and βCD and therefore, their cavities are suitable to accommodate the 
BUD molecule compared to the TRIMEB cavity. The relatively higher K values 
for complexation of BUD with DIMEB and βCD indicated a more stable host-
guest complex formation by the presence of a better geometric fitting compared 
to TRIMEB. The highest stability was obtained with DIMEB, indicating that it has 
the most suitable size to fit and accommodate the BUD into its cavity. This has 
led us to propose the host-guest model for BUD in each of the three CDs shown 
in Figure 4.48. 
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Figure 4.48: Inclusion complex of the budesonide and (a) βCD, (b) DIMEB and (c) TRIMEB. The 
black balls represent the methoxyl groups in the DIMEB and TRIMEB molecules. 
The K values obtained from the NMR method for the complex formed were 
considerably higher compared to those obtained from the UV method for both 
βCD and TRIMEB. This was in agreement to the study conducted by Lee et al. 
which found higher K value from NMR at 295 M-1 compared to that obtained 
from UV studies at 125 M-1 for 6-Hydroxyquinoline in DIMEB. This difference 
was owing to the difference in the principle of both techniques used.174 Also, 
another study conducted by Mic et al. to study the complex formation between 
benzocaine and βCD by NMR which found the K value (1227.7 M-1) was 
higher215 compared to other spectroscopic methods which the K value was 
equal to 549 M-1.216 
However, in this study conflicting results were obtained where the K value 
obtained with βCD was higher compared to the TRIMEB (1129 and 429 M-1) 
from NMR whereas a lower value for βCD versus TRIMEB (94 and 205 M-1) 
from the UV method. It is well known that the UV method is considered 
sensitive and works well for compounds with reasonable solubility levels. 
However, the UV results have some uncertainty as the absorbance values of 
the samples studied in this work were very low (around 0.1 AU). Determination 
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of subtle increases in absorbance is very difficult to perform with high degrees 
of accuracy and precision and leads to significant errors. This can be enhanced 
by the increasing the budesonide concentration, though this is limited by the 
insoluble character of BUD in water (23 µg/mL). Though NMR is inherently far 
less sensitive than UV, determining the chemical shift value of the resonances 
in question can be done accurately and precisely, even for signals with very 
poor S:N. Some studies of compounds that are structurally related to the 
budesonide supported our NMR findings, where the complex showing greatest 
association was βCD compared to TRIMEB. In addition, NMR is considered a 
more useful technique than spectroscopic approaches as the measured 
chemical shift change provides structural information on the host-guest complex 
allows us to propose structural models of their interaction in addition to 
providing the means to calculate the association constants. This information is 
very difficult to extract from spectroscopic titrations.151 In this study, it is clearly 
shown that the shifts observed with βCD were considerably higher compared to 
those of TRIMEB (Table 4.45).  
Table 4.45: The chemical shift difference of budesonide peaks without and with the addition of βCD 
and TRIMEB 
Proton 
position 
Chemical shift, δ (ppm)  
BUD 
(δfree) 
BUD/βCD 
(δcomplex) 
∆δ 
BUD/TRIMEB 
(δcomplex) 
∆δ 
H-C19 1.2570 1.3812 -0.1242 1.2952 -0.0382 
H-C4 5.9645 5.9347 0.0298 5.9456 0.0189 
H-C2 6.1744 6.1024 0.072 6.2310 -0.0566 
H-C2 6.1931 6.1192 0.0739 6.2481 -0.055 
∆δ = δfree - δcomplex 
 
In conclusion, data generated with solid state techniques (vibrational 
spectroscopy and solution based measurements using both UV and NMR have 
allowed us to determine stability constants and complexation models for the 
systems under study. NMR has the additional advantage of probing the 
structure of the complexes formed using the relative displacements of the 
assigned chemical shifts for both the host and guest molecules, and provides a 
powerful means to study the systems in isolation. Furthermore, it allows us to 
study complexes in solvents that are volatile in nature and have not been 
studied in this way before. The development of methods associated with these 
systems is the focus of Chapter 5. 
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5 Host:guest interactions in HFA solvents using NMR 
spectroscopy  
The method developed for budesonide in D2O (Chapter 4.2.4) was used to 
study the complexation of corticosteroids; (i) BUD, (ii) BDP, (iii) FLU and (iv) 
MOM and with cyclodextrins in fluorinated solvent. The volatility of the HFAs 
solvents makes the analysis challenging in terms of their manipulation during 
sample preparation and with the instrumentation. Therefore, methods were 
developed using HPFP as a model to the fluorinated solvent (HFA 134a and 
227) based on the study performed by Rogueda that concludes both of HFA 
134a and 227 propellants have similar properties to that of HPFP.166 This 
assists the studies as HPFP is a volatile liquid compared to both HFA 134a and 
227 which are gases at STP. The developed method can be applied to study 
the volatile propellants using pressurised NMR. When the prepared samples 
were analysed a large resonance from HPFP was observed in the form of a 
complex multiplet, resulting from the J-coupling observed between protons and 
fluorines in the molecule. This brings about a large dynamic range mismatch in 
the same way as the residual water resonance in the experiments performed in 
D2O discussed previously (Section 4.2.4). Therefore, a presaturation method 
similar to that developed in the experiments performed on BUD in D2O was 
applied with some modifications in terms of the position of the suppressed peak 
and the concentration of both the host and the guest. Before starting the study, 
the solubility of all CDs (βCD, TRIMEB and DIMEB) which were used to study 
the complex formation was determined in HPFP by NMR. The solubility of the 
TRIMEB and DIMEB were determined and found to be around 6 and 1 mg/mL 
respectively. However, the solubility of βCD in HPFP was below the limit of 
NMR detection (their peaks were not observed in the spectrum) and it was, 
therefore, not studied as a complexation agent in HPFP. 
During the experimentation performed on BUD in HPFP, it was noted that some 
of the NMR resonances changed chemical shift positions and multiplicity when 
complexed with the derivatised CDs, whereas some remained unaffected. 
These changes were investigated further using a chirally pure form of BUD ((22-
R)-budesonide) to make a true assignment (Section 5.2.1). 
 116 
 
 
5.1 Assignment of corticosteroids in HPFP 
Solutions of the four corticosteroids under investigation (BUD, BDP, MOM and 
FLU) were prepared at 75.3, 208, 20.8 and 20 µg/mL, equivalent to 0.175, 0.4, 
0.04 and 0.04 mM respectively. These concentrations were chosen to be 
slightly lower than the previously determined solubility values for each in 
HPFP.179 BUD was used as a model to study the complexation in HPFP based 
on the developed method used to study its complexation in D2O (Chapter 
4.2.4). The same co-axial NMR tube with the internal standard of CHCl3 in 
CD3CN (100 µg/mL) was used. NMR spectra of BUD in HPFP showed the 
multiplet of HPFP at 4.38 ppm with another intense peak related to the CH3CN 
residual being observed at 2.15 ppm. In this system, two resonances required 
suppression to obtain the levels of sensitivity required for routine observation of 
the analyte signals.  A dual suppression method was developed to suppress 
both peaks at 4.38 ppm (HPFP) and at 2.15 ppm simultaneously (CH3CN 
residual) using separate attenuations of (30,40), (40,40), (50,40), (30,50), 
(40,50), (50,50), (60,50), (44,50), (46,50), (45,50). The most suitable 
combination to maximise the suppression, and hence the S:N of the analyte 
peaks, was 45 and 50 dB respectively. This method was used in concert with 
extended acquisition times (2048 scans).  A representative spectrum of BUD in 
HPFP acquired using this approach is shown as Figure 5.1. This method was 
used to study the other corticosteroids complexation with TRIMEB and DIMEB 
in HPFP with the exception of BDP which was analysed with a reduced scan 
number (1024 scans) due to the increased solubility of BDP in HPFP relative to 
BUD (Section 2.2.4.4).  
 
Figure 5.1: 1H NMR spectra of BUD with solvent suppression at 4.38 and 2.15 ppm in HPFP. 
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The assignment of BUD, BDP, MOM and FLU in HPFP was made based on 
their assignment in CDCl3,180,217-219 as it was expected that only small shifts 
would occur for the peaks in two different solvents (CDCl3 to HPFP). The peaks 
at 4-5 ppm were affected by the presaturation of HPFP at 4.38 ppm and were 
therefore difficult to assign. The other peak assignments are presented in 
Tables 5.1 and 5.2, and show a relatively consistent upfield shift in HPFP when 
compared to CDCl3 (Figures 5.2 and 5.3).  
Table 5.1: Chemical shift of BUD, BDP, MOM and FLU in HPFP compared to their chemical shift in 
CDCl3  
Carbon No. 
δ BUD (ppm) δ BDP (ppm) δ MOM (ppm) δ FLU (ppm) 
CDCl3 HPFP CDCl3 HPFP CDCl3 HPFP CDCl3 HPFP 
1 7.23 6.55 7.18 6.51 7.19 6.47 7.15 6.42 
2 6.27 5.47 6.34 5.52 6.37 5.53 6.46 5.56 
4 6.01 5.24 6.09 5.29 6.13 5.32 6.40 5.64 
16 − − 1.34 0.64 0.99 0.27 1.07 0.32 
17 − − 1.16 0.48 − − − − 
18 0.98 0.33 0.99 0.36 1.15 0.48 1.16 0.44 
19 1.44 0.80 1.65 1.02 1.68 1.02 1.55 0.85 
21 − − 1.16 0.48 − − − − 
25 0.91 0.26 − − − − − − 
F3 − − − − 7.25 6.61 − − 
F4 − − − − 6.54 5.79 − − 
F5 − − − − 7.63 6.84 − − 
 
 
Table 5.2: Assignment of BUD, BDP, MOM and FLU in HPFP. 
Carbon No. 
Chemical shift (ppm) 
BUD BDP MOM FLU 
1 6.55 (dd) 6.51(d) 6.47 (s) 6.42 (d) 
2 5.47 (d) 5.52 (d) 5.53 (d) 5.56 (d) 
4 5.24 (s) 5.29 (s) 5.32 (s) 5.64 (s) 
Me-16 − 0.64 (d) 0.27 (d) 0.32 (d) 
17 Me propionate − 0.48 (dt) / / 
Me-18 0.33 (s) 0.36 (s) 0.48 (s) 0.44 (t) 
Me-19 0.80 (s) 1.02 (s) 1.02 (s) 0.85 (s) 
21 Me propionate − 0.48 (dt) − − 
25 0.26 (t) − − − 
F3 − − 6.61 (s) − 
F4 − − 5.79 (s) − 
F5 − − 6.84 (s) − 
Spectra are assigned referenced to CHCl3 from the co-axial insert. Multiplicity given with the 
abbreviations: s (singlet), d (doublet), t (triplet), dd (doublet of triplets), dd (doublet of doublets). 
 118 
 
 
 
Figure 5.2: Chemical shift of (a) BUD, (b) BDP, (c) MOM and (d) FLU in CDCl3 (lower) and HPFP 
(upper) in high field region showing an upfield chemical shift in HPFP compared to CDCl3. 
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Figure 5.3: Chemical shift of (a) BUD, (b) BDP, (c) MOM and (d) FLU in CDCl3 (lower) and HPFP 
(upper) in low field region showing an upfield chemical shift in HPFP compared to CDCl3. 
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The stability constant was determined by recording the chemical shift values of 
each of the corticosteroids peaks (referenced to CHCl3 from the co-axial insert) 
for all five different solutions prepared with increasing CD concentrations 
(Section 2.2.4.4) and calculating their displacement relative to compound peaks 
from a pure solution without CD addition. 
5.2 Complexation study of BUD and TRIMEB 
The complexation of BUD and TRIMEB was investigated in HPFP and the 
results showed very minor shifts occurred for H-C18 and H-C19 peaks at 0.3354 
and 0.7992 ppm chemical shift respectively. The H-C25 peak did not shift, 
though its multiplicity changed as the TRIMEB concentration was increased. An 
additional peak appeared at 0.2889 ppm chemical shift in the spectrum of the 
complexed BUD which was then shifted downfield with the increasing TRIMEB 
concentration until it merged with the H-C18 at around 0.34 ppm at higher 
TRIMEB concentration (at 0.4 and 0.5 mM). The spectra of the complexed BUD 
in the high field region are shown in Figure 5.4. 
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Figure 5.4: Budesonide (0.0875 mM) chemical shift in high field region (0.1-0.9 ppm) with the 
addition of TRIMEB at 0, 0.1, 0.2, 0.3, 0.4 and 0.5 mM in HPFP. 
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In addition, a downfield shift was observed for the H-C1 proton of the quinone 
ring, and a distinct multiplicity change was noted (J-coupling constants increase 
with increasing CD concentration). A very small upfield shift occurred for H-C4, 
and no observable shift was noted for the H-C2 of the quinone ring (Figure 5.5). 
 
Figure 5.5: Budesonide (0.0875 mM) chemical shift in low field region (5.1-6.7 ppm) with the 
addition of TRIMEB at 0, 0.1, 0.2, 0.3, 0.4 and 0.5 mM in HPFP. 
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These results demonstrate that some protons display only small shifts with 1 
mM TRIMEB concentration. A second series of experiments was performed 
with a more concentrated solution of TRIMEB (4 mM) in order to enhance the 
chemical shift displacements observed. It has been noted that the resonance at 
0.34 ppm chemical shift appears as a singlet at 0.4 mM TRIMEB concentration, 
which is consistent with that obtained in the last experiment where one peak 
appeared at around 0.34 ppm chemical shift (at 0.4 and 0.5 mM of TRIMEB). 
The peak was split into two peaks; one showing no significant shift with 
increasing CD concentration, the second moving significantly to 0.44 ppm at 2 
mM TRIMEB concentration. The first one (0.34 ppm chemical shift) could be 
assigned to the H-C18 peak of the S-enantiomer of BUD whereas the latter could 
be related to the H-C18 peak of R-enantiomer of BUD. Other peaks in the high 
field region such as H-C25 and H-C19 showed no shift, however, the peak shape 
changed where H-C25 was split into many peaks whereas the H-C19 resonance 
that showed a partial split initially was fully split into two distinctive peaks at 2 
mM TRIMEB concentration (Figure 5.6). 
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Figure 5.6: Budesonide (0.0875 mM) chemical shift in high field region (0.1-0.9 ppm) with the 
addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
In the low field region, a significant downfield shift occurred for the H-C1 proton 
of the quinone ring and the peak was split into four peaks as the concentration 
of TRIMEB was increased. A slight upfield shift for the H-C4 proton with partial 
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splitting into two peaks at higher TRIMEB concentration (1.6 and 2 mM) was 
observed, with no significant shift for the H-C2 proton of the quinone ring. The 
spectra of the complexed BUD in the low field region are shown in (Figure 5.7). 
 
Figure 5.7: Budesonide (0.0875 mM) chemical shift in low field region (5.1-6.7 ppm) with the 
addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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5.2.1  (22-R)-budesonide (pure enantiomer) with TRIMEB 
The experiments performed to study the complexation between BUD and 
TRIMEB (4 mM) in HPFP (Section 5.2) showed two peaks appearing at ca. 0.34 
and 0.44 ppm chemical shift that displayed a significant displacement on 
addition of TRIMEB. The same experiment as preformed on racemic BUD was 
repeated with a sample of pure R-enantiomer of BUD (Section 2.3.5) in order to 
unequivocally assign the two displaced peaks of H-C18 proton to the R- and S-
enantiomers of BUD. It has been shown that the peak at 0.34 ppm (annotated 
with a star in Figure 5.8) appears as a singlet at 0.4 mM TRIMEB concentration 
and is shifting significantly to 0.44 ppm at 2 mM TRIMEB concentration. The 
peak at 0.3354 ppm of the H-C18 peak of the S-enantiomer of BUD was not 
observed in the spectrum of pure R-enantiomer. This was consistent with data 
obtained in the previous experiment of the racemic BUD (Section 5.2) where the 
singlet peak in the pure R-enantiomer spectrum matched the moving peak at 
0.44 ppm at 2 mM (annotated with star in Figure 5.9) in the racemic BUD 
confirming the assignment of the H-C18 peak to the R-enantiomer of BUD. The 
peak displaying no shift at 0.34 ppm (annotated with a dot in Figure 5.9) in the 
spectrum of racemic BUD is now assigned to the H-C18 peak of the S-
enantiomer of BUD. 
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Figure 5.8: pure R-enantiomer of BUD (0.0875 mM) chemical shift in high field region (0.2-0.85 ppm) 
with the addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. The shifted peak annotated 
with star was assigned to R-enantiomer of BUD. 
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Figure 5.9: Racemic BUD (0.0875 mM) chemical shift in high field region (0.2-0.85 ppm) with the 
addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. The shifted peak annotated with star 
was assigned to R-enantiomer of BUD whereas the peak at 0.34 ppm (annotated with dot) was 
assigned to S-enantiomer of BUD 
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In the low field region, there was no shift observed for H-C2 of the R-enantiomer 
whereas a small downfield shift was observed for H-C1 at 6.5491 and 6.5666 
ppm (Figure 5.10). The H-C4 proton however showed a small upfield shift at the 
higher TRIMEB concentration (2 mM). The racemic BUD results showed a very 
small upfield shift for H-C4 proton, and no observable shift was noted for the H-
C2 of the quinone ring. A downfield shift was observed for the H-C1 proton of the 
quinone ring, and a distinct multiplicity change was noted (J-coupling constants 
increase with increasing CD concentration). Therefore, the two peaks at 6.5491 
and 6.5666 ppm were related to the R-enantiomer of BUD whereas the other 
two peaks at 6.5431 and 6.5600 ppm were related to the S-enantiomer of BUD 
(Figure 5.11). 
 
Figure 5.10: Pure R-enantiomer of BUD (0.0875 mM) chemical shift in low field region (5.1-6.7 ppm) 
with the addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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Figure 5.11: Racemic BUD (0.0875 mM) chemical shift in low field region (5.1-6.7 ppm) with the 
addition of TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. The peaks annotated with star and  dot 
were related to R- and S-enantiomer of BUD.  
The assignment of the proton resonance shifts for the optically pure forms of 
BUD has allowed the stability constants for R- and S-enantiomers of BUD to be 
calculated using the H-C1 proton chemical shift at 6.5491/6.5666 and 
6.5431/6.5600 ppm respectively. Table 5.3 shows the results of the experiments 
performed on the racemic BUD, with those from the S- and R-enantiomers 
shown in Tables 5.4 and 5.5, with reciprocal plots for the two enantiomers 
shown in Figures 5.12 and 5.13. 
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Table 5.3: Results of the chemical shift of budesonide and TRIMEB added at 0, 0.4, 0.8, 1.2, 1.6 and 
2 mM in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
TRIMEB concentration (mM) 
0 0.4 0.8 1.2 1.6 2 
Chemical shift (ppm) 
1 
H-C1  6.5666 
6.5935 6.6107 6.6247 6.6344 6.6401 
2 6.5929 6.6103 6.6234 6.6322 6.6395 
3 6.5927 6.6086 6.6240 6.6327 6.6379 
Mean 6.5930 6.6099 6.6240 6.6331 6.6392 
SD 0.0004 0.0011 0.0007 0.0012 0.0011 
% CV 0.0063 0.0169 0.0098 0.0174 0.0171 
1 
H-C1  6.5600 
6.5653 6.5693 6.5743 6.5763 6.5803 
2 6.5649 6.5689 6.5727 6.5755 6.5793 
3 6.5652 6.5688 6.5741 6.5760 6.5807 
Mean 6.5651 6.5690 6.5737 6.5759 6.5801 
SD 0.0002 0.0003 0.0009 0.0004 0.0007 
% CV 0.0032 0.0040 0.0133 0.0061 0.0110 
1 
H-C1  6.5491 
6.5761 6.5946 6.6086 6.6169 6.6235 
2 6.5756 6.5937 6.6071 6.6145 6.6229 
3 6.5758 6.5929 6.6071 6.6152 6.6236 
Mean 6.5758 6.5937 6.6076 6.6155 6.6233 
SD 0.0003 0.0009 0.0009 0.0012 0.0004 
% CV 0.0038 0.0129 0.0131 0.0187 0.0057 
1 
H-C1  6.5431 
6.5462 6.5508 6.5568 6.5599 6.5628 
2 6.5461 6.5511 6.5555 6.5589 6.5622 
3 6.5461 6.5499 6.5561 6.5594 6.5629 
Mean 6.5461 6.5506 6.5561 6.5594 6.5626 
SD 0.0001 0.0006 0.0007 0.0005 0.0004 
% CV 0.0009 0.0095 0.0099 0.0076 0.0058 
 
Table 5.4: Results of the complexation between R-enantiomer of budesonide and TRIMEB added at 
0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP using 1H NMR depending on the chemical shift differnce of H-C1 
proton 6.5666 and 6.5491 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (6.5666 ppm) 1/∆δobs (6.5491 ppm) 
1 2 3 Mean 1 2 3 Mean 
0.4 2.5 37.2 38 38.3 38 37 37.7 37.5 37.6 
0.8 1.3 22.7 22.9 23.8 23.1 22 22.4 22.8 22.4 
1.2 0.8 17.2 17.6 17.4 17.4 16.8 17.2 17.2 17.1 
1.6 0.6 14.7 15.2 15.1 15 14.7 15.3 15.1 15.1 
2 0.5 13.6 13.7 14.0 13.8 13.4 13.6 13.4 13.5 
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Table 5.5: Results of the complexation between S-enantiomer of budesonide and TRIMEB added at 
0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP using 1H NMR depending on the chemical shift differnce of H-C1 
proton at 6.5431 and 6.5600 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (6.5431 ppm) 1/∆δobs (6.5600 ppm) 
1 2 3 Mean 1 2 3 Mean 
0.4 2.5 323 333 333 330 188.7 204 192.3 195 
0.8 1.3 130 125 147 134 107.5 112 113.6 111 
1.2 0.8 73.0 80.6 76.9 76.9 69.9 78.7 70.9 73.2 
1.6 0.6 59.5 63.3 61.3 61.4 61.3 64.5 62.5 62.8 
2 0.5 50.8 52.4 50.5 61.2 49.3 51.8 48.3 49.8 
 
 
Figure 5.12: Reciprocal plot for the determination of association constant between R-enantiomer of 
BUD and TRIMEB in HPFP by 1H NMR depending on the chemical shift differnce of H-C1 proton at 
6.5666 and 6.5491 ppm (Mean ± SD, n=3). 
 
Figure 5.13: Reciprocal plot for the determination of association constant between S-enantiomer of 
BUD and TRIMEB in HPFP by 1H NMR depending on the chemical shift differnce of H-C1 proton at 
6.5431 and 6.5600 ppm (Mean ± SD, n=3). 
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The reciprocal plot showed good linearity indicating that the complexation had a 
stoichiometry of 1:1. The mean K was found to be 621 and 222 M-1 for R and S 
enantiomers of BUD respectively as shown in Table 5.6. 
Table 5.6: Results of the stability constant between R and S-enantiomers of budesonide and 
TRIMEB added at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP using 1H NMR. 
Proton 
NO. 
BUD 
enantiomer 
Chemical 
shift 
(ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C1 
R 
6.5666 630 624 621 625 4.6 0.7 
6.5491 610 617 624 617 7 1.1 
S 
6.56 227 213 219 220 7 3.2 
6.5431 228 224 217 223 5.6 2.5 
 
The Job’s method of continuous variation was adopted (Section 2.2.3.3) to 
verify the stoichiometry of the complex based on the induced chemical shift 
changes of H-C1 proton of BUD at 6.5666 ppm (Table 5.7). The plot is shown in 
Figure 5.14. 
Table 5.7: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and TRIMEB in HPFP based on the chemical shift at H-C1 proton of budesonide at 6.5666 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.175 1 6.5666 0 0 0 
0.1575 0.9 6.5674 0.0008 12.6 x 10-5 1.26 
0.14 0.8 6.5683 0.0017 23.8 x 10-5 2.38 
0.1225 0.7 6.5693 0.0027 33.1 x 10-5 3.31 
0.105 0.6 6.571 0.0044 46.2 x 10-5 4.62 
0.0875 0.5 6.5725 0.0059 51.6 x 10-5 5.16 
0.07 0.4 6.5735 0.0069 48.3 x 10-5 4.83 
0.0525 0.3 6.5747 0.0081 42.5 x 10-5 4.25 
0.035 0.2 6.5764 0.0098 34.3 x 10-5 3.43 
0.0175 0.1 6.5784 0.0118 20.7 x 10-5 2.07 
0 0 0 0 0 0 
δfree = 6.5666 ppm     
 
The stoichiometry of the complex is shown to be 1:1, as the highest value of r 
was at 0.5. These data are in agreement with the titration experiments which 
returned a linear response when using the Hildebrand-Benesi approach.  
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Figure 5.14: Determination of the stoichiometry of the complex between budesonide and TRIMEB 
in HPFP by 1H NMR based on H-C1 proton of budesonide. 
 
5.3 Complexation study of BDP and TRIMEB  
The complexation of BDP and TRIMEB in HPFP demonstrate that some 
protons display only very minor shifts with 1 mM TRIMEB concentration where 
the values were small to calculate the stability constant. The experiment was 
then conducted with a more concentrated solution of TRIMEB (4 mM). It has 
been noted that small shifts occurred for the H-C19 peak at 1.0206 ppm 
chemical shift, and no significant shifts were observed for H-C18 or the methyls 
at C17 and C21. In addition, a minor downfield shift occurred for H-C4 at 5.2943 
ppm, with no observable shifts for the H-C1 and H-C2 of the quinone ring 
(Figures 5.15 and 5.16). 
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Figure 5.15: BDP (0.2 mM) chemical shift in high field region (0.1-1.2 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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Figure 5.16: BDP (0.2 mM) chemical shift in low field region (5.2-6.7 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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The chemical shift differences of both H-C19 and H-C4 protons at 1.0206 and 
5.2943 ppm respectively were used to calculate the stability constant as these 
peaks displayed considerable shifts when compared to the other protons in the 
BDP molecule. The results of the triplicate experiments are presented in Table 
5.8. 
Table 5.8: Results of the chemical shift of BDP and TRIMEB added at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM 
in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
TRIMEB concentration (mM) 
0 0.4 0.8 1.2 1.6 2 
Chemical shift (ppm) 
1 
H-C19 1.0206 
1.0335 1.0439 1.0515 1.0647 1.0743 
2 1.0338 1.0451 1.0552 1.0630 1.0724 
3 1.0337 1.0474 1.0546 1.0612 1.0725 
Mean 1.0337 1.0455 1.0538 1.0630 1.0731 
SD 0.0002 0.0018 0.0020 0.0018 0.0011 
% CV 0.0148 0.1701 0.1884 0.1647 0.0996 
1 
H-C4 5.2943 
5.3123 5.3269 5.3381 5.3547 5.3689 
2 5.3119 5.3271 5.3376 5.3536 5.3653 
3 5.3120 5.3283 5.3383 5.3524 5.3648 
Mean 5.3121 5.3274 5.3380 5.3536 5.3663 
SD 0.0002 0.0008 0.0004 0.0012 0.0022 
% CV 0.0039 0.0142 0.0068 0.0215 0.0417 
 
The determination of K depending on the chemical shift differences at 1.0206 
and 5.2943 ppm is presented in Table 5.9, with the Hildebrand-Benesi plots 
being shown in Figure 5.17. 
Table 5.9: Results of the complexation between BDP and TRIMEB added at 0.4, 0.8, 1.2, 1.6 and 2 
mM in HPFP using 1H NMR depending on the chemical shift at 1.0206 and 5.2943 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (1.0206 ppm) 1/∆δobs (5.2943 ppm) 
1 2 3 Mean 1 2 3 Mean 
0.4 2.5 77.5 75.8 76.3 76.5 55.6 56.8 56.5 56.3 
0.8 1.3 42.9 40.8 37.3 40.4 30.7 30.5 29.4 30.2 
1.2 0.8 32.4 28.9 29.4 30.2 22.8 23.1 22.7 22.9 
1.6 0.6 22.7 23.6 24.7 23.6 16.6 16.9 17.2 16.9 
2 0.5 18.6 19.3 19.3 19.1 13.4 14.1 14.2 13.9 
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Figure 5.17: Reciprocal plot for the determination of association constant between BDP and 
TRIMEB in HPFP by 1H NMR depending on the chemical shift at 1.0206 and 5.2943 ppm (Mean ± SD, 
n=3). 
The reciprocal plot showed good linearity indicating that the complexation had a 
stoichiometry of 1:1. The mean K value was calculated and found to be 197.5 
M-1 based on the chemical shift for H-C4 and H-C19 protons (Table 5.10).  
Table 5.10: Results of the stability constant between BDP and TRIMEB  added at 0.4, 0.8, 1.2, 1.6 
and 2 mM in HPFP using 1H NMR. 
Proton 
position 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C4 5.2943 198 196 199 198 1.5 0.8 
H-C19 1.0206 197 200 193 197 3.5 1.8 
 
5.4 Complexation study of MOM and TRIMEB 
The experiments of the complexation study of MOM and TRIMEB in HPFP 
showed that the values of the chemical shift differences with 1 mM TRIMEB 
concentration were too small and not reliable to do the reciprocal plot for the 
stability constant determination. A second series of experiments was then 
performed with a more concentrated solution of TRIMEB (4 mM) with the 
purpose of obtaining more chemical shift displacements for the MOM protons. 
The results showed a downfield shift occurred for H-C19 peak at 1.0263 ppm 
chemical shift, however, other peaks in the high field region were not shifted 
such as H-C18 and methyls at C16 (Figure 5.18).  
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Figure 5.18: MOM (0.02 mM) chemical shift in high field region (0.1-1.2 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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The MOM peaks in the low field region of the complexed spectra were of low 
S/N ratio and therefore difficult to investigate the effect of TRIMEB on them 
(Figure 5.19). This was because of the low concentration of MOM in the 
complexed solution with CD (decreased to half, 0.02 mM) compared to the pure 
solution of MOM without CD and this the highest concentration that can be 
prepared according to its solubility in HPFP. 
 
Figure 5.19: MOM (0.02 mM) chemical shift in low field region (5.2-6.9 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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The chemical shift displacements of H-C19 peak at 1.0263 ppm was used to 
determine the stability constant, this peak was the only one observed with 
considerable shift when compared to the other protons of the MOM compound. 
The results are presented in Table 5.11. 
Table 5.11: Results of the chemical shift of MOM and TRIMEB added at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM 
in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
TRIMEB concentration (mM) 
0 0.4 0.8 1.2 1.6 2 
Chemical shift (ppm) 
1 
H-C19 1.0263 
1.0324 1.0394 1.0461 1.0557 1.0667 
2 1.0325 1.0397 1.0475 1.0549 1.0650 
3 1.0323 1.0404 1.0457 1.0540 1.0655 
Mean 1.0324 1.0398 1.0464 1.0549 1.0657 
SD 0.0001 0.0005 0.0009 0.0009 0.0009 
% CV 0.0097 0.0494 0.0903 0.0806 0.0820 
 
The determination of the K based on the chemical shift displacements at 1.0263 
ppm is shown in Table 5.12 with the reciprocal plot being shown in Figure 6.20. 
Table 5.12: Results of the complexation between MOM and TRIMEB added at 0.4, 0.8, 1.2, 1.6 and 2 
mM in HPFP using 1H NMR depending on the chemical shift at 1.0263 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (1.0263 ppm) 
1 2 3 Mean 
0.4 2.5 163.9 161.3 166.7 164 
0.8 1.3 76.3 74.6 70.9 74 
1.2 0.8 50.5 47.2 51.6 49.7 
1.6 0.6 34 35 36.1 35 
2 0.5 24.8 25.8 25.5 25.4 
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Figure 5.20: Reciprocal plot for the determination of association constant between MOM and 
TRIMEB in HPFP by 1H NMR depending on the chemical shift at 1.0263 ppm (Mean ± SD, n=3).. 
The reciprocal plot showed a linear relationship between the 1/[TRIMEB] and 
1/∆δobs which indicated the complexation had a stoichiometry of 1:1. The mean 
K value was calculated and found to be 130 M-1 (Table 5.13).  
Table 5.13: Results of the stability constant between MOM and TRIMEB  added at (0, 0.4, 0.8, 1.2, 
1.6 and 2 mM) in HPFP using 1H NMR. 
Proton NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C19 1.0263 131 125 134 130 4.6 3.5 
 
5.5 Complexation study of FLU and TRIMEB 
The complexation study of FLU with TRIMEB in HPFP showed that very small 
shifts were noted for all the FLU peaks with 1 mM TRIMEB concentration, it was 
difficult to apply the Hildebrand-Benesi approach to calculate the stability 
constant. Therefore, further experiment was performed using a concentrated 
solution of TRIMEB (4 mM) to display more chemical shift displacements for the 
FLU peaks. The results showed a downfield shift was observed for only the H-
C19 proton at 0.8560 ppm chemical shift when the TRIMEB concentration was 
increased, and no observable shift was noted for the other peaks in the high 
field region such as methyls at C16 and H-C18 protons (Figure 5.21).  
 
y = 68.814x - 8.9506
R² = 0.9989
0
20
40
60
80
100
120
140
160
180
0 0.5 1 1.5 2 2.5 3
1
/∆
δ
o
b
s
1/[TRIMEB] mM-1
 143 
 
 
 
Figure 5.21: FLU (0.02 mM) chemical shift in high field region (0.1-1.2 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
In addition, no considerable shift was observed for the H-C2 proton of the 
quinone ring at 5.64 ppm chemical shift. However, the other two protons of the 
quinone rings (H-C1 and H-C4) were not clearly observed in the complexed 
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spectra of FLU and displayed a low S/N ratio and therefore it was difficult to 
study the effect of TRIMEB on the chemical shift of those protons (Figure 5.22). 
This was owing to the low concentration of FLU in the complexed solution with 
CD (decreased to half, 0.02 mM) compared to the pure solution of FLU without 
CD, and this the highest concentration that can be prepared according to its 
solubility in HPFP. 
 
Figure 5.22: FLU (0.02 mM) chemical shift in low field region (5.5-6.6 ppm) with the addition of 
TRIMEB at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM in HPFP. 
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The chemical shift displacements of the H-C19 proton at 0.8560 ppm are 
presented in Table 5.14, where they used to calculate the K as shown in Table 
5.15 with reciprocal plot shown in Figure 5.23. 
Table 5.14: Results of the chemical shift of FLU and TRIMEB added at 0, 0.4, 0.8, 1.2, 1.6 and 2 mM 
in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
TRIMEB concentration (mM) 
0 0.4 0.8 1.2 1.6 2 
Chemical shift (ppm) 
1 
H-C19 0.8560 
0.8600 0.8629 0.8671 0.8708 0.8751 
2 0.8598 0.8636 0.8662 0.8696 0.8739 
3 0.8599 0.8634 0.8677 0.8689 0.8739 
Mean 0.8599 0.8633 0.8670 0.8698 0.8743 
SD 0.0001 0.0004 0.0008 0.0010 0.0007 
% CV 0.0116 0.0418 0.0871 0.1105 0.0792 
 
Table 5.15: Results of the complexation between FLU and TRIMEB added at 0.4, 0.8, 1.2, 1.6 and 2 
mM in HPFP using 1H NMR depending on the chemical shift at 0.8560 ppm. 
TRIMEB 
(mM) 
1/TRIMEB 
(mM-1) 
1/∆δobs (0.8560 ppm) 
1 2 3 Mean 
0.4 2.5 250 263.2 256.4 256.5 
0.8 1.3 144.9 131.6 135.1 137.2 
1.2 0.8 90.1 98 85.5 91.2 
1.6 0.6 67.6 73.5 77.5 72.9 
2 0.5 52.4 55.9 55.9 54.7 
 
 
Figure 5.23: Reciprocal plot for the determination of association constant between FLU and 
TRIMEB in HPFP by 1H NMR depending on the chemical shift at 0.8560 ppm (Mean ± SD, n=3). 
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The reciprocal plot showed a linear relationship which suggested the 
stoichiometric ratio was 1:1. The mean K value was calculated as shown in 
Table 5.16 and found to be 86 M-1. 
Table 5.16: Results of the stability constant between FLU and TRIMEB  added at 0, 0.4, 0.8, 1.2, 1.6 
and 2 mM in HPFP using 600 MHz 1H NMR. 
Proton 
NO. 
Chemical shift 
(ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C19 0.8560 87 81 90 86 4.6 5.3 
 
5.6 Complexation study of BUD and DIMEB 
The study of the complexation between BUD and DIMEB was performed using 
the same developed method of BUD with TRIMEB. The findings demonstrated 
that very small shifts occurred for H-C18 and H-C19 peaks at 0.3354 and 0.7992 
ppm respectively. The H-C25 peak was not shifted, though its multiplicity 
changed as the TRIMEB concentration was increased. However, the peak at 
0.2667 ppm (annotated with star in Figure 5.24) experienced a very minor shift 
and could be attributed to the H-C18 peak of the R-enantiomer of BUD.  
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Figure 5.24: BUD (0.0875 mM) chemical shift in high field region (0.1-0.9 ppm) with the addition of 
DIMEB at 0, 0.075, 0.15, 0.225, 0.3 and 0.375 mM in HPFP. The peak annotated with star was related 
to R-enantiomer of BUD. 
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In the low field region, a slight downfield shift occurred for the H-C1 proton of the 
quinone ring, as the concentration of TRIMEB was increased, and no significant 
shift was observed for both H-C2 and H-C4 protons of the quinone ring. The 
spectra of the complexed BUD in the low field region are shown in Figure 5.25. 
 
Figure 5.25: BUD (0.0875 mM) chemical shift in low field region (5.2-6.7 ppm) with the addition of 
DIMEB at 0, 0.075, 0.15, 0.225, 0.3 and 0.375 mM in HPFP. 
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The chemical shift differences of the H-C1 proton at 6.5666 ppm are shown in 
Table 5.17 and the stability constant determination is presented in Table 5.18 
with the reciprocal plot shown in Figure 5.26. 
Table 5.17: Results of the chemical shift of budesonide and DIMEB added at 0, 0.075, 0.15, 0.225, 
0.3 and 0.375 mM in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
DIMEB concentration (mM) 
0 0.075 0.15 0.225 0.3 0.375 
Chemical shift (ppm) 
1 
H-C1 6.5666 
6.5694 6.5725 6.5754 6.5771 6.5829 
2 6.5692 6.5725 6.5741 6.5764 6.5823 
3 6.5692 6.5718 6.5744 6.5763 6.5837 
Mean 6.5693 6.5723 6.5746 6.5766 6.5830 
SD 0.0001 0.0004 0.0007 0.0004 0.0007 
% CV 0.0018 0.0061 0.0104 0.0066 0.0107 
 
Table 5.18: Results of the complexation between budesonide and DIMEB added at 0.075, 0.15, 
0.225, 0.3 and 0.375 mM in HPFP using 1H NMR depending on the chemical shift at 6.5666 ppm. 
DIMEB 
(mM) 
1/DIMEB 
(mM-1) 
1/∆δobs (6.5666 ppm) 
1 2 3 Mean 
0.075 13.3 357.1 384.6 384.6 375.5 
0.15 6.7 169.5 169.5 192.3 177.1 
0.225 4.4 113.6 133.3 128.2 125.1 
0.3 3.3 95.2 102 103.1 100.1 
0.375 2.7 61.4 63.7 58.5 61.2 
 
 
Figure 5.26: Reciprocal plot for the determination of association constant between budesonide and 
DIMEB in HPFP by 1H NMR depending on the chemical shift at 6.5666 ppm (Mean ± SD, n=3). 
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The reciprocal plot showed linearity, which suggested that the stoichiometric 
ratio was 1:1. The mean K value was calculated as shown in Table 5.19 and 
found to be 199 M-1 based on the chemical shift difference of the H-C1 proton.  
Table 5.19: Results of the stability constant between budesonide and DIMEB added at 0, 0.075, 
0.15, 0.225, 0.3 and 0.375 mM in HPFP using 1H NMR. 
Proton NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C1 6.5666 203 194 200 199 4.6 2.3 
 
The stoichiometry of the complex was confirmed by Job’s diagram as described 
in Section 2.2.3.3, based on the chemical shift changes of H-C1 proton of BUD 
at 6.5666 and 6.5600 ppm (Tables 5.20 and 5.21). 
Table 5.20: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and DIMEB in HPFP based on the chemical shift at H-C1 proton of budesonide at 6.5666 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.175 1 6.5666 0 0 0 
0.1575 0.9 6.5674 0.0008 12.6 x 10-5 1.26 
0.14 0.8 6.5685 0.0019 26.6 x 10-5 2.66 
0.1225 0.7 6.5706 0.004 49 x 10-5 4.9 
0.105 0.6 6.573 0.0064 67.2 x 10-5 6.72 
0.0875 0.5 6.5756 0.009 78.8 x 10-5 7.88 
0.07 0.4 6.5763 0.0097 67.9 x 10-5 6.79 
0.0525 0.3 6.5771 0.0105 55.1 x 10-5 5.51 
0.035 0.2 6.5791 0.0125 43.8 x 10-5 4.38 
0.0175 0.1 6.5814 0.0148 25.9 x 10-5 2.59 
0 0 0 0 0 0 
δfree = 6.5666 ppm     
 
Table 5.21: Results of 1H NMR analysis for the determination of stoichiometry between budesonide 
and DIMEB in HPFP based on the chemical shift at H-C1 proton of budesonide at 6.5600 ppm. 
[BUD] (mM) r δcomplex (ppm) ∆δobs (ppm) ∆δ[BUD] ∆δ[BUD]*104 
0.175 1 6.5600 0 0 0 
0.1575 0.9 6.5617 0.0017 26.8 x 10-5 2.68 
0.14 0.8 6.5636 0.0036 50.4 x 10-5 5.04 
0.1225 0.7 6.566 0.006 73.5 x 10-5 7.35 
0.105 0.6 6.5683 0.0083 87.2 x 10-5 8.72 
0.0875 0.5 6.5714 0.0114 99.8 x 10-5 9.98 
0.07 0.4 6.5733 0.0133 93.1 x 10-5 9.31 
0.0525 0.3 6.5751 0.0151 79.3 x 10-5 7.93 
0.035 0.2 6.5768 0.0168 58.8 x 10-5 5.88 
0.0175 0.1 6.5791 0.0191 33.4 x 10-5 3.34 
0 0 0 0 0 0 
δfree = 6.5600 ppm    
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The continuous variation plot confirmed the 1:1 stoichiometry as the maximum 
was at r = 0.5 (Figure 5.27). These data are in agreement to those obtained 
from the titration experiments which followed a linear trend when using the 
Hildebrand-Benesi approach. 
 
Figure 5.27: Determination of the stoichiometry of the complex between budesonide and DIMEB in 
HPFP by 1H NMR based on H-C1 proton of budesonide. 
 
5.7 Complexation study of BDP and DIMEB 
The study of the complexation between BUD and DIMEB was performed using 
the same previous method to study the complexation of BDP with TRIMEB. The 
findings demonstrated that very minor shift was observed for only H-C19 peak at 
1.0206 ppm, other peaks in the high field region such as H-C18 and methyls at 
C17 and C21 were not shifted (Figure 5.28).  
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Figure 5.28: BDP (0.2 mM) chemical shift in high field region (0.1-1.1 ppm) with the addition of 
DIMEB at 0, 0.075, 0.15, 0.225, 0.3 and 0.375 mM in HPFP. 
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In addition, a slight downfield shift was observed for the H-C4 proton at 5.2943 
ppm of the quinone ring, as the concentration of TRIMEB was increased, and 
no observable shift was noted for both H-C1 and H-C2 protons of the quinone 
ring. The spectra of the complexed BDP in the low field region are shown in 
Figure 5.29. 
 
Figure 5.29: BDP (0.2 mM) chemical shift in low field region (5.2-6.6 ppm) with the addition of 
DIMEB at 0, 0.075, 0.15, 0.225, 0.3 and 0.375 mM in HPFP. 
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The chemical shift differences of the H-C4 proton at 5.2943 ppm are presented 
in Table 5.22 and the stability constant calculations using the Hildebrand-Benesi 
approach are showed in Table 5.23 with reciprocal plot shown in Figure 5.30. 
Table 5.22: Results of the chemical shift of BDP and DIMEB added at 0, 0.075, 0.15, 0.225, 0.3 and 
0.375 mM in HPFP using 1H NMR. 
Experiment 
number 
Proton 
position 
(ppm) 
DIMEB concentration (mM) 
0 0.075 0.15 0.225 0.3 0.375 
Chemical shift (ppm) 
1 
H-C4 5.2943 
5.2976 5.3015 5.3040 5.3073 5.3086 
2 5.2974 5.3009 5.3036 5.3067 5.3075 
3 5.2973 5.3007 5.3033 5.3063 5.3070 
Mean 5.2974 5.3010 5.3036 5.3068 5.3077 
SD 0.0002 0.0004 0.0004 0.0005 0.0008 
% CV 0.0029 0.0079 0.0066 0.0095 0.0154 
 
Table 5.23: Results of the complexation between BDP and DIMEB added at 0.075, 0.15, 0.225, 0.3 
and 0.375 mM in HPFP using 1H NMR depending on the chemical shift at 5.2943 ppm. 
DIMEB 
(mM) 
1/DIMEB 
(mM-1) 
1/∆δobs (5.2943 ppm)  
1 2 3 Mean 
0.075 13.3 303 322.6 333.3 319.7 
0.15 6.7 138.9 151.5 156.3 148.9 
0.225 4.4 103.1 107.5 111.1 107.2 
0.3 3.3 76.9 80.7 83.3 80.3 
0.375 2.7 69.9 75.8 78.7 74.8 
 
 
Figure 5.30: Reciprocal plot for the determination of association constant between BDP and 
TRIMEB in HPFP by 1H NMR depending on the chemical shift at 5.2943 ppm (Mean ± SD, n=3). 
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The reciprocal plot showed a good linearity which indicated the stoichiometry 
was 1:1. The mean K value was calculated and found to be 168 M-1 (Table 
5.24). 
Table 5.24: Results of the stability constant between BDP and DIMEB added at 0.075, 0.15, 0.225, 
0.3 and 0.375 mM in HPFP using 1H NMR. 
Proton NO. 
Chemical 
shift (ppm) 
Stability constant, K (M-1) 
SD % CV 
1 2 3 Mean 
H-C4 5.2943 168 164 171 168 3.51 2.09 
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5.8 Discussion 
 
5.8.1 Comparison between corticosteroids compounds 
 
 
The complexation between the corticosteroids BUD, BDP, MOM and FLU with 
TRIMEB in HPFP was examined in this work. The results of the chemical shift 
displacements of some protons of the compounds involved in the complexation 
are presented in Table 5.25.  
Table 5.25: A summary of the chemical shift displacements (in ppm) for BUD, BDP, MOM and FLU 
with 2 mM TRIMEB in HPFP related to the chemical shift of the free compounds. 
Compound 
Chemical shift displacements (ppm) 
H-C1 H-C2 H-C4 H-C18 H-C19 
BUD 
D** (0.07, R) 
D* (0.02, S) 
NS U* (0.01) D** (0.17, R) D* (0.01) 
BDP NS NS D* (0.07) NS D* (0.05) 
MOM NA NA NA NS D* (0.04) 
FLU NA NA NA NS D* (0.02) 
D* = small downfield, D** = large downfield, U* = small upfield, NS = no significant shift, NA = 
S/N too low to interpret, R, S = enantiomers of BUD 
The K values of BDP, MOM and FLU were 197.5, 130 and 86 M-1 respectively, 
which were less than that of BUD enantiomers (621 and 222 M-1 for R and S 
enantiomers respectively). The reciprocal plot of 1/[TRIMEB] versus 1/∆δobs for 
the all studied corticosteroids followed a linear trend, indicating that the 
complexation had a stoichiometry of 1:1. The continuous variation method was 
then adopted to verify the stoichiometry 1:1 of the inclusion complex for BUD 
only (as a representative model for the other compounds) with TRIMEB. The 
Job’s plot showed a maximum at r = 0.5 which suggests a 1:1 stoichiometry of 
the inclusion complex and corroborates the data obtained in the titration 
methods. 
The complexation of all studied corticosteroids with TRIMEB in HPFP can be 
ranked as BUD > BDP > MOM > FLU based on the stability constant values. 
This might be owing to the presence of the substitution groups at C17 which are 
a furan ring in MOM and propionate chains in BDP and FLU structures (Figure 
5.31). These groups are likely to cause steric hindrance, which hinder the 
entrance of BDP, FLU and MOM deeper into the TRIMEB cavity compared to 
BUD which does not have a bulky group at C17. Also, the presence of a Cl 
atom at C9 in BDP and MOM, and F atoms at C6 and C9 in FLU can cause an 
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extra hindrance for the compounds to enter into the TRIMEB cavity compared to 
the simple H atom at C9 in BUD.  
 
Figure 5.31: Chemical structure of BUD, BDP, MOM and FLU 
A similar explanation is suggested by Larsen et al. who studied the 
complexation of 6α-methyl prednisolone and prednisolone with γCD and βCD. 
They found that the 6α-methyl prednisolone prefers the γCD with large cavity 
whereas prednisolone forms stronger complex with βCD of smaller cavity.202 
This might be explained by the presence of methyl group at 6 position in the 
structure of 6α-methyl prednisolone (Figure 5.32) which causes hindrance for 
the compound to go further into the small cavity of βCD compared to the 
prednisolone. 
 
Figure 5.32: Chemical structure of (a) prednisolone and (b) 6α-methyl prednisolone. 
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5.8.2 CD type and its effect on complexation  
The complexation between BUD and BDP with DIMEB in HPFP was 
determined and the displacements values of both complexed compounds are 
presented in Table 5.26 compared to the chemical shift of the pure compound.  
Table 5.26: Chemical shift displacements of the BUD and BDP with 0.375 mM DIMEB compared to 
the chemical shift of the free compound. 
Compound 
Chemical shift displacements (ppm) 
H-C1 H-C2 H-C4 H-C18 H-C19 
BUD D* (0.02) NS NS D* (0.01) D* (0.01) 
BDP NS NS D* (0.01) NS D* (0.01) 
  D* = small downfield, NS = no significant shift 
The small shift of some protons of both compounds suggested that both 
molecules partially entered into the DIMEB cavity, as it might be situated near 
the DIMEB rim. The small shift change of H-C19 proton of BUD and BDP could 
be attributed to the interaction of this proton with the outside surface of DIMEB.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The K values were determined for BUD and BDP with DIMEB and found to be 
199 and 168 M-1 respectively. The results of the stability constant between BUD 
and DIMEB (199 M-1) was less than that obtained with TRIMEB at 621 and 222 
M-1 for both R- and S-enantiomers in HPFP. These results contradict those 
obtained for BUD with TRIMEB/DIMEB in D2O, MeOD and CDCl3 in which 
higher K values were obtained with DIMEB than with TRIMEB. The K values of 
BUD were 4446, 116 and 73 M-1 with DIMEB and 429, 91 and 64 M-1 with 
TRIMEB in D2O, MeOD and CDCl3 respectively. Zoppi et al. found that the 
affinity constant of sulfamethazine with methyl βCD (MβCD, the OH group at C2 
was substituted with methyl group) was less than that with βCD in water (higher 
solubility of MβCD in water compared to that of βCD). They suggest that no 
hydrogen bond was formed between the guest and the substituted OH in the 
MβCD or that it could be related to the steric hindrance of the methyl group 
which hampers the entrance of the guest into the CD cavity.220 It has been 
reported that higher CD solubility in the solvent leads to the availability of more 
guest molecules for the complexation. The key findings with this series of 
experiments is the solubility of the CD (host) in the solvent under study, drives 
the level of complexation observed i.e. the more soluble the host is in the given 
solvent, the more is available for complexation and the higher the association 
constant observed.221 Our experiments have shown the strongest complexation 
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of BUD in D2O was with DIMEB whereas in HPFP with TRIMEB. This could be 
explained by the solubility of the CD in the solvent where the water solubility of 
DIMEB and TRIMEB is 57 and 31 g/100 mL whereas their solubility in HPFP 
are 1 and 6 mg/mL (0.1 and 0.6 g/100 mL) respectively. As the CD solubility is 
higher in D2O, there are more CD molecules available for complex formation. 
Therefore, because DIMEB solubility in water is higher than TRIMEB, with the 
inverse true in HPFP where TRIMEB solubility is higher than DIMEB, this leads 
to the availability of more CD molecules in the solution to form complexation 
with BUD. This might justify the stronger complexation of BUD with DIMEB in 
D2O and with TRIMEB in HPFP.   
5.8.3 Chiral discrimination of BUD by TRIMEB 
The complexation between BUD and TRIMEB in HPFP was examined in this 
work. The results showed that the peak at 0.34 ppm appears as a singlet at 0.4 
mM TRIMEB concentration which was then split into two peaks; the one 
observed at 0.34 ppm showing no significant shift with increasing CD 
concentration, the second moving significantly to 0.44 ppm at 2 mM TRIMEB 
concentration. Both peaks could be assigned to the H-C18 peak of the S-
enantiomer of BUD whereas the latter could be related to the H-C18 peak of R 
enantiomer of BUD. Accordingly, further experiments on the pure enantiomer R-
BUD were carried out for the purpose of full assignment of these peaks, by 
comparing the results to those of the racemic BUD experiments.  
The results showed one singlet peak at 0.44 ppm at 2 mM TRIMEB 
concentration, which was consistent with the peak located at the same chemical 
shift in the racemic BUD spectrum (annotated with a star in Figure 5.33, b and 
c). This resonance could therefore be assigned to the H-C18 peak of the R-
enantiomer of BUD. The peak which displayed no displacement at 0.34 ppm 
(annotated with a dot in Figure 5.33, b) in the spectrum of racemic BUD could 
be assigned to the H-C18 peak of the S-enantiomer of BUD. The H-C19 proton of 
the racemic BUD was fully split into two distinctive peaks at 2 mM TRIMEB 
concentration (Figure 5.33, b). However, this proton in the R-enantiomer 
appeared as singlet in the complexed form (Figure 5.33, c) suggesting that 
another peak appeared in the spectrum of the racemic BUD was related to the 
S-enantiomer (annotated with a dot in Figure 5.33, b). 
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Figure 5.33: Chemical shift in high field region (0.2-0.85 ppm) of (a) pure BUD, (b) racemic and (c) 
pure R-enantiomer of BUD (0.0875 mM) with 2 mM TRIMEB in HPFP. The peaks annotated with star 
and dot were assigned to R- and S-enantiomer of BUD.  
 
The H-C4 proton of the pure R-enantiomer appeared as singlet peak (Figure 
5.34, c) whereas in the racemic solution the signal was partially split, and 
showed an increase in displacement when the amount of TRIMEB was 
increased (Figure 5.34, b). This indicated that this peak of the racemic BUD was 
related to both enantiomers. No significant change was observed for H-C2 
proton of the quinone ring. A downfield shift was observed for the H-C1 proton 
of the quinone ring with a multiplicity change (J-coupling constant increase with 
increasing CD concentration) for racemic BUD (Figure 5.34, b) whereas the 
peak was observed as doublet for R-enantiomer (Figure 5.34, c). Accordingly, 
the two peaks with the highest downfield shift in the racemic BUD spectrum 
were related to the R-enantiomer whereas the other two appear to be related to 
the S-enantiomer (annotated with a star and a dot in Figure 5.34, b 
respectively).  
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Figure 5.34: Chemical shift in low field region (5.1-6.7 ppm) of (a) pure BUD, (b) racemic and (c) 
pure R-enantiomer of BUD (0.0875 mM) with 2 mM TRIMEB in HPFP. The peaks annotated with star 
and dot were assigned to R- and S-enantiomer of BUD.  
 
The downfield shift of H-C1 proton of both R and S-enantiomers and only H-C18 
proton for R-enantiomer may account for the structure rearrangement and 
conformational changes of guest (BUD) molecule after the complexation200  and 
also to the change in the local polarity214 or a deshielding effect resulting from 
van der Waals interaction with the carbohydrate chains.213 It may also be due to 
the interaction of these protons (H-C1 and H-C18) with the hydrophilic, external 
region of the TRIMEB.201 Consequently, it could be expected that these protons 
were located at a large distance from the oxygen compared to the hydrogen 
atom. The small upfield shift observed for the H-C4 proton of both enantiomers 
could be ascribed to the conformational changes resulting from the 
complexation and from the shielding effect of the oxygen atoms (rich in π 
electron) located on the inner surface of the CD cavity. This could suggest that 
this proton was located close to the oxygen atom in the CD cavity.155,201,213 This 
leads us to suggest that both enantiomers of BUD formed a complex by taking 
the position where only H-C4 proton of the quinone ring (experienced upfield 
shift) entered and interacted with the oxygen atom located on the inner surface 
of TRIMEB.  
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The small shift observed resulted from partial entrance of the quinone ring into 
the TRIMEB cavity, with the other H-C1 and H-C2 protons of the quinone ring 
were situated outside the cavity. The downfield shift of the H-C1 proton could be 
accounted for by its interaction with the methoxyl oxygen of TRIMEB. However, 
the shift change of H-C1 proton of the pure R-enantiomer was larger than S-
enantiomer, suggesting that it was closer to the methoxyl oxygen atoms 
compared to S-enantiomer. The spatial structure of the R-enantiomer made the 
H-C18 proton interact with the oxygen atom of the TRIMEB more significantly 
than that in the S-enantiomer, where the H-C18 proton was situated away from 
the TRIMEB cavity. A more downfield shift of both H-C1 and H-C18 protons of R-
enantiomer led to the stronger complexation with TRIMEB compared to S-
enantiomer in which a smaller downfield shift of the H-C1 proton was observed 
with no shift for H-C18 proton. In conclusion, both enantiomers formed 
complexation with TRIMEB in which only the H-C4 proton was inside the cavity, 
the H-C1 is thought to be outside, but near the cavity. The downfield shift of the 
H-C18 proton of R-enantiomer was due to its different spatial structure which 
could cause this proton to be closer to the oxygen atom of the TRIMEB cavity, 
when compared to the S-enantiomer.  
The K values of R- and S-enantiomers were 621 and 222 M-1 respectively, this 
was in agreement with the experimental results of the NMR titration, where the 
R-enantiomer displayed the largest chemical shift changes and thus 
demonstrates that a stronger complexation occurs in R when compared to the 
S-enantiomer, and shows that TRIMEB displays chiral discrimination. From this 
preliminary analysis, TRIMEB can be chosen as a chiral selector for BUD, the 
CDs in general can be used as chiral solvating agents (CSAs) and can cause 
enantiomeric discrimination by two main mechanisms. Firstly, the complexes of 
the enantiomer pairs with the CD as CSA are diastereomers and thus display 
different chemical shifts. The second is the difference in the association 
constants of the two enantiomers with the CD as one of the enantiomers 
preferentially binds with the CD, with the time-averaged solvation of both of 
them being different.222 The enantiomers interact with the chiral solvating agent 
through hydrogen bonding, π stacking and dipole–dipole interactions and are 
thus able to form diastereomers with the CD, which can be detected by NMR.223  
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6 Development of Cyclodextrin-Functionalised Metal 
Nanoparticles as Receptors for as Surface Enhanced Raman 
Spectroscopy of Corticosteroids 
The steroid binding properties of CD systems offers a potential application in 
selective identification agents. In a pharmacological context steroid species may 
be present in a complicated array of species and creating a sensitive and 
selective probe for these compounds for direct application (overcoming the 
need for extraction and/or separation processes) would be highly desirable. 
This chapter addresses the development of selective Raman spectroscopic 
probes for the corticosteroid utilising the Surface Enhanced Raman 
Spectroscopy (SERS).  
 
Figure 6.1: Schematic view of the design of selective SERS substrates through functionalisation of 
metal nanoparticle surfaces with per-6-thio--cyclodextrin. 
The chosen strategy for development of these materials involves replacement 
of primary hydroxyl groups at the narrower rim of -cyclodextrin (C6) with thiol 
groups to tether the CD host to the metal nanoparticle surface. It is anticipated 
that this will provide a means to orientate the steroid at the metal nanoparticle 
surface and allow selective enhancement of appropriate Raman signals. 
Nanoparticle 
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 164 
 
 
The thiolated-cyclodextrin was prepared in two steps from -cyclodextrin 
following the method described by Rojas et al.167 (Figure 6.2). Characterisation 
data corresponded with the published values. 
 
Figure 6.2: The synthesis of per-6-thio-β-cyclodextrin.167 
 
6.1 Characterisation of the Silver and Gold Nanoparticle 
Formulations 
Silver nanoparticle formulations (Ag-NP) were prepared by borohydride 
reduction of silver nitrate in aqueous solution.168 Gold nanoparticles were 
prepared in a two-step process:169 seed solutions were prepared from aqu. 
chloroauric acid (HAuCl4) by citrate reduction and these seed were then added 
to an aqueous solution of HAuCl4 followed by sodium citrate. In each case, 
solutions were centrifuged to homogenise the nanoparticle content. In the 
following sections, typical characterisation data for these NP formulations are 
discussed. 
6.1.1 Plasmon resonance 
The optical activity of the metal nanoparticles is a result of  their surface 
plasmon resonance.224 UV-Vis spectroscopy is an established technique used 
to identify the formation and infer the shape of the metal nanopartciles.225 The 
absorption spectra for both Au- and Ag-NP formulations were recorded in the 
range of 300-900 nm. The Ag-NP formulation showed a single intense peak 
(λmax) at 397 nm which is characteristic of the surface plasmon resonance Ag-
NPs226,227 corresponding with a yellow colouration of the sol (Figure 6.3). 
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Figure 6.3: UV-Vis absorption spectrum of Ag-NP formulation (λmax = 397 nm).  
For the Au-NP formulations, the UV-Vis spectrum again showed a single 
intense peak (λmax) at 520 nm for seed samples and at 532 nm for the final Au-
NP formulations. These are typical of the surface plasmon resonance bands of 
Au-NPs.226,227 The bathochromic shift from 520 to 532 nm at the second stage 
of production can be attributed to the increase in size of the Au-NPs and 
corresponds with the change of the colour from red to purple in the sol (Figure 
6.4). 
 
Figure 6.4: UV-Vis absorption spectra of seed (solid line, λmax = 520 nm) and final (dashed line, λmax 
= 532 nm) Au-NP formulations showing the bathochromic shift of the final formulation consistent 
with its larger particle size. 
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In addition, the presence of single surface plasmon resonance bands with 
relatively narrow bandwidths is consistent with the presence of isometric 
(essentially spherical) particles formation in both Ag- and Au-NP 
formulations.227,228  
6.1.2 Particle analysis: Dynamic Light scattering  
Dynamic light scattering (DLS) experiments were conducted for each final Au- 
and Ag-NP formulation to evaluate the particle dimensions and their distribution. 
The technique characterises the colloidal dispersion size by exploiting the 
illumination of particles solution that undergo Brownian motion by a laser beam. 
The time-dependent fluctuations in the scattered light intensity are analysed by 
autocorrelation to yield particle dimensions that correlate with the hydrodynamic 
radius that includes the immobilised solvent sheath associated with each 
particle.229 
Uncentrifuged and centrifuged Ag-NP formulations were studied. Intensity plot 
(Figure 6.5) show a dominant maximum at ca. 59 nm and a smaller peak at 5 
nm that is attributed to an artefact from the rotation motion of anisometric NPs, 
a common observation with this technique.230 The indicated particle size is 
considerably larger than that given with TEM but this can be attributed to the 
measurement of the hydrodynamic radius by DLS (i.e. particle plus any 
immobilised solvent sheath). After centrifugation, the average particle size was 
increased to be 183 nm due to agglomeration of the nanoparticles; a narrowing 
of the peak-width is noticeable that suggested the narrowing of the size 
distribution.  
 
Figure 6.5: Particle size of (a) uncentrifuged and (b) centrifuged Ag-NPs from DLS. 
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After treatment of both uncentrifuged and centrifuged Ag NPs with per-6-thio--
cyclodextrin (SCD) to form the functionalised Ag-SCD-NPs peak maxima 
moved to larger particle size. It has been shown that the indicated particle size 
for the uncentrifuged Ag NPs increased in each case: 65 vs. 59 nm for 
uncentrifuged formulation and 189 vs. 183 nm in the centrifuged system (Figure 
6.6). This increase, clearly larger than the width of the SCD molecule itself, 
does result from the presence of the chemisorbed SCD. Structuring of the 
aqueous solvent sheath around the nanoparticles is likely to result from to 
hydrogen bonding networks involving the hydroxyls of the upper rim (C3,4) of 
SCD. 
 
Figure 6.6: Particle size of (a) uncentrifuged Ag-NPs without and with SCD and (b) centrifuged Ag-
NPs without and with SCD from DLS. 
DLS plots for seed and final Au-NPs (Figure 6.7) show feature that broadly 
correspond with the Ag-NP analogues. Peak maxima indicate mean particle 
dimensions of 32 nm for the seed Au-NPs vs. 55 nm for the final large Au-NP 
formulation. Again, artefacts are present in the DLS trace: at 1 and 5 nm for 
seed and large Au NPs solutions and attributable to rotation motion of 
anisometric.230 When the Au NPs solution was centrifuged, the average particle 
size increased to be 192 nm consistent with significant to agglomeration of the 
nanoparticles. 
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Figure 6.7: Particle size of (a) seed Au-NPs, (b) uncentrifuged and (c) centrifuged final Au-NPs from 
DLS. 
On mixing with SCD to form SCD-Au NPs significant increases in particle 
dimension were observed (Figure 6.8):  59 nm vs. 55 for the uncentrifuged Au-
NPs with SCD and 195 nm vs. 192 in the centrifuged cases. Again this is 
attributed to the structuring influence of the absorbed SCD at the surface 
indicated that SCD formed a little zone around the NPs. 
 
Figure 6.8: Particle size of (a) uncentrifuged Au-NPs without and with SCD and (b) centrifuged Au-
NPs without and with SCD from DLS. 
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6.1.3 Particle analysis: Transmission Electron Microscopy. 
The morphology and the particle size of the Ag-NP formulations were studied by 
Transmission Electron Microscopy (TEM). Visual inspection of the images 
indicates that the particles are largely spherical in shape (Figure 6.9, a) 
although some exhibit less regular shape (Figure 6.9, b). A size-distribution 
histogram derived from the images shows a relatively normal distribution of 
sizes giving an average particle size of 21 ± 7.5 nm (Figure 6.9, c). After 
centrifugation, agglomeration of the particles is clearly apparent in the images 
with intense black mass (Figure 6.9, d) corresponding to materials stacked upon 
itself while in other areas, particles form ribbons of material though association 
(Figure 6.9, e). Within these agglomerations, however, discrete largely spherical 
Ag-NPs are apparent and it is clear that the association caused by 
centrifugation has not resulted in the fusion of particles. Clearly, the images are 
consistent with the observations from bulk DLS measurements but provide 
additional information that in the massed materials, Ag-NP structures appear to 
remain. 
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Figure 6.9: TEM images of Ag-NP formulations: (a),(b) two images for the same non-centrifuged 
sample; (c) the size distribution histogram of  non-centrifuged material; (d),(e) two images for the 
same centrifuged sample showing the agglomeration of particles. 
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When the uncentrifuged and centrifuged Ag-NPs were mixed with SCD, the 
TEM images (Figure 6.10) were similar to those described above. Notably, the 
particulates showed a light grey layer around the nanoparticles which can be 
attributed to the SCD and is consistent with the presence of the lighter elements 
(carbon and oxygen) that constitute the SCD structure. Using analogous 3D 
electron tomography, Andrate et al.231 identified evidence corresponding with a 
layer of βCD around Ag-NPs. 
 
Figure 6.10: TEM different images of SCD-Ag-NP prepared with the same sample of (a) non-
centrifuged Ag-NP and (b) centrifuged Ag-NP. 
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Similar investigation of Au-NP formulations yielded corresponding observations. 
Images of the Au-NP formulation indicated that the NPs were spherical in shape 
with some association into chains (Figure 6.11, a). Analysis of particle sizes 
derived from the images shows a relatively narrow size distribution: the average 
particle size was determined to be 18 ± 3.4 nm (Figure 6.11, b). 
 
Figure 6.11: TEM analysis of seed Au-NPs: (a) TEM images showing largely spherical nanoparticles 
loosely associated in chains; (b) a size distribution histogram  
 
TEM images of the final Au-NP formulations showed that the particles were of 
mixture of spherical and oval shapes, again loosely associated into chain 
structures (Figure  6.12, a). The size distribution histogram (Figure  6.12, b) 
reflects a rather wider particle size distribution and, while the average particle 
size was 36 ± 7.1 nm, the relatively large standard deviation points to a rather 
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greater irregularity of particle shape. After centrifugation, Au-NPs showed the 
expected agglomeration although discrete particulates of similar dimension to 
the parent formulation were apparent (Figure  6.12, c). 
 
Figure 6.12: TEM analysis of final Au-NP formulations: (a) two images of the same non-centrifuged 
Au NPs solution showing both spherical and ellipsoidal particles; (b) size distribution histogram of 
particle sizes; (c) two images of the same centrifuged product showing loose associate of 
spherical and ellipsoidal NPs.  
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Again, when the uncentrifuged and centrifuged Au-NPs were mixed with SCD, 
the TEM images (Figure 6.13) showed a light diffuse layer around the 
nanoparticles as observed for Ag-NPs. This is attributed to the attachment of 
SCD to the NPs and it generates a more diffuse image because of the light 
atoms (oxygen and carbon) that constitute the SCD structure.  
 
Figure 6.13: TEM different images of the same sample of (a) non-centrifuged SCD-Au-NP and (b) 
centrifuged SCD-Au-NP 
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6.1.4 Concentrations of Nanoparticles 
The discontinuous nature of the silver and gold sols formed, means that direct 
evaluation of the amount of metal in the products can be presented in several 
ways. The average number of Ag/Au atoms per nanoparticle (N) can be 
estimated by using the average core diameters of the particles (D, nm) obtained 
from TEM analysis. By assuming spherical particles and a uniform face-
centered cubic packing, the average number of Ag/Au atoms (N) per 
nanoparticle be calculated: 
𝑁 =  
𝜋𝜌𝐷3
6𝑀
𝑁𝐴 
where ρ is the density of the face-centred cubic crystal [Ag (10.5 g cm-3) or Au 
(19.3 g cm-3)], M is the atomic mass of Ag (107.86 g) or Au (196.96 g), and NA is 
the Avogadro’s number. This yields N = 30.88 D3 for Au-NPs and N = 30.68 D3 
for Ag-NPs. Metal concentrations in the final formulations were determined by 
ICP-OES after digestion with concentrated nitric acid. Further detail is provided 
in Appendix A1. 
Table 6.1: Calculation of the % NP yield for prepared Ag and Au-NP. 
Formulation 
Da 
/nm 
Nb 
[M]initialc 
/ppm 
[M]finald 
/ppm 
% NP 
yielde 
Ag-NP 
non-centrifuged 
21 2.84 x 105 26.97 
22.22 79 
centrifuged 17.36 64 
Au-NP (seed) 18 1.80 x 105    
Au-NP 
(final) 
non-centrifuged 
36 14.40 x 105 37.47 
29.55 87 
centrifuged 26.90 78 
a Mean core diameter (TEM); b Number of atoms per nanoparticle; c initial metal salt 
concentration; d final metal concentration (ICP-OES); e based on 100% reduction of salts. 
 
6.2 Raman Spectroscopic Study of Selected Corticosteroids  
In order to evaluate the influence of immobilised SCD on the SERS signals from 
metal nanoparticle substrates, the selected corticosteroids (CSs) (Figure 6.14) 
were studied with Raman spectroscopy at 633 nm. A relatively detailed spectral 
assignment exercise, based on established studies of budesonide and 
fluticasone,232,233 was undertaken to correlate spectral regions with molecular 
features of the CSs species. In this way, it was anticipated that intensity 
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changes in SERS spectra for both naked and decorated NPs could be 
correlated to molecular interactions with the nanoparticle surfaces. 
Inspection of the structures of the corticosteroids shows several common 
functional features that might be expected to show similar Raman signals: the 
A-ring is an unsaturated dien-one system with a carbonyl substituent at C3; C10 
and C13 are methyl substituted and C11 has a hydroxyl substituent. Structural 
diversity is shown at C9 where MOM, BCL and BDP have chloro-substituents 
and FLU features a fluoro-substituent. A second fluoro-substituent at C6 in FLU 
contrasts with the unsubstituted methylenes in the other CSs. At C16, all apart 
from BUD are methyl substituted – in BUD the ether oxygen forms part of the 
1,3-dioxalane 5-membered ring.  Above the steroid plane a range of functional 
groups substitute the carbonyl at C17: CH2OH for BUD and BCL; CH2Cl for 
MOM; a propionate ester (O2CPr) for BDP. Below the ring plane at C17, the 
hydroxyl is unsubstituted in BCL but is esterified with propionate in BDP and 
FLU, and with 2-furanylcarboxylate in MOM. In BUD, the oxygen at C17 forms 
part of 1,3-dioxalane ring. 
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Figure 6.14: The general ring numbering scheme for the steroid ring framework and the 
corticosteroids selected for Raman spectroscopy studies. 
With the exception of BCL, each of the CS compounds gave good quality 
Raman spectra at 633 nm (Figure 6.15). It is not immediately obvious, given the 
structural similarity to other CSs, why the BCL spectrum was swamped by a 
fluorescent background - only features at ca. 2986, 2953, 2906 cm-1 
(corresponding with aliphatic C-H stretching modes) and 1658, 1619, 1601 cm-1 
(corresponding with dien-one ring stretching modes) were apparent above 
background. For the other spectra, detailed assignments are presented in Table 
6.2.  
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Figure 6.15: Offset Raman Spectra for selected corticosteroids (BUD = budesonide, FLU = 
fluticasone proprionate, BDP = beclomethasone dipropionate, MOM = mometasone furoate, BCL = 
beclomethasone).    
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Table 6.2: Assignment of the Raman peaks of the Raman spectra of budesonide (BUD), fluticasone propionate (FLU), beclomethasone dipropionate (BDP) and 
mometasone furoate (MOM). 
Assignment 
Raman peaks (cm-1) 
BUD BDP FLU MOM 
3200-2800 cm-1     
(C-H) furan − − − 3143, 3118, 3099 
(C=C-H) dienone 3041 3076, 3053, 3032 3073, 3057, 3024 3084, 3054, 3023 
as(CH3) 2998 3002, 2994 2997 2998 
as(CH2), as(CH3) 2969sh 2967 2976, 2966 2963 
as(CH2) 2941, 2954, 2941 2939 2943 
s(CH3) 2900 2906 2891sh 2907 
s(CH2) 2911, 2872 2919, 2889 2882 2883 
1780-1550 cm-1     
(C=O) propionate − 1737 1743 − 
(C=O) furanyl − − − 1728 
(C=O) thioester − − 1700 − 
(C=O) dienone 1721, 1714 − − 1724 
(C=C) dienone 1657 1662 1662 1656 
as(C=O, C=C) dienone 1627, 1603 1629,1606 1616, 1605 1611, 1603 
as(C=O, C=C) furan − − − 1562 
1500-1380 cm-1     
(C=C-C=C) furan − − − 1466 
(CH3), (CH2) 1471, 1452 1448, 1421 1454, 1420 1450, 1438 
(C-C) furan − − − 1392 
(CH3) 1393 1393 1389, 1373 1392 
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Table 6.2 cont. Assignment of the Raman spectra of the BUD, BDP, FLU and MOM 
Assignment 
Raman peaks (cm-1) 
BUD BDP FLU MOM 
1380-1000 cm-1     
as(C-OH)  1352, 1329 1351, 1325, 1305 1342, 1320, 1307 1348, 1321, 1306 
s(C-OH)  1298, 1269 1292, 1281 1286 1270 
(C-O), as(CH), as(CCH) 1240, 1199 1251, 1235, 1209 1235, 1198 1232, 1201 
(C-O) furanyl − − − 1219 
s(CH), s(CCH), (C-CH3) 1162 1162 1172 1184 
(C-O) propionate − 1150, 1138 − − 
(C-H) in-plane bending 1138, 1110 1135 1147, 1106 1144, 1126, 1098 
(C-O) furanyl − − − 1073 
(C-OH)  1030 1046 1056 1044 
(O=C-O-C) − 1025 1024 1016 
(F-C-S) − − 1024 − 
< 1000 cm-1     
(CH3)  968, 956, 931 988, 939, 912 993, 970, 953, 931 997, 927, 901 
(C-O-C=O) stretching − 
823 888, 845 829 
(C-H) 820 
(C-C) 767 773 774 792, 757 
(C-F)   737, 693 − 
(C-S) stretching − − 650, 623 − 
(ring) 670,642, 530, 416 667, 553, 466 697, 563, 551, 508, 
408 
677, 659, 637, 549, 
477 
(CH3) torsional mode − − 262, 233 273, 221 
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Raman spectra of the CSs were considered in several spectral regions. 
Assignments were achieved with reference by comparison with ab initio 
vibrational modelling studies of budesonide232 and fluticasone propionate233 and 
supported by reference to characteristic functional group frequencies.234  
6.2.1 Spectral Region 3200-2800 cm-1 
 
Figure 6.16: Raman spectra of selected corticosteroids (BUD = budesonide, FLU = fluticasone 
proprionate, BDP = beclomethasone dipropionate, MOM = mometasone furoate} in the region 3200-
2700 cm-1. 
Bands in this region of the spectra correspond with carbon-hydrogen stretching 
modes. Bands above 3100 cm-1 appear only for MOM and correspond with the 
furan C-H stretching modes of the furoate ester.235 All CSs studied show one or 
more bands ca. 3050 cm-1, attributed to the C-H stretching modes of the 
dienone A-ring of steroid framework. Below this, asymmetric stretching modes 
of aliphatic methylene and methyl groups appear while at lower ranges the 
corresponding symmetric modes are apparent. These originate with ester and 
dioaxalane substituents of the D ring along with the saturated BCD rings of the 
steroid framework. 
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6.2.2 Region 1780-1550 cm-1  
 
Figure 6.17: Raman spectra of selected corticosteroids (BUD = budesonide, FLU = fluticasone 
proprionate, BDP = beclomethasone dipropionate, MOM = mometasone furoate} in the region 1800-
1500 cm-1. 
Bands in this region of the spectra can be attributed to stretching modes of 
unsaturated (C=O and C=C) functions in the species. Towards the higher 
wavenumbers, bands attributable to the carbonyl stretching modes of the ester 
substituents of the D ring are apparent. Below this, the important spectral 
modes of the dienone A-ring are assigned. Weak to absent features at ca. 1720 
cm-1, correspond with the isolated C=O stretching mode of the dienone – the 
weak intensity of this mode is consistent with Raman selection rules and has 
been noted in these systems previously.232,233 In contrast, the C=C stretching 
modes of the dienone create amongst the strongest features each spectrum 
with bands at ca. 1660 cm-1. Coupling of modes of C=C and C=O modes gives 
rise to two further bands of medium intensity around in the ranges 1627-1611 
and 1606-1603 cm-1. The significant variation in position of the higher 
wavenumber of these modes may indicate some associations in the solid state. 
The expected effects of electronegative substituents at C6 and C9 in FLU, BDP 
and MOM show no clear pattern - while MOM and FLU show closest similarity, 
the 9-chloro-substituted BDP is similar to BUD. The only remaining feature in 
this region, a weak-to-medium intensity band at 1562 cm-1, is unique to MOM 
and can be assigned to the coupling of C=C and C=O modes of its furoyl ester.  
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6.2.3 Region 1500-100 cm-1  
 
 
Figure 6.18: Raman spectra of selected corticosteroids (BUD = budesonide, FLU = fluticasone 
propionate, BDP = beclomethasone dipropionate, MOM = mometasone furoate) in the region 1450-
165 cm-1. 
Between 1450-1380 cm-1, MOM shows strong bands associated with coupled 
double- and single-bond stretching modes in the 5-membered ring (1466 and 
1392 cm-1). Aside from these features, this region between 1500 and 1380 cm-1 
is dominated by stretching and deformation modes of saturated carbons 
predominantly from the steroid framework although contributions from the 
aliphatic esters appended to C17 of BUD, BDP and FLU are also present. 
Below 1380 cm-1, a complex set of bands correspond with carbon-oxygen 
modes including the secondary hydroxyls at C11 and the C-O bonds of ester 
and dioxalane substituents at  the D-ring. Below 1000 cm-1, the bands can be 
attributed to methyl torsion modes (ca. 950 cm-1) alongside an array of in- and 
out-of-plane deformations of aliphatic hydrocarbons. Deformation of the 
saturated carbon ring of the steroid framework is assigned to an array of modes 
ca. 650 cm-1. In summary, portions of this spectral region can potentially be 
utilised for non-group specific molecular regions: 1500-1380 cm-1 for C/D rings 
of the steroid and the D-ring substituents; indicators: 1380-1000 cm-1 for D-ring 
substituents and ca. 650 cm-1 for steroid framework. 
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6.3 Raman Spectroscopic Study of per-6-thio--cyclodextrin (SCD) 
SCD was analysed by Raman spectroscopy at 633 nm and, in common with 
other polysaccharides, these studies indicates that the cyclodextrin has a 
relatively low Raman cross-section and hence the resulting spectrum was of low 
relative intensity. It was only after a relatively large number of co-additions of 
the spectrum that a spectrum of suitable quality for assignment was obtained 
(Figure 6.19). While the spectrum showed an elevated background, peaks were 
clearly discernible and relatively well resolved. 
 
Figure 6.19: Raman spectrum of SCD collected using 633 nm excitation, 50x objective, 100% laser 
power, 10 s exposure time: (a) 856 accumulations; (b) 10 accumulations. 
The assignment of the SCD was made with reference to the assignment βCD236 
(Table 6.3). The spectra of the two cyclodextrins are similar but, as might be 
expected, some peaks are shifted on replacement of the hydroxyl at C6 of the 
βCD with thiol. Importantly, the appearance of the band at 2575 and 668 cm-1 in 
SCD is consistent with the thiol substitution.237 Asymmetric and symmetric 
stretching vibrations of the substituted-C6 methylene are shifted from βCD with 
the presence of the sulfur238 as are bands at ca. 1340 and ca. 1240 cm-1 where 
the coupled vibrational modes include CH2SH vibration vs CH2OH in βCD. The 
weak scattering of SCD is a potential advantage in this application as its 
background spectrum is unlikely to interfere with the analyte. 
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Table 6.3: Assignment of SCD Raman spectrum on the basis of the βCD assignment. 
βCD Raman 
peak (cm-1) 
SCD Raman 
peak (cm-1) 
Assignment 
2942 2939 as(CH2) 
2910 2899 s(CH2), 
--- 2575 (SH) 
1415 1415 (OCH), (CCH) 
1390 1376 (OCH), (CCH), (COH) 
1340 1336 (CCH), (COH), (HCH) + CH2SH vibration 
1250 1231 (OCH), (COH), (CCH) + CH2SH vibration 
1130 1130 Pyranose ring vibration mode + as(C-O-C) 
1080 1074 (CO) +  (COH) bending mode + (CC) 
1050 1028 (CO), (CC) 
1010 999 (CC), (OCH, (CCH), (CCO) 
950 946 Skeletal vibration (α-1,4 linkage) 
850 893 (CO) and (CC) stretching, (CCH) mode of 
the anomeric vibration 
--- 668 (C-S) stretching 
580 585 Skeletal vibration involving α-1,4 linkage 
480 486 Skeletal vibration involving α-1,4 linkage 
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6.4 Raman Spectroscopic Studies of SCD-Ag-NP and SCD-Au-NP 
 
Figure 6.20: Raman spectrum of metal SCD-M-NP formulations compared to reference spectrum of 
SCD: (i) the SCD reference spectrum (after background removal), (ii) uncentrifuged Ag-NP after 
treatment with SCD, (iii) centrifuged Ag-NP after treatment with SCD, (iv) uncentrifuged Au-NP after 
treatment with SCD, (v) centrifuged Au-NP after treatment with SCD. 
The metal NP formulations were prepared with and without centrifugation. The 
RS spectrum of dried drops of these materials on an aluminium foil substrate 
gave no significant Raman responses. The spectra obtained after these 
materials were mixed with SCD and analysed are given in Figure 6.20. For the 
Ag-NP formulation, no features from the SCD were discernible with the non-
centrifuged formulation; in contrast, the centrifuged formulation gives a clear 
spectrum that corresponds closely with SCD reference spectrum. Notably in this 
case, the SH stretch at ca. 2575 cm-1 is absent in the SCD-Ag-NP system and 
the methylene symmetric and asymmetric stretching modes (centred around 
2900 cm-1) are considerably enhanced in relative intensity. These factors are 
consistent with the expected chemisorption of the SCD to the nanoparticle via 
the 6-CH2SH deprotonation. No significant features relating to direct S-Ag 
vibration were discernible in the spectrum but features of these types can be 
broad and difficult to resolve in some cases.239,240 
Both uncentrifuged and centrifuged Au-NP formulations give a discernible 
Raman spectrum. These are essentially similar but spectral quality and overall 
signal intensity is enhanced with the centrifuged formulation. Notable spectral 
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features are again consistent with chemisorption of SCD to the metal NP 
surface: the correspondence of the spectrum with SCD, the absence of thiol 
stretching mode and the relative enhancement of methylene stretching regions 
in the spectrum. In addition, there are some broad features in the region 150-
200 cm-1 that are consistent with Au-S vibrational modes.241 The origin of other 
features that appear in the SCD-Au-NP are less clear. Broad features across 
the range 1600-1000 cm-1 have been observed as an instrument artefact with 
the 20x objective lens used for these studies and the 180 light path to a foil 
substrate may have amplified this effect on these occasions. It is reasonable to 
conclude that the chemisorbed SCD metal nanoparticles have been prepared 
though these processes. The increased enhancement of signals with the 
centrifuged formulations is consistent with the agglomeration observed with 
TEM and DLS in these systems and the consequent creation of ‘hot-spots’ for 
SERS enhancement at the junctions between nanoparticles.242  
 
6.5 Raman Spectroscopic Studies of Budesonide with Metal 
Nanoparticles 
6.5.1 BUD with Ag-NP 
To test the possible enhancement of the Raman spectrum of BUD, a drop of a 
mixture of BUD and the appropriate Ag-NP formulation was placed on a foil 
covered glass slide. In each case, a spectrum was obtained from the dried 
materials (Figure 6.21). 
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Figure 6.21: Raman spectra of budesonide (BUD) after mixing with Ag-NP formulations: (i) BUD 
reference spectrum (after background removal), (ii) BUD with uncentrifuged Ag-NP (iii) BUD with 
centrifuged Ag-NP. 
The SERS spectrum in each case, is dominated by the strong bands in the high 
frequency spectral region (3200-2800 cm-1): it appears that specifically as(CH2) 
and s(CH2) at 2931 and 2880 cm-1 respectively dominate the enhancement on 
interaction with the Ag-NP centrifuged formulation and, while these modes also 
appear enhanced in the non-centrifuged sample, peaks in this envelope appear 
to correspond to as(CH3) at 2903 cm-1 and a lower frequency s(CH2) mode at 
2851 cm-1 (ascribed to ester methylene). In contrast, the relative intensity of the 
dienone (ring A) bands appears to be significantly reduced in the spectra. The 
(C=C) dienone band at ca. 1655 cm-1 still forms the most noticeable band in 
this region. In the non-centrifuged formulation however, other enone features 
[e.g. the coupled as(C=O, C=C) at ca. 1627, 1603 cm-1 are of similar intensity 
although significantly broadened.  
In the 1500-1380 cm-1 region, the C-C modes are relatively enhanced 
compared to the reference spectrum. Again, the spectral envelope differs 
between formulations: the peak maximum is at 1470 cm-1 [(CH2] for non-
centrifuged sample and at 1440 cm-1 [(CH3)], for centrifuged samples and this 
appears to be consistent with relative enhancements of the C-H modes.  
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In the 1380-1000 cm-1 region, the band at ca. 1300 cm-1 and ca. 1026 cm-1 
appears in each sample while the 1056 cm-1 band is enhanced only in the 
centrifuged formulation. In contrast, bands at 889, 857 cm-1 [(C-O-C)] are 
significant only in the non-centrifuged example. The broader bands observed in 
the non-centrifuged examples, potentially correlates to a wider range of analyte-
surface interactions. The non-centrifuged Ag-NP formulation has greater 
polydispersity (Figure 6.5), and this potentially leads to a greater diversity of 
sites with SERS ‘hot-spots’ and hence micro-environments for BUD functions. 
Viewed overall, it appears that significant SERS enhancements are associated 
with the 1500-1380 cm-1 region, corresponding to C- and D-ring and the D-ring 
oxalane substituents and portions of the 1380-1000 cm-1 region associated with 
the ether modes of the dioxalane (ca. 1300 and 1050 cm-1). Deformation modes 
of the steroid framework (ca. 650 cm-1) are noticeably absent and therefore, 
taken together, these observations indicate that the D-ring / D-ring substituent 
experience the greatest enhancements with the Ag-NP formulation. Consistent 
with this, and the most noticeable change in the spectra, is the significant 
reduction in the relative intensity of the A-ring bands, particularly the (C=C) 
dienone at 1657 cm-1. Therefore, it is inferred that the BUD interacts with the 
naked Ag-NP predominantly through the D-ring / D-ring substituents (Figure 
6.22). 
 
Figure 6.22: Predicted interaction of Bud with naked Ag NPs 
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Studies with the SCD-Ag-NP formulations yielded noticeably different 
enhancement of spectral regions than the naked Ag-NP (Figure 6.23). The 
centrifuged SCD-Ag formulation gave a significantly weaker spectrum (ca. two 
orders of magnitude than the uncentrifuged sample). The origin of this is 
unclear although centrifugation has been observed to affect SERS studies with 
SCD-decorated Au-NP.243 Consequently, uncentrifuged Ag-NP and SCD-Ag-NP 
formulation provides the clearest comparison of the effect of surface-
functionalisation on the SERS spectra of BUD (Figure 6.23). 
 
Figure 6.23: Baseline-subtracted Raman spectra of budesonide (BUD) after mixing with Ag-NP 
formulations (after baseline removal) showing the different enhancements for naked and SCD-
functionalised Ag-NP: (i) BUD reference spectrum, (ii) BUD with uncentrifuged Ag-NP (iii) BUD with 
uncentrifuged Ag-SCD-NP. 
In the 3200-2800 cm-1 region, the envelope with the SCD-Ag formulation is 
relatively less intense than that of the BUD with naked Ag-NP. The (C=C-H) 
modes from the steroid A-ring (dienone) at ca. 3050 cm-1 and the as(CH3) 
mode at ca. 2980 cm-1 (from methyl A-ring substituent at C10) are clearly 
discernible. The s(CH2) ‘shoulder’ in the naked Ag-NP at ca. 2880 cm-1 is 
absent with the SCD-Ag-NP. 
In the 1780-1550 cm-1 region, spectral features associated with BUD’s dienone 
A-ring are relatively enhanced with the SCD-Ag-NP and (C=C) dienone at 
1657 cm-1 forms the most intense feature in this region. Interestingly, the 
as(C=O, C=C) dienone mode at ca. 1600 cm-1 appears enhanced while the 
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other of these coupled enone modes at ca. 1627 cm-1 is absent – the opposite 
relative intensities are observed with the naked Ag-NP. 
Remarkably, between 1500 and 1380 cm-1 few significant features in the 
spectrum with the SCD-Ag-NPs in contrast to the naked Ag-NPs where this 
region is significantly enhanced. The sole, relatively weak feature at ca. 1450 
cm-1 can be attributed to (CH3) at C10.    
In the region 1380-1000 cm-1, bands corresponding to as(C-OH) at 1358 and 
1328 cm-1 are strongly enhanced (particularly for the 1358 band) as is the (C-
OH) band at 1056 cm-1. Each of these features can be attributed to the C11 
hydroxyl, and again are very weak or absent in the corresponding spectrum 
obtained with naked Ag-NP. Similarly, the torsional (CH3) mode at ca. 947 cm-1 
(attributable to C10 methyl) is enhanced with SCD-Ag-NP (and absent with 
naked Ag-NP) as are the various ring vibration modes between 700 and 480 
cm-1. 
These observations lead to the conclusion that decorating the Ag-NP with SCD 
has reversed the approach of the CS to the Ag surface and, consistent with 
BUD-CD binding studies, the coordination of the A-ring into the CD cavity, 
orientating the C=O of the enone towards lower rim and closer to the metal 
surface (Figure 6.24). This is the first observation that decorating the 
nanoparticle surface with a ‘receptor’ can reorient the molecular species to 
reverse selective SERS enhancement. 
 
Figure 6.24: Predicted interaction of BUD with Ag-SCD NPs 
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6.5.2 BUD with Au-NP 
With the Au-NP systems, the centrifuged formulations gave the most interesting 
results with all the CSs. In the non-centrifuged systems, no significant 
enhancement was observed on addition of the CS analyte to the solution. The 
spectra of SCD-Au-NP and naked Au-NP (after centrifugation) are shown with 
BUD in Figure 6.25. 
 
Figure 6.25: Baseline-subtracted Raman spectra of budesonide (BUD) after mixing with Au-NP 
formulations (after baseline removal) showing the different enhancements for naked and SCD-
functionalised Au-NP: (i) BUD reference spectrum, (ii) BUD with centrifuged Au-NP (iii) BUD with 
centrifuged SCD-Au-NP. 
Studies with Au-NP formulations and BUD gave quality spectra when the Au-NP 
formulation was centrifuged in advance. The study produced results that are 
broadly similar with the Ag-NP observations although the spectra are 
considerably more complicated, indicating that the regioselectivity of 
enhancement is lower in these systems. Additionally, it is noticeable that the 
overall enhancement intensity was greater with the Ag formulations and, while 
there are several factors influencing the sensitivity of SERS plasmon 
response244 such an observation is not uncommon in comparable systems.  
Neither Au-NP formulations generates any significant enhancements in the 
3200-2800 cm-1 region of the spectrum and in the region 1780-1550 cm-1, 
several modes of the A-ring vibrations are enhanced although those directly 
attributable to the A-ring, bands at ca. 1660, 1610 and 1590 cm-1 [(C=C) 
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dienone and as(C=O, C=C) dienone] are relatively enhanced in the SCD-Au-
NP formulation. The strongest enhancement for BUD by the naked Au-NP is at 
ca. 1560 cm-1, which might be attributed to a modified, coupled enone [(C=O, 
C=C)] and clearly the array of enhancements here are consistent with 
significant A-ring interaction with un-modified Au-NP surface.    
Again, while the spectral envelopes are different in the 1500-1380 cm-1 region, 
both Au-NP and SCD-Au-NP appear to enhance interactions with aliphatic 
carbon bonds in the structures, although, clearly with SCD-Au, these can 
potentially arise from enhancement of SCD itself on the NP surface (Section 
6.4). The remaining significant difference between the systems is observed with 
bands at ca. 1040 and 950 cm-1 that appear to be exclusively enhanced in the 
naked NP system. These are ascribed to (C-O-C) and (CH3) modes of the 
dioxalane D-ring substituent and are notable absent with the decorated Au-NP. 
These observations appear to indicate that the naked nano-particle has multiple 
sites for interaction with BUD and both A-ring and D-ring extremities of the CS 
appear to interact with the surface. In contrast, functionalisation of the SCD-Au-
NP surface again appears to act to orientate the A-ring functions of BUD 
towards the NP surface and consistent with this is the absence of significant 
signals attributable to dioxalane D-ring substituent. By implication this is inferred 
to be orientated away from the NP surface. However, it is important to note that 
with SCD-Au-NP, the potential interference from aliphatic modes of the SCD 
can complicate the interpretation, in contrast to the SCD-Ag-NP system.  
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6.6 Raman Spectroscopic Studies of Beclometasone Dipropionate 
with Metal Nanoparticles 
Studies with BDP yielded enhanced spectra with most formulations with the 
exception of SCD-NP prepared with non-centrifuged substrates.  The spectra of 
BDP with the corresponding Ag- and Au-materials are broadly similar (Figure 
6.26) and therefore will be discussed together.  
 
Figure 6.26: Baseline-subtracted Raman spectra of beclomethasone dipropionate (BDP) after 
mixing with metal-NP formulations (after baseline removal) showing the different enhancements for 
naked and SCD-functionalised particles: (i) BDP reference spectrum, (ii) BDP with centrifuged Ag-
NP (iii) BDP with centrifuged SCD-Ag-NP, (iv) BDP with centrifuged Au-NP, (v) BDP with 
centrifuged SCD-Au-NP. 
 
The interaction of BDP with naked Ag- and Au-NP leads to similar gross 
features in the spectra with the exception of the 3200-2800 cm-1 region where 
the Au-NP system showed significant enhancement. Most noticeably, in the 
region 1780-1550 cm-1, bands at ca. 1728 cm-1 appear strongly enhanced. 
These are a little shifted from the parent (C=O) propionate, perhaps though 
reduction of bond order from charge-dipole interaction with the metal surface. 
The alternative assignment to (C=O) dienone, while closer to the frequency of 
this mode in the parent species, seems less likely as no significant peaks in the 
spectrum correspond with the accompanying (C=C) dienone (observed 
throughout these studies to be significantly a more intense feature in the 
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spectra) and it seems unlikely that the C=O would be exclusively enhanced 
through a surface interaction. 
Broad features ca. 1580 cm-1 in the BDP Ag-NP, resolve to two significant 
bands with Au-NP at 1600 and 1584 cm-1 and similarly the complicated set of 
peaks in the 1500-1380 cm-1 region for the BDP Ag-NP spectrum, simplifies in 
the Au-NP system to the band at ca. 1450 cm-1, due to (CH3) and (CH2) 
vibrations. Bands at ca. 1100, 1070 and 1040 cm-1, are can be attributed to (C-
O) and (C-O-C) of propionate. Taken together, these observations are indicate 
a consistent enhancement of bands associated with the propionate D-ring 
substituents indicating with a significant orientation of molecule with respect to 
the M-NP surface (Figure 6.27, a). 
In contrast, the SCD-M-NP materials appear to orientate the molecule in the 
opposite direction. Inclusion of the molecule in the SCD host orientates the A-
ring functions towards the metal surface (Figure 6.27, b). Key evidence for this 
again lies with the significant relative enhancement of the band at ca. 1660    
cm-1, due to (C=C) dienone, that is virtually absent in the spectra with the 
naked NP formulation. Other bands associated with the A-ring, coupled 
as(C=O, C=C) modes at ca. 1630 and 1600 cm-1 are present in each spectrum 
and particularly well resolved in the SCD-Ag-NP. The relatively well resolved 
spectra with the SCD-functionalised NPs again points to specificity in the 
analyte to M-NP interaction and the proposed model is clearly consistent with 
the structural features inferred from NMR studies. 
 
(a)                                                (b) 
  
         
Figure 6.27: Predicted interaction of BDP with metal NPs in (a) naked metal NP and (b) SCD-
functionalised NPs. 
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6.7 Raman Spectroscopic Studies of Fluticasone Propionate and 
Mometasone Furoate with Metal Nanoparticles 
Both FLU and MOM yielded similar SERS behaviour with metal nanoparticle 
formulations: neither gave significant signals with SCD-functionalised Ag-NP 
and Au-NP and so therefore only centrifuged samples are compared here 
(Figure 6.28 for FLU and 6.29 for MOM). 
With naked Ag-NPs, significant enhancements are observed in the 3200-2800 
cm-1 regions of the FLU and MOM spectra. With FLU, this region is well-
resolved and bands corresponding with asymmetric/symmetric methyl and 
methylene stretching modes (2987, 2963 and 2934, 2874 cm-1) give the most 
intense bands of the spectrum. With MOM, this region is less well resolved 
although the strong, the relatively broad feature centred at ca. 2920 cm-1 has 
sufficient structure to suggest it comprises overlapped bands from similar 
asymmetric/symmetric methyl and methylene stretching modes. Importantly for 
MOM, there is no evidence of (C-H) furan although a small peak at ca. 3050 
cm-1 is consistent with (C=C-H) from the steroid Ring A. 
In the 1780-1550 cm-1 regions, bands associated with the Band A dienone 
stretching modes, especially the (C=C) dienone that dominates the free CSs, 
are present but as very weak features. In FLU, aside from the thioester band at 
ca. 1712 cm-1 and the weak band corresponding with the (C=C) dienone 
mode, no other features are present in this region. In MOM, the principal 
features in this region correspond with the furanyl substituent of Ring D. The 
(C=O) furanyl mode may be attributed to bands at ca. 1750 and 1695 cm-1, but 
the strongest features that emerge from a broad spectral envelope are bands at 
ca. 1608 cm-1 and ca. 1560 cm-1. These may originate with correspond with 
coupled (C=O, C=C) furan modes, possibly from symmetric and asymmetric 
vibrations of the ring and the enhancement of the former is notable, as it is 
possibly obscured in the spectrum of the pure material. In the remaining regions 
of each spectrum, the features are largely attributable to methyl and methylene 
deformation modes or to ester (C-O) modes.  
Broadly similar enhancement patterns are apparent for the Au-NPs and can be 
concluded that the species appear to interact most strongly with the metal 
nanoparticle through the Band D substituents. 
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Figure 6.28: Baseline-subtracted Raman spectra of fluticasone propionate (FLU) after mixing with 
metal-NP formulations showing the different enhancements for naked and SCD-functionalised 
particles: (i) FLU reference spectrum, (ii) FLU with Ag-NP (iii) FLU with SCD-Ag-NP, (iv) FLU with 
Au-NP, (v) FLU with SCD-Au-NP. 
 
Figure 6.29: Baseline-subtracted Raman spectra of mometasone furoate (MOM) after mixing with 
metal-NP formulations showing the different enhancements for naked and SCD-functionalised 
particles: (i) MOM reference spectrum, (ii) MOM with Ag-NP (iii) MOM with SCD-Ag-NP, (iv) MOM 
with Au-NP, (v) MOM with SCD-Au-NP. 
 
Comparison of the spectra arising from the SCD-functionalised metal 
nanoparticles present a rather less clear picture, compared to the other CSs 
(BUD and BDP). While enhancements of dienone functions through interaction 
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with SCD-Ag in particular are clearly apparent in the spectra (corresponding 
with the binding modes proposed for these species that, other modes also 
appear enhanced. Notably in the FLU SCD-Ag-NP system, the strongest 
enhancements occur for bands at ca. 1690 cm-1 that correspond with the fluoro-
thioether moiety. It is not inconceivable that alternative SCD-CS interactions 
may occur with these systems and the spectra correspond with a range of direct 
and SCD-mediated interactions. This is clearly consistent with the lower binding 
affinity that FLU and MOM display for SCD (possibly related to their bulkier Ring 
D substituents) and would correspond with the more complex spectra seen with 
these systems. In summary, it can be concluded that MOM and FLU interact 
most strongly with the naked metal NPs through the Ring D substituents 
(offering little enhancement of Ring A modes). However, in the decorated 
systems, the picture is more complicated and, while enhancements that 
correspond with the SCD hosting the CSs and thereby facilitating the approach 
of Ring A to the NP surface are observed, strong enhancements of other 
molecular functions (e.g. fluorothioester in FLU) must arise from alternative 
CS…SCD-M-NP interaction. The non-selectivity of interaction is consistent with 
lower binding affinities for MOM and FLU.  
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7 Conclusion 
7.1 NMR Studies 
The work conducted in this thesis has established a developed method allowing 
us to study the physical chemistry of corticosteroid-CD complexation for the 
purpose of controlling the solubility and the stability of pMDI inhaler devices. 
The method was applied to investigate the complexation of BUD in a range of 
solvents with different polarities which was applied further to study the 
complexation of different corticosteroids; BUD, BDP, FLU and MOM with the 
derivatised CDs TRIMEB and DIMEB in HPFP using NMR.  
Spectroscopic methods have been developed to study host:guest interactions of 
BUD : βCD/TRIMEB complexes in a mixture of EtOH/H2O and in water and also 
for better comprehensive understanding of the stability constant and 
stoichiometry determination. The results showed a higher complexation (larger 
association constant) of BUD with both βCD and TRIMEB occurred in H2O 
compared to the co-solvent system of EtOH/H2O, where the K values were 
found to be 205 and 138 M-1 with TRIMEB and 94 and 72 M-1 with βCD in H2O 
and EtOH/ H2O mixture respectively. This is attributed to the polarity of BUD 
and its solubility in the solvent where BUD as a non-polar guest prefers to be 
more solvated in EtOH and thus reduces the driving force towards the CD cavity 
which is more polar in nature than the bulk solvent. This leads to the partial 
existence of BUD outside the cavity and thus a formation of weak complexation. 
However, in aqueous solution, BUD was driven into the CD cavity with a 
reduced polarity compared to the bulk solvent and leads to the formation of 
stronger complexation.  
NMR methods have been used to study BUD:CDs (DIMEB/TRIMEB) in a range 
of different polarity solvents (CD3CN, MeOD, CDCl3 and D2O). However, the 
complexation between BUD and βCD was not assessed in the organic solvents 
due to its limited solubility. The K values of the complexation of BUD with 
DIMEB were 116 and 73 M-1 and with TRIMEB were 91 and 64 M-1 in MeOD 
and CDCl3 respectively. No complexation was formed in CD3CN.The 
complexation in D2O was the strongest observed of all the solvents assessed 
with the highest K value obtained with DIMEB followed by βCD and the lowest 
value with TRIMEB, where the values were 4446, 1129 and 429 M-1 
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respectively. The forming of the strong complexation in different solvents 
assessed can be summarised as D2O > MeOD > CDCl3 > CD3CN. No 
complexation was formed in CD3CN which is ascribed to the similarity in the 
polarity of the solvent to the interior cavity of the CD. There is therefore no drive 
for the BUD to enter the CD cavity and form a complex. BUD as a nonpolar 
guest preferred the CD cavity of less polarity compared to bulk water, and as a 
result the strongest complexation was formed in the aqueous environment. In 
the presence of MeOD and CDCl3 solvents, the CD cavity is more polar than 
the bulk solvent and thus the driving force towards the CD cavity entrance is 
reduced as BUD is relatively soluble in both solvents. It shows a preference 
therefore for being located outside the cavity (solvated in the bulk solvent) over 
interacting with the CD. Hence, a lower association constant is observed with 
MeOD and CDCl3 when compared to water. The reciprocal plot of the titration 
experiments showed good linearity and the continuous variation approach 
showed a maximum at r = 0.5, confirming the complex had a stoichiometry of 
1:1.  
The effect of CD type on the complexation was studied utilising three different 
types of CDs; (i) βCD, (ii) DIMEB and (iii) TRIMEB with BUD. The results are 
summarised in Table 7.1. 
Table 7.1: A summary of the chemical shift displacements observed (in ppm) for BUD with 2 mM 
βCD, DIMEB and TRIMEB in D2O related to the chemical shift of free BUD. 
CD type 
Chemical shift displacements (ppm) 
H-C1 H-C2 H-C4 H-C18 H-C19 
βCD D* (0.01) U** (0.07) U** (0.03) D* (0.05) D** (0.12, 0.16) 
DIMEB U** (0.06) U** (0.11) U** (0.06) D* (0.03) D** (0.11) 
TRIMEB NS D* (0.01) U* (0.02) NS D* (0.04) 
D* = small downfield, D** = large downfield, U* = small upfield, U** = large upfield, NS = no 
significant shift. 
The complexation of BUD with βCD and DIMEB in D2O caused downfield shift 
changes for the H-C18 and H-C19 protons and upfield chemical shift changes of 
the quinone ring protons (H-C1, H-C2 and H-C4), with the exception of H-C1 
proton where it was observed with downfield shift in the complexation with βCD. 
This suggested that entrance of the quinone ring of BUD into DIMEB cavity is 
deeper than that of BUD in βCD where we anticipate the H-C1 proton (exhibiting 
a downfield shift) is located outside or near the cavity. These observations are 
consistent with the higher association constant derived for the complex with 
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BUD-DIMEB compared to BUD-βCD. The chemical shift differences observed in 
the quinone ring (with the exception of H-C1 proton) with βCD could be 
attributed to the shielding effect of the hydrophobic CD cavity: suggesting these 
protons are closer in proximity to the oxygen atoms located on the inner side of 
the cavity. Both H-C18 and H-C19 with downfield shift were supposed to be 
outside the βCD and DIMEB cavities and interacted with the external surfaces 
of the CD and they were situated far from the oxygen atom inside the CD cavity. 
The H-C19 was expected to be closer to the CD cavity than H-C18 and this 
explained the large chemical shift differences observed with the former proton. 
In the complexation with TRIMEB, the quinone ring of BUD enters partially into 
the CD cavity where only H-C4 proton of the quinone ring (experienced upfield 
shift) was located in the TRIMEB cavity. The H-C2 proton of the quinone ring 
and H-C19 proton were located outside the cavity as they were observed to have 
a downfield shift. As the quinone ring partially entered the TRIMEB cavity, 
therefore, the H-C18 proton (with no chemical shift differences) was situated far 
from the cavity compared to the same proton in the complexation with βCD and 
DIMEB. The larger chemical shift differences resulted in the stronger 
complexation and thus show a higher value for the stability constant. 
Accordingly, it can be concluded that both DIMEB and βCD cavities were 
suitable in size to accommodate and interact with BUD to form stronger 
complexation with a better geometric fitting compared to the weaker 
complexation with TRIMEB. The predicted interaction of BUD with the three 
types of CDs has shown in Figure 7.1. 
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Figure 7.1: Inclusion complex of the budesonide and (a) βCD, (b) DIMEB and (c) TRIMEB. The black 
balls represent the methoxyl groups in the DIMEB and TRIMEB molecules. 
 
The developed NMR method was then applied to study the complexation 
between different corticosteroids (BUD, BDP, MOM and FLU) with the 
derivatised CD (DIMEB and TRIMEB) in the fluorinated solvent system HPFP 
(of the type used in pMDIs). The results of the chemical shift displacements of 
the key protons of the compounds involved in the complexations studied with 
TRIMEB are presented in Table 7.2. 
Table 7.2: A summary of the chemical shift displacements (in ppm) for BUD, BDP, MOM and FLU 
with 2 mM TRIMEB in HPFP related to the chemical shift of the free compounds. 
Compound 
Chemical shift displacements (ppm) 
H-C1 H-C2 H-C4 H-C18 H-C19 
BUD 
D** (0.07, R) 
D* (0.02, S) 
NS U* (0.01) D** (0.17, R) D* (0.01) 
BDP NS NS D* (0.07) NS D* (0.05) 
MOM NA NA NA NS D* (0.04) 
FLU NA NA NA NS D* (0.02) 
D* = small downfield, D** = large downfield, U* = small upfield, NS = no significant shift, NA = 
S/N too low to interpret, R, S = enantiomers of BUD 
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The results showed the strongest complexation was with BUD among all the 
investigated corticosteroids, followed by BDP and MOM, with the weakest 
complexation observed with FLU based on the stability constant values. The K 
values of BDP, MOM and FLU were 197.5, 130 and 86 M-1 respectively, 
whereas the K values of BUD enantiomers were 621 and 222 M-1 for R and S 
enantiomers respectively. 
The complexation of BUD with TRIMEB showed a downfield shift for the H-C1 
proton of the quinone ring and a very small upfield shift occurred for H-C4, with 
no shift observed for the H-C2 proton. A significant downfield shift was observed 
for H-C18 whereas the H-C19 resonance was observed with very small downfield 
shift and was fully split into two distinctive peaks at higher TRIMEB 
concentrations. The complexation of BDP showed minor downfield shift 
differences for the H-C4 proton whereas the H-C19 proton was observed to show 
a downfield shift (no shift was noted for the other protons). Both MOM and FLU 
showed only a small downfield shift for the H-C19 proton in their complexation 
with TRIMEB. However, the other protons in the low field region were not clearly 
observed in the complexed spectra of both compounds as they displayed a low 
S/N ratio and therefore it was difficult to investigate the effect of TRIMEB on the 
chemical shift of those protons. The reciprocal plot of the titration experiments 
for the all studied corticosteroids followed a linear trend, demonstrating that the 
stoichiometric ration of the complexation was 1:1. The continuous variation 
method was also applied to confirm the 1:1 stoichiometry of the inclusion 
complex of BUD with TRIMEB. The Job’s plot showed a maximum at r = 0.5 
which suggests a 1:1 stoichiometry of the complexation and supports the data 
obtained in the titration experiments using Hildebrand-Benesi approach.  
The complexation was also investigated in HPFP between BUD, BDP and 
DIMEB and the findings were similar to those obtained with TRIMEB in that the 
strongest complexation was observed with BUD. The chemical shift 
displacements of some quinone ring protons of BUD and BDP with TRIMEB 
and DIMEB in HPFP suggested the formation of the inclusion complex was 
similar to those observed in the other solvent systems, with the quinone ring 
entering both CD cavities. However, it difficult to estimate the mechanism of the 
interaction of MOM and FLU with TRIMEB as the quinone ring protons did not 
appear in the spectra of both compounds due to low S/N ratio for those protons. 
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The strongest complexation was achieved with BUD compared to the other 
corticosteroids studied. We propose that this is due to the presence of the 
substitution groups such as a furan ring at C17 in MOM and the propionate 
chains in BDP and FLU structures. These groups are expected to cause steric 
hindrance, which impede the deeper inclusion of BDP, FLU and MOM into the 
TRIMEB cavity when compared to BUD. Further, an extra hindrance results 
from the presence of halogenated atoms such as a Cl at C9 in BDP and MOM, 
and F at C6 and C9 in FLU which hamper the entrance of these compounds 
into the TRIMEB cavity compared to the H atom at C9 in the BUD molecule. 
Further work was carried out on the pure enantiomer of BUD (R-BUD) in order 
to assign the peaks in the complexed BUD spectra correctly by relating to both 
enantiomers of BUD. The findings showed the splitting peaks of the H-C18 
proton were related to the R and S-enantiomers of BUD. The resonance that 
showed a chemical shift displacement during the NMR titration was shown to be 
the R-enantiomer, with the S-form showing no displacement. The H-C19 proton 
of the R-enantiomer appeared as singlet in the complexed form whereas it was 
fully split into two distinctive peaks in the racemic mixture of BUD at high 
TRIMEB concentration indicating that another peak appeared in the spectrum of 
the racemic BUD was assigned to the S-enantiomer. The same results were 
obtained with H-C4 proton where in the pure R-enantiomer it appeared as 
singlet peak whereas it partially split in the racemic solution suggesting that this 
peak in the racemic BUD spectra was related to both enantiomers. The H-C1 
proton of the quinone ring was observed to display a downfield shift, with a 
concurrent multiplicity change as the TRIMEB concentration was increased. 
The originally observed doublet (R-enantiomer) was split into four peaks, 
therefore, the two peaks with the highest downfield shift in the racemic BUD 
spectrum were assigned to the R-enantiomer whereas the other two peaks 
were related to the S-enantiomer. 
The studies presented in this thesis have shown the formation of the strongest 
host:guest complex of BUD was with DIMEB in D2O whereas it was with 
TRIMEB in HPFP. This is explained by the solubility of the host in the solvent as 
its solubility controls the strength of the complexation i.e. with higher CD 
solubility, more molecules are solvated in the solution and are available for the 
complexation with the guest molecules; hence a higher association constant is 
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observed. The water solubility of DIMEB and TRIMEB is 57 and 31 g/100 mL 
whereas their solubility in HPFP is 1 and 6 mg/mL (0.1 and 0.6 g/100 mL) 
respectively. In aqueous solution, DIMEB solubility is higher than TRIMEB; i.e. 
more DIMEB molecules are available to interact with the BUD in the system and 
thus more BUD molecules are engaged in the complexation. This results in 
more significant chemical shift displacements in the NMR performed and in turn 
a high stability constant is observed. The converse is true in the case of HPFP 
where the solubility of TRIMEB is higher than DIMEB. Therefore, more TRIMEB 
molecules in the solution are available to form complexation with BUD than with 
the DIMEB system and explains why the strongest complexation observed in 
D2O is with BUD and DIMEB, and in HPFP is with the TRIMEB system. 
The methods developed and applied to the study of corticosteroids and CD 
have allowed us to probe the interactions with significant detail. We have 
derived numerical values for the systems studied to make direct comparison 
between corticosteroids of different functionality, CD with different 
derivatisations and solvents of different polarity. We have been able to postulate 
the ‘structure’ of the complexes formed through the observations made of the 
chemical shift displacements in the NMR titrations performed and have, for the 
first time, studied these interactions in fluorinated solvent systems of the type 
used in pMDI based medications. The significance of the differences observed 
in the systems studied underpins the importance of being able to study these 
systems in-situ and provides extremely useful data for people looking to control 
solubility in fluorinated solvent media. 
7.2 SERS Studies 
As discussed in Section 7.1, the NMR methods employed have allowed us to 
establish the thermodynamics of binding with (relatively) polar solvents and 
have found that the association constants rank as BUD > BDP > MOM > FLU, 
showing a loose (inverse) correlation with steric bulk of D-ring substituents. We 
have established detailed structural information on the host-guest interaction 
and demonstrated in each case, the enone functionality of the A-ring inserts into 
guest cavity.  
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7.2.1 Conventional Raman Spectroscopic Studies of Corticosteroids 
A detailed study of CSs with Raman for MOM and BDP has been undertaken 
for the first time. We have established a strategy that broadly correlates spectral 
regions to regions of the molecular structure in order to establish regioselectivity 
of SERS interaction. This strategy was required as complex spectra have 
significant overlaps and isolated, discrete spectral bands are unlikely to be 
available. The following relationships between molecular regions and spectral 
ranges were established: 1780-1550 cm-1 correlates with CS A-ring and specific 
D-ring substituent modes (e.g. ester carbonyls); 1500-1380 cm-1 correlates with 
C- and D-rings and to the D-ring substituents for this set of species; 1380-1000 
cm-1 correlated to D-ring substituents (particularly ester functions) although 
certain specific bands could be used to probe the hydroxyl substituents on the 
steroid framework [e.g. as/s(C-OH)]; below 1000 cm-1, an array of bands was 
correlated with vibrations of the steroid framework in addition to a number of 
indicative D-ring substituent bands.  
7.2.2  Nanoparticle Synthesis and Characterisation 
We have developed the methodologies to prepare metal nanoparticle 
formulations and load the surface with SCD. TEM observations (‘sulfur halo’) 
and marginal changes in particle size indicated that the metal nanoparticle 
surface had been functionalised with SCD. The potential importance of 
centrifugation was identified. The synthetic step was shown to reduce 
polydispersity and this appeared to correlate with enhanced SERS performance 
(especially with Au-NP and SCD-NP). 
7.2.3 SERS with CSs  
Significant enhancements were observed with all systems, with increases in 
intensity of the order of 103-104 routinely observed using short exposures and 
minimal co-additions. Generally, with the naked metal nanoparticles, 
regiospecific enhancements were observed that correlated to steroid D-ring 
substituents. It is expected that the enhancement relates to the proximity (and 
appropriate orientation) of these molecular regions to the NP surface (with its 
partial charge). These correlate with more polar regions of the molecule 
(consistent with NMR studies where the D-ring is shown have an affinity with 
the solvent medium (aqueous), leading to A-ring insertion to the (relatively) 
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apolar CD cavity). Ag-NPs have been observed to be generally more active and 
more regio-selective than Au-NP. 
7.2.4 SERS with SCD-M-NP  
In these studies, ’selective’ SERS has been demonstrated for the first time. The 
studies indicate that surface functionalisation of the metal NP with CD moieties 
orientates different regions of the molecular species to interact with the metal 
surface – in all cases, enhancement has been observed in several (correlated) 
spectral regions. Silver NP formulations appeared to be more active than gold 
with most systems and, in many cases, led to better resolved spectra. A link 
between spectral resolution with the SERS microenvironment was inferred. The 
potential importance of creating homogenous metal NPs (e.g. through control of 
centrifugation steps in preparation) may be the topic for future development of 
these systems. In some cases, SCD-Au-NP formulations showed enhancement 
for bands from SCD host. While not desirable because of the potential 
interference, the SCD vibrations cover a relatively small spectral window and, in 
particular, obscured only the 1500-1380 cm-1 regions. In the cases where these 
effects were experience, other spectral regions could be used to give diagnostic 
information. Interestingly, the SCD-Ag-NP formulations showed no interference 
of this type. Regioselectivity appears to follow binding affinity for Ag: BUD~BDP 
> FLU~MOM. In the latter group, spectral complexity indicates greater diversity 
of enhancement possibly indicating different structural units interacting the 
metal-N centre. 
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8 Further work 
The work in this thesis can be extended in a number of different directions. The 
NMR methods developed could be used to study the SCD systems employed in 
the SERS study to derive binding constants and formalise the stoichiometry of 
the systems, complementing the data obtained from the SERS study well. 
Additional thermodynamic data is relatively easily obtainable on all the systems 
studied, with some simple modifications to the NMR approaches used. Variable 
temperature work could be performed to derive van’t Hoff plots allowing 
extraction of data to further understand enthalpic vs. entropic control of the 
systems studied with the different CD, solvent and ICS combinations. 
The methodology summarised in this work also form the basis for transfer to  
investigate the complexation in HFAs 134a and 227 commonly used as 
propellants in pMDI products. Being gaseous at STP, most analytical 
approaches are cumbersome and difficult to implement for such systems. As 
the NMR setup used can be easily modified to incorporate a cap capable of 
holding the tube at pressure, HFAs 134a and 227 can be studied under the 
conditions present in a pMDI canister i.e. as liquids at room temperature.  
Furthermore, other compounds of significance in inhalational therapies such as 
β2 agonists (salbutamol, terbutaline, salmeterol and formoterol) could be 
assessed for their behaviour with CDs in these HFA solvents to interrogate any 
complexation exhibited and establish a greater understanding of formulation 
characteristics of inhaled drugs in-situ and develop more efficacious treatments. 
The SERS studies reported have provided a fundamental insight into the SCD-
Au and SCD-Ag systems and their interaction with ICS compounds. Work to 
study the relative quantification of regions to quantify the enhancements 
observed would be of benefit, leading to the possibility of quantifying the loading 
of SCDs. Further work to characterise the SCD and how this is oriented on the 
surface of the NPs would be of great value. 
 
 
 
 209 
 
9 References 
1. Grossman J. The evolution of inhaler technology. The Journal of asthma : official 
journal of the Association for the Care of Asthma. 1994;31(1):55-64. 
2. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting 
therapeutic effectiveness of aerosolized medications. British journal of clinical 
pharmacology. 2003;56(6):588-599. 
3. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical 
challenges of dry powder inhalers and formulations. Advanced drug delivery reviews. 
2014. 
4. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the 
lungs. Nature reviews Drug discovery. 2007;6(1):67-74. 
5. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and 
clinical use. Lancet. 2011;377(9770):1032-1045. 
6. Keith IM, Olson EB, Jr., Wilson NM, Jefcoate CR. Immunological identification and 
effects of 3-methylcholanthrene and phenobarbital on rat pulmonary cytochrome P-
450. Cancer research. 1987;47(7):1878-1882. 
7. Ji CM, Cardoso WV, Gebremichael A, et al. Pulmonary cytochrome P-450 
monooxygenase system and Clara cell differentiation in rats. The American journal of 
physiology. 1995;269(3 Pt 1):L394-402. 
8. Yang MY, Chan JGY, Chan H. Pulmonary drug delivery by powder aerosols. Journal of 
controlled release. 2014:1-13. 
9. Welbanks L. Compendium of pharmaceuticals and specialties. In. 35 ed: Ontario: 
Canadian Pharmacists Association; 2000. 
10. Ritchie TJ, Luscombe CN, Macdonald SJ. Analysis of the calculated physicochemical 
properties of respiratory drugs: can we design for inhaled drugs yet? Journal of 
chemical information and modeling. 2009;49(4):1025-1032. 
11. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. 
Journal of pharmaceutical sciences. 1971;60(10):1559-1564. 
12. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation 
of tobramycin using PulmoSphere technology. Journal of aerosol medicine and 
pulmonary drug delivery. 2011;24(4):175-182. 
13. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive 
Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), www.goldcopd.org. 2014. Accessed 12-07-2014. 
14. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 
2001;119(6):1691-1695. 
15. Chronic obstructive pulmonary disease, Management of chronic obstructive 
pulmonary disease in adults in primary and secondary care (partial update), National 
Institute for Health and Clinical Excellence (NHS). www.nice.org.uk. 2010. 
16. Barnes PJ. New treatments for COPD. Nature reviews Drug discovery. 2002;1(6):437-
446. 
17. Bousquet J, Khaltaev AN. Global surveillance, prevention and control of chronic 
respiratory diseases: a comprehensive approach. Global Alliance against Chronic 
Respiratory Diseases. Geneva: World Health Organization. 2007. 
18. Olaguibel JM, Quirce S, Julia B, et al. Measurement of asthma control according to 
Global Initiative for Asthma guidelines: a comparison with the Asthma Control 
Questionnaire. Respiratory research. 2012;13:50. 
19. Global Strategy for Asthma Management and Prevention, Global Initiative for asthma 
(GINA), 2014,www.ginasthma.org. 
20. Bousquet J, Kiley J, Bateman E, Viegi G, Cruz AA. Prioritised research agenda for 
prevention and control of chronic respiratory diseases. . Eur Respir J 2010;36:995-
1001. 
 210 
 
21. Shapiro SD. Animal models for COPD. Chest. 2000;117(5 Suppl 1):223S-227S. 
22. Barnes PJ. Asthma and COPD : basic mechanisms and clinical management. 2nd ed. ed. 
Amsterdam ; London: Academic; 2009. 
23. Mason JR, et al. Murray and Nadel's textbook of respiratory medicine. 5th ed ed. 
Philadelphia, PA: Saunders/Elsevier; 2010. 
24. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, 
evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373. 
25. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor 
necrosis factor-alpha in induced sputum from patients with chronic obstructive 
pulmonary disease or asthma. American journal of respiratory and critical care 
medicine. 1996;153(2):530-534. 
26. de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: Struggle 
between oxidants and cytokines. International Journal of COPD. 2007;2(3):205-228. 
27. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet. 
2004;364(9436):791-802. 
28. Wouters EF. Management of severe COPD. Lancet. 2004;364(9437):883-895. 
29. Evans DJ, et al. A comparison of low-dose inhaled budesonide plus theophylline and 
high-dose inhaled budesonide for moderate asthma. The New England Journal of 
Medicine. 1997;337(20):1412-1418. 
30. Tinkelman DG, et al. Aerosol beclomethasone dipropionate compared with 
theophylline as primary treatment of chronic, mild to moderately severe asthma in 
children. Pediatrics. 1993;92(1):64-77. 
31. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. 
International Journal of COPD. 2006;1(4):409-423. 
32. Johnston SL, et al. Community study of role of viral infections in exacerbations of 
asthma in 9–11 year old children. BMJ. 1995;13(310):1225–1229. 
33. Bueving HJ, Bernsen RM, de Jongste JC, et al. Influenza vaccination in children with 
asthma: randomized double-blind placebo-controlled trial. American journal of 
respiratory and critical care medicine. 2004;169(4):488-493. 
34. Nicholson KG, R. Snacken, and A.M. Palache. Influenza immunization policies in Europe 
and the United States. Vaccine. 1995;13(4):365-369. 
35. Tata LJ, et al. Does influenza vaccination increase consultations, corticosteroid 
prescriptions, or exacerbations in subjects with asthma or chronic obstructive 
pulmonary disease? Thorax. 2003;58(10):835-839. 
36. Rothbarth PH, Kempen BM, Sprenger MJ. Sense and nonsense of influenza vaccination 
in asthma and chronic obstructive pulmonary disease. American journal of respiratory 
and critical care medicine. 1995;151(5):1682-1685; discussion 1685-1686. 
37. Alton EW, Boushey HA, Garn H, et al. Clinical expert panel on monitoring potential lung 
toxicity of inhaled oligonucleotides: consensus points and recommendations. Nucleic 
acid therapeutics. 2012;22(4):246-254. 
38. Ferrari N, Seguin R, Renzi P. Oligonucleotides: a multi-targeted approach for the 
treatment of respiratory diseases. Future medicinal chemistry. 2011;3(13):1647-1662. 
39. Rahman I. Antioxidant therapies in COPD. International journal of chronic obstructive 
pulmonary disease. 2006;1(1):15-29. 
40. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for 
COPD. Biochimica et Biophysica Acta. 2012;1822(5):714-728. 
41. Shaheen SO, Sterne JA, Thompson RL, Songhurst CE, Margetts BM, Burney PG. Dietary 
antioxidants and asthma in adults: population-based case-control study. American 
journal of respiratory and critical care medicine. 2001;164(10 Pt 1):1823-1828. 
42. Patel BD, Welch AA, Bingham SA, et al. Dietary antioxidants and asthma in adults. 
Thorax. 2006;61(5):388-393. 
 211 
 
43. Matera MG, L. Calzetta, and M. Cazzola. TNF-a inhibitors in asthma and COPD: We 
must not throw the baby out with the bath water. Pulm Pharmacol Ther. 
2010;23(2):121-128. 
44. Berry M, et al. TNF-alpha in asthma. Current Opinion in Pharmacology. 2007;7(3):279-
282. 
45. Suissa S, P. Ernst, and M. Hudson. TNF-a antagonists and the prevention of 
hospitalisation for chronic obstructive pulmonary disease. Pulmonary Pharmacology & 
Therapeutics. 2008;21(1):234-238. 
46. Barnes PJ, Adcock IM. How Do Corticosteroids Work in Asthma? Ann Intern Med. 
2003;139(5):359-370. 
47. Bateman ED, et al. Global strategy for asthma management and prevention: GINA 
executive summary. Eur Respir J. 2008;31(1):143–178. 
48. Barnes PJ. Glucocorticosteroids: current and future directions. British journal of 
pharmacology. 2011;163(1):29-43. 
49. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. 
British journal of pharmacology. 2006;148(3):245-254. 
50. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency 
department treatment of acute asthma with systemic corticosteroids. The Cochrane 
database of systematic reviews. 2001(1):CD002178. 
51. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for 
the new millennium. Drug safety : an international journal of medical toxicology and 
drug experience. 2000;23(1):11-33. 
52. Bandi N, Wei W, Roberts CB, Kotra LP, Kompella UB. Preparation of budesonide- and 
indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, 
organic-solvent-free supercritical fluid process. European journal of pharmaceutical 
sciences : official journal of the European Federation for Pharmaceutical Sciences. 
2004;23(2):159-168. 
53. Rubin BK. Air and soul: the science and application of aerosol therapy. Respiratory 
care. 2010;55(7):911-921. 
54. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax. 1997;52 
Suppl 2:S31-44. 
55. Hess DR. Aerosol delivery devices in the treatment of asthma. Respiratory care. 
2008;53(6):699-723; discussion 723-695. 
56. Talasila GKM, Mukkala BVP, Vattikuri S. Formulation and evaluation of CFC free 
inhalers for beclomethasone dipropionate Brazilian Journal of Pharmaceutical 
Sciences. 2013;49(2):221-231. 
57. Newman SP. Principles of Metered-Dose Inhaler Design. Respiratory care. 
2005;50(9):1177-1190. 
58. Zhou QT, Tang P, Leung SS, Chan JG, Chan HK. Emerging inhalation aerosol devices and 
strategies: Where are we headed? Advanced drug delivery reviews. 2014. 
59. Khale A, Bajaj A. Formulation and development of metered dose inhalations of 
salbutamol in solution form. Indian journal of pharmaceutical sciences. 
2011;73(5):543-549. 
60. O'Byrne PM. Clinical comparisons of inhaler systems: what are the important aspects? 
Journal of aerosol medicine : the official journal of the International Society for 
Aerosols in Medicine. 1995;8 Suppl 3:S39-46; discussion S47. 
61. Chrystyn H. The Diskus: a review of its position among dry powder inhaler devices. 
International journal of clinical practice. 2007;61(6):1022-1036. 
62. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respiratory care. 
2005;50(9):1209-1227. 
63. Maggi L, Bruni R, Conte U. Influence of the moisture on the performance of a new dry 
powder inhaler. International journal of pharmaceutics. 1999;177(1):83-91. 
 212 
 
64. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated 
with misuse of conventional metered-dose inhalers and newer dry powder inhalers in 
experienced adults. Annals of allergy, asthma & immunology : official publication of 
the American College of Allergy, Asthma, & Immunology. 2004;93(5):439-446. 
65. Frijlink HW, De Boer AH. Drug powder inhalers for pulmonary dug delivery. Expert Opin 
Drug Deliv. 2004;1(1). 
66. Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. 
Respiratory care. 2005;50(9):1201-1208. 
67. Forte R, Dibble C. The role of international environmental agreements in metered-
dose inhaler technology changes. The Journal of Allergy and Clinical Immunology. 
1999;104(6):s217-s220. 
68. Ibiapina CC, Cruz ÁA, Camargos PAM. Hydrofluoroalkane as a propellant for 
pressurized metered-dose inhalers: history, pulmonary deposition, pharmacokinetics, 
efficacy and safety. Jornal de Pediatria. 2004;80(6):441-446. 
69. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-
beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur 
Respir J. 1998;12(6):1346-1353. 
70. Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI 
with CFC and HFA-134a formulations in a human airway replica. Journal of aerosol 
medicine : the official journal of the International Society for Aerosols in Medicine. 
2001;14(2):255-266. 
71. Smyth HDC. The influence of formulation variables on the performance of alternative 
propellant-driven metered dose inhalers. Advanced Drug Delivery Reviews. 
2003;55(7):807-828. 
72. Smith IJ. The challenge of reformulation. Journal of aerosol medicine : the official 
journal of the International Society for Aerosols in Medicine. 1995;8 Suppl 1:S19-27. 
73. Brambilla G, Ganderton D, Garzia R, Lewis D, Meakin B, Ventura P. Modulation of 
aerosol clouds produced by pressurised inhalation aerosols. International journal of 
pharmaceutics. 1999;186(1):53-61. 
74. Ibiapina CC, A.A. Cruz, and P.A.M. Camargos. Hydrofluoroalkane as a propellant for 
pressurized metered-dose inhalers: history, pulmonary deposition, pharmacokinetics, 
efficacy and safety. Jornal de Pediatria. 2004;80(6):441-446. 
75. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite: a means 
of designing the aerosols generated by pressurized metered dose inhalers. Respiratory 
medicine. 2002;96 Suppl D:S3-8. 
76. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement 
techniques. ISRN pharmaceutics. 2012;2012:195727. 
77. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance 
bioavailability of poorly water-soluble drugs. Journal of drug delivery. 
2013;2013:340315. 
78. Kumar A, et al. Review on solubility enhancement techniques for hydrophobic drugs. 
Pharmacie Globale (IJCP). 2011;2(3):1-7. 
79. Podczeck F, J.M. Newton, and M.B. James. The adhesion strength of particles of 
salmeterol base and a series of salmeterol salts to compacted lactose monohydrate 
surfaces. J ADHES SCI TECHNOL 1995;9(12):1547-1558. 
80. Seville PC, Simons C, Taylor G, Dickinson PA. Prodrug to probe solution HFA pMDI 
formulation and pulmonary esterase activity. International journal of pharmaceutics. 
2000;195(1-2):13-16. 
81. Sukasame N, P. Boonme, and T. Srichana. Development of budesonide suspensions for 
use in an HFA pressurized metered dose inhaler. ScienceAsia. 2011;37:31-37. 
82. Ramteke KH, S.S. Gunjal, and Y.P. Sharma. Formulation and quality control of metered 
dose inhaler: a review. JPSI. 2012;1(2):44-49. 
 213 
 
83. Gardenhire DS. Rau's Respiratory Care Pharmacology 8th ed: Elsevier Health Sciences; 
2012. 
84. Fairhurst D, Lee RW. Aggregation, agglomeration - how to avoid aggravation when 
formulating particulate suspensions. Drug Delivery Technology. 2008;8(8):48-52. 
85. Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: 
investigation of the role of stabilizers on Ostwald ripening. International journal of 
pharmaceutics. 2011;406(1-2):145-152. 
86. Soni S, et al. Nanosuspension: An Approach to Enhance Solubility of Drugs. IJPI’s 
Journal of Pharmaceutics and Cosmetology. 2012;2(9):50-63. 
87. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose 
inhalers: a multicentric study. CESEA Group. Respiration; international review of 
thoracic diseases. 1998;65(3):195-198. 
88. Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on 
pressurized metered dose inhaler suspension stability. The Journal of allergy and 
clinical immunology. 1999;104(6):S221-226. 
89. Tan Y, Yang Z, Pan X, et al. Stability and aerosolization of pressurized metered dose 
inhalers containing thymopentin nanoparticles produced using a bottom-up process. 
International journal of pharmaceutics. 2012;427(2):385-392. 
90. Nyambura BK, Kellaway IW, Taylor KM. Insulin nanoparticles: stability and 
aerosolization from pressurized metered dose inhalers. International journal of 
pharmaceutics. 2009;375(1-2):114-122. 
91. Dickinson PA, Howells SW, Kellaway IW. Novel nanoparticles for pulmonary drug 
administration. Journal of drug targeting. 2001;9(4):295-302. 
92. Smyth HD, Hickey AJ. Multimodal particle size distributions emitted from HFA-134a 
solution pressurized metered-dose inhalers. AAPS PharmSciTech. 2003;4(3):E38. 
93. Smyth HDC, Hickey AJ. Controlled pulmonary drug delivery. New York ; London: 
Springer; 2011. 
94. Zhu B, Traini D, Chan HK, Young PM. The effect of ethanol on the formation and 
physico-chemical properties of particles generated from budesonide solution-based 
pressurized metered-dose inhalers. Drug development and industrial pharmacy. 
2013;39(11):1625-1637. 
95. Evans RM, Farr SJ, Armstrong NA, Chatham SM. Formulation and in vitro evaluation of 
pressurized inhalation aerosols containing isotropic systems of lecithin and water. 
Pharmaceutical research. 1991;8(5):629-635. 
96. Saleem IY, Smyth HD. Tuning aerosol particle size distribution of metered dose inhalers 
using cosolvents and surfactants. BioMed research international. 2013;2013:574310. 
97. Nalluri BN, Chowdary KP, Murthy KV, Hayman AR, Becket G. Physicochemical 
characterization and dissolution properties of nimesulide-cyclodextrin binary systems. 
AAPS PharmSciTech. 2003;4(1):E2. 
98. Gonda I. Development of a systematic theory of suspension inhalation aerosols-I. A 
framework to study the effects of aggregation on the aerodynamic behaviour of drug 
particles. Int J Pharm. 1985;27:99-116. 
99. Stein SW. Estimating the number of droplets and drug particles emitted from MDIs. 
AAPS PharmSciTech. 2008;9(1):112-115. 
100. Stein SW, Sheth P, Myrdal PB. A model for predicting size distributions delivered from 
pMDIs with suspended drug. International journal of pharmaceutics. 2012;422(1-
2):101-115. 
101. Ivey JW, Lewis D, Church T, Finlay WH, Vehring R. A correlation equation for the mass 
median aerodynamic diameter of the aerosol emitted by solution metered dose 
inhalers. International journal of pharmaceutics. 2014;465(1-2):18-24. 
102. Stein SW, Myrdal PB. A theoretical and experimental analysis of formulation and 
device parameters affecting solution MDI size distributions. Journal of pharmaceutical 
sciences. 2004;93(8):2158-2175. 
 214 
 
103. Szejtli Jz. Cyclodextrin technology. Dordrecht: Kluwer Academic Publishers; 1988. 
104. Ali SM, et al. Complexation of enalapril maleate with  β-cyclodextrin: NMR 
spectroscopic study in solution Quim Nova. 2006;29(4):685-688. 
105. Cramer F. Einschlusverbindungen (Inclusion Compounds). Berlin: Springer-Verlag; 1954. 
106. Panda S, Sahu R. Inclusion complex with cyclodextrin: a boon to pharmaceutical world. 
IJBPAS. 2014;3(6):915-926. 
107. Rekharsky MV, Inoue Y. Complexation Thermodynamics of Cyclodextrins. Chemical 
reviews. 1998;98(5):1875-1918. 
108. Iacovino R, Caso JV, Rapuano F, et al. Physicochemical characterization and cytotoxic 
activity evaluation of hydroxymethylferrocene:beta-cyclodextrin inclusion complex. 
Molecules. 2012;17(5):6056-6070. 
109. Saenger W, Jacob J, Gessler K, et al. Structures of the Common Cyclodextrins and Their 
Larger Analogues-Beyond the Doughnut. Chemical reviews. 1998;98(5):1787-1802. 
110. Miranda JCd, Martins TEA, Veiga F, Ferraz HG. Cyclodextrins and ternary complexes: 
technology to improve solubility of poorly soluble drugs. Brazilian Journal of 
Pharmaceutical Sciences. 2011;47(4):665-681. 
111. Jambhekar SS, Breen P. Cyclodextrins in pharmaceutical formulations II: solubilization, 
binding constant, and complexation efficiency. Drug Discov Today. 2016;21(2):363-
368. 
112. Kanaka Durga Devi N, Prameela Rani A, Muneer Javed M, Sai Kumar K, Kaushik J, 
Sowjanya V. Cyclodextrins in pharmacy- an overview. Pharmacopore. 2010;1(3):155-
165. 
113. Van Hees T, Piel G, de Hassonville SH, Evrard B, Delattre L. Determination of the 
free/included piroxicam ratio in cyclodextrin complexes: comparison between UV 
spectrophotometry and differential scanning calorimetry. European journal of 
pharmaceutical sciences : official journal of the European Federation for 
Pharmaceutical Sciences. 2002;15(4):347-353. 
114. Lin SZ, et al. Indomethacin and cyclodextrin complexes. International journal of 
pharmaceutics. 1991;69:211-219. 
115. Veiga MD, Diaz PJ, Ahsan F. Interactions of griseofulvin with cyclodextrins in solid 
binary systems. Journal of pharmaceutical sciences. 1998;87(7):891-900. 
116. Moyano JR, Arias-Blanco MJ, Gines JM, et al. Nuclear magnetic resonance 
investigations of the inclusion complexation of gliclazide with beta-cyclodextrin. 
Journal of pharmaceutical sciences. 1997;86(1):72-75. 
117. Veiga FJ, Fernandes CM, Carvalho RA, Geraldes CF. Molecular modelling and 1H-NMR: 
ultimate tools for the investigation of tolbutamide: beta-cyclodextrin and tolbutamide: 
hydroxypropyl-beta-cyclodextrin complexes. Chemical & pharmaceutical bulletin. 
2001;49(10):1251-1256. 
118. Cserhati T, Forgacs E. Inclusion complex formation of steroidal drugs with 
hydroxypropyl-beta-cyclodextrin studied by charge-transfer chromatography. Journal 
of pharmaceutical and biomedical analysis. 1998;18(1-2):179-185. 
119. Nakanishi K, Masukawa T, Nadai T, Yoshii K, Okada S, Miyajima K. Sustained release of 
flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex. Biological & 
pharmaceutical bulletin. 1997;20(1):66-70. 
120. Siefert B, Pleyer U, Muller M, Hartmann C, Keipert S. Influence of cyclodextrins on the 
in vitro corneal permeability and in vivo ocular distribution of thalidomide. Journal of 
ocular pharmacology and therapeutics : the official journal of the Association for 
Ocular Pharmacology and Therapeutics. 1999;15(5):429-438. 
121. Otero Espinar FJ, et al. Reduction in the ulceragenicity of naproxen by complexation 
with β-cyclodextrin. Int J Pharm. 1991;70:35-41. 
122. Chadha R, Kashid N, Saini A. Account of analytical techniques employed for the 
determination of thermodynamics of inclusion complexationof drugs with 
cyclodextrins. JSIR. 2004;63(3):211-229. 
 215 
 
123. Siegel B, Breslow R. Lyophobic binding of substrates by cyclodextrins in nonaqueous 
solvents. Journal of the American Chemical Society. 1975;97(23):6869-6870. 
124. Danil de Namor AF, Traboulssi R, Lewis DFV. Host properties of cyclodextrins towards 
anion constituents of antigenic determinants. A thermodynamic study in water and in 
N,N-dimethylformamide. Journal of the American Chemical Society. 
1990;112(23):8442-8447. 
125. Kida T, Fujino Y, Miyawaki K, Kato E, Akashi M. 6-O-Modified beta-cyclodextrin 
enabling inclusion complex formation in nonpolar media. Org Lett. 2009;11(22):5282-
5285. 
126. Williams RO, 3rd, Liu J. Influence of formulation technique for hydroxypropyl-beta-
cyclodextrin on the stability of aspirin in HFA 134a. European journal of pharmaceutics 
and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische 
Verfahrenstechnik eV. 1999;47(2):145-152. 
127. Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) 
suspensions. International journal of pharmaceutics. 2004;284(1-2):75-82. 
128. Singh R, et al. Characterization of cyclodextrin inclusion complexes – A review. Journal 
of Pharmaceutical Science and Technology. 2010;2(3):171-183. 
129. Szejtli J. Introduction and General Overview of Cyclodextrin Chemistry. Chem Rev. 
1998;98(5):1743-1754. 
130. Kanaka Durga Devi N. Cyclodextrins in pharmacy- an overview. Pharmacopore. 
2010;1(3):1-7. 
131. Rekharsky MV, Inoue Y. Complexation Thermodynamics of Cyclodextrins. Chemical 
Reviews. 1998;98(5):1875-1918. 
132. Tabushi I, Kiyosuke Y, Sugimoto T, Yamamura K. Approach to the aspects of driving 
force of inclusion by .alpha.-cyclodextrin. Journal of the American Chemical Society. 
1978;100(3):916-919. 
133. Matsui Y. Molecular Mechanical Calculation on Cyclodextrin Inclusion Complexes. I. 
The Structures of α-Cyclodextrin Complexes Estimated by van der Waals Interaction 
Energy Calculation. Bulletin of the Chemical Society of Japan. 1982;55(4):1246-1249. 
134. Avakyan VG, Nazarov VB, Alfimov MV, Bagatur"yants AA, Voronezheva NI. The role of 
intra- and intermolecular hydrogen bonds in the formation of β-cyclodextrin head-to-
head and head-to-tail dimers. The results of ab initio and semiempirical quantum-
chemical calculations. Russian Chemical Bulletin. 2001;50(2):206-216. 
135. Shi J-H, Chen K, Xu Y. Characterization of the inclusion interaction between 
prednisolone and di-O-methyl-β-cyclodextrin: Spectroscopic methods and molecular 
modeling. Journal of Molecular Liquids. 2014;194:172-178. 
136. Rekharsky MV, Inoue Y. Complexation and chiral recognition thermodynamics of 6-
amino-6-deoxy-beta-cyclodextrin with anionic, cationic, and neutral chiral guests: 
counterbalance between van der Waals and coulombic interactions. Journal of the 
American Chemical Society. 2002;124(5):813-826. 
137. Buha SM, Baxi GA, Shrivastav PS. Liquid Chromatography Study on Atenolol--
Cyclodextrin Inclusion Complex. ISRN Analytical Chemistry. 2012;2012:1-8. 
138. Park JW, Lee SY, Song HJ, Park KK. Self-inclusion behavior and circular dichroism of 
aliphatic chain-linked beta-cyclodextrin-viologen compounds and their reduced forms 
depending on the side of modification. J Org Chem. 2005;70(23):9505-9513. 
139. Marangoci N, Mares M, Silion M, et al. Inclusion complex of a new propiconazole 
derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies. 
Results in pharma sciences. 2011;1(1):27-37. 
140. Mokhtar M, Adnan R. Preparation method and characterisation of inclusion complex of 
theophylline/beta ESTEEM Academic Journal. 2012;8(2):50-63. 
141. Yang X, Ke W, Zi P, Liu F, Yu L. Detecting and identifying the complexation of 
nimodipine with hydroxypropyl-beta-cyclodextrin present in tablets by Raman 
spectroscopy. Journal of pharmaceutical sciences. 2008;97(7):2702-2719. 
 216 
 
142. Wen J, Liu B, Yuan E, Ma Y, Zhu Y. Preparation and physicochemical properties of the 
complex of naringenin with hydroxypropyl-beta-cyclodextrin. Molecules (Basel, 
Switzerland). 2010;15(6):4401-4407. 
143. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced Drug 
Delivery Reviews. 2007;59(7):645-666. 
144. Loukas YL. Measurement of Molecular Association in Drug: Cyclodextrin Inclusion 
Complexes with Improved 1H NMR Studies. Journal of Pharmacy and Pharmacology. 
1997;49(10):944-948. 
145. Marangoci N, et al. Inclusion complex of a new propiconazole derivative with b-
cyclodextrin: NMR, ESI–MS and preliminary pharmacological studies. Results in 
Pharma Sciences. 2011;1(1):27-37. 
146. Upadhyay SK, Kumar G. NMR and molecular modelling studies on the interaction of 
fluconazole with beta-cyclodextrin. Chemistry Central journal. 2009;3:9. 
147. Ali SM, et al. High resolution NMR spectroscopic study of complexation of hydroxyzine 
hydrochloride with β-cyclodextrin in aqueous solution. Journal of the Chinese Chemical 
Society. 2006;53(4):867-871. 
148. Bernatowicz P, Nowakowski M, Dodziuk H, Ejchart A. Determination of association 
constants at moderately fast chemical exchange: Complexation of camphor 
enantiomers by α-cyclodextrin. Journal of Magnetic Resonance. 2006;181(2):304-309. 
149. Schalley CA, ProQuest. Analytical Methods in Supramolecular Chemistry. 2nd 
completely rev. and enlarg ed. Weinheim, Germany: Wiley-VCH; 2012. 
150. Yujuan C, Runhua L. 1H NMR titration and quantum calculation for the inclusion 
complexes of cis-cyclooctene, cis, cis-1, 3-cyclooctadiene and cis, cis-1, 5-
cyclooctadiene with beta-cyclodextrin. Spectrochim Acta A Mol Biomol Spectrosc. 
2009;73(4):713-718. 
151. Schneider HJ, Hacket F, Rudiger V, Ikeda H. NMR Studies of Cyclodextrins and 
Cyclodextrin Complexes. Chemical reviews. 1998;98(5):1755-1786. 
152. Rawat S, Jain SK. Solubility enhancement of celecoxib using beta-cyclodextrin inclusion 
complexes. European journal of pharmaceutics and biopharmaceutics : official journal 
of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2004;57(2):263-
267. 
153. Al-Rawashdeh NAF, Al-Sadeh KS, Al-Bitar MB. Inclusion Complexes of Sunscreen 
Agents withβ-Cyclodextrin: Spectroscopic and Molecular Modeling Studies. Journal of 
Spectroscopy. 2013;2013:1-11. 
154. Saha S, Roy A, Roy K, Roy MN. Study to explore the mechanism to form inclusion 
complexes of β-cyclodextrin with vitamin molecules. Scientific Reports. 2016;6:35764. 
155. Shi J-H, Zhou Y-f. Inclusion interaction of chloramphenicol and heptakis (2,6-di- O-
methyl)-β-cyclodextrin: Phase solubility and spectroscopic methods. Spectrochimica 
Acta Part A: Molecular and Biomolecular Spectroscopy. 2011;83(1):570-574. 
156. Aggarwal RL, Farrar LW, Diebold ED, Polla DL. Measurement of the absolute Raman 
scattering cross section of the 1584-cm−1band of benzenethiol and the surface-
enhanced Raman scattering cross section enhancement factor for femtosecond laser-
nanostructured substrates. Journal of Raman Spectroscopy. 2009;40(9):1331-1333. 
157. Fleischmann M, Hendra PJ, McQuillan AJ. Raman spectra of pyridine adsorbed at a 
silver electrode. Chemical Physics Letters. 1974;26(2):163-166. 
158. Guillot N, de la Chapelle ML. The electromagnetic effect in surface enhanced Raman 
scattering: Enhancement optimization using precisely controlled nanostructures. 
Journal of Quantitative Spectroscopy and Radiative Transfer. 2012;113(18):2321-2333. 
159. Kedem O, Tesler AB, Vaskevich A, Rubinstein I. Sensitivity and optimization of localized 
surface plasmon resonance transducers. ACS Nano. 2011;5(2):748-760. 
160. Haes AJ, Zou S, Schatz GC, Van Duyne RP. A Nanoscale Optical Biosensor:  The Long 
Range Distance Dependence of the Localized Surface Plasmon Resonance of Noble 
Metal Nanoparticles. The Journal of Physical Chemistry B. 2004;108(1):109-116. 
 217 
 
161. Dieringer JA, McFarland AD, Shah NC, et al. Introductory Lecture : Surface enhanced 
Raman spectroscopy: new materials, concepts, characterization tools, and 
applications. Faraday Discuss. 2006;132:9-26. 
162. Sharma B, Frontiera RR, Henry A-I, Ringe E, Van Duyne RP. SERS: Materials, 
applications, and the future. Materials Today. 2012;15(1-2):16-25. 
163. Patil JS, et al. Inclusion complex system; a novel technique to improve the solubility 
and bioavailability of poorly soluble drugs: A review. International Journal of 
Pharmaceutical Sciences Review and Research. 2010;2(2):29-34. 
164. Menger FM, Dulany MA. Chemistry of a heptane-soluble cyclodextrin derivative. 
Tetrahedron Letters. 1985;26(3):267-270. 
165. Uccello-Barretta G, Sicoli G, Balzano F, Schurig V, Salvadori P. Highly efficient NMR 
enantiodiscrimination of 1,1,1,3,3-pentafluoro-2-(fluoromethoxy)-3-methoxypropane, 
a chiral degradation product of sevoflurane, by heptakis(2,3-di-O-acetyl-6-O-tert-
butyldimethylsilyl)-β-cyclodextrin. Tetrahedron: Asymmetry. 2006;17(17):2504-2510. 
166. Rogueda PG. HPFP, a model propellant for pMDIs. Drug development and industrial 
pharmacy. 2003;29(1):39-49. 
167. Rojas MT, Koeniger R, Stoddart JF, Kaifer AE. Supported Monolayers Containing 
Preformed Binding Sites. Synthesis and Interfacial Binding Properties of a Thiolated 
.beta.-Cyclodextrin Derivative. Journal of the American Chemical Society. 
1995;117(1):336-343. 
168. Soloman SD, Bahadory M, Jeyarajasingam AV, Rutkowsky SA, Boritz C, Mulfinger L. 
Synthesis and study of silver nanoparticles. Journal of Chemical Education. 
2007;84(2):322. 
169. Drake P, Chang H-W, Lin Y-J. The design of a peptide linker group to enhance the SERS 
signal intensity of an atto680 dye-nanoparticle system. Journal of Raman 
Spectroscopy. 2010;41(10):1248-1253. 
170. Polovinkin V, Balandin T, Volkov O, et al. Nanoparticle surface-enhanced Raman 
scattering of bacteriorhodopsin stabilized by amphipol A8-35. J Membr Biol. 
2014;247(9-10):971-980. 
171. Balasubramanian SK, Yang L, Yung LY, Ong CN, Ong WY, Yu LE. Characterization, 
purification, and stability of gold nanoparticles. Biomaterials. 2010;31(34):9023-9030. 
172. Johari SA, Kalbassi MR, Soltani M, Yu IJ. Toxicity comparison of colloidal silver 
nanoparticles in various life stages of rainbow trout (Oncorhynchus mykiss). Iranian 
Journal of Fisheries Sciences. 2013;12(1):76-95. 
173. Pirnau A, Bogdan M, Floare CG. NMR Spectroscopic characterization of β-cyclodextrin 
inclusion complex with vanillin. Journal of Physics. 2009;182:1-5. 
174. Lee YS, Park HJ, Jang DJ. Encapsulation of 6-Hydroxyquinoline in Heptakis(2,6-di-O-
methyl)-β-cyclodextrin. Bull Korean Chem Soc. 2006;27(9):1450-1452. 
175. Sambasevam KP, Mohamad S, Sarih NM, Ismail NA. Synthesis and Characterization of 
the Inclusion Complex of beta-cyclodextrin and Azomethine. International journal of 
molecular sciences. 2013;14(2):3671-3682. 
176. Claridge TDW. High-resolution NMR techniques in organic chemistry. 1st ed. 
Amsterdam ; New York: Pergamon; 1999. 
177. Jacobsen NE. NMR spectroscopy explained : simplified theory, applications and 
examples for organic chemistry and structural biology. Hoboken, N.J.: Wiley ; 
Chichester : John Wiley [distributor]; 2007. 
178. NMR Consumables, Small Volume and External Referencing. wwwwilmad-labglasscom. 
[Accessed on 15-10-2014]. 
179. Telford R. The physical chemistry of pMDI formulations derived from 
hydrofluoroalkane propellants. University of Bradford, thesis. 2013. 
180. Thalen A. Epimers of budesonide and related corticosteroids. III. Synthesis and 
structure elucidation by carbon-13 and proton nuclear magnetic resonance 
spectroscopy. Acta pharmaceutica Suecica. 1987;24(3):97-114. 
 218 
 
181. Jing Z, Xuan Z, Xian J, ling X, Song Y. NMR studies on the two epimers of budesonide 
[Chinese paper]. Journal of Shenyang Pharmaceutical University. 2009;26(1):30-35. 
182. Raval MK, Ramani RV, Sheth NR. Formulation and evaluation of sustained release 
enteric-coated pellets of budesonide for intestinal delivery. International journal of 
pharmaceutical investigation. 2013;3(4):203-211. 
183. Gangurde HH, Chordiya MA, Tamizharasi S, Sivakumar T. Optimization of budesonide 
pH dependent coated pellets for potential colon targeted drug delivery. Insight 
Pharmaceutical Sciences. 2013;3(1):1-13. 
184. Roik NV, Belyakova LA. IR spectroscopy, X-ray diffraction and thermal analysis studies 
of solid “β-cyclodextrin - para-aminobenzoic acid ” inclusion complex. Physics  and 
Chemistry of Solid State. 2011;12(1):168-173. 
185. Rabadiya B, Thakkar V, Rabadiya P. Drug-excipients interaction and solubiliy 
enhancement study of simvastatin. IJPRBS. 2013;2(1):168-185. 
186. Ali HR, Edwards HG, Kendrick J, Munshi T, Scowen IJ. An experimental and 
computational study on the epimeric contribution to the infrared spectrum of 
budesonide. Drug testing and analysis. 2010;2(9):447-451. 
187. Viernstein H, Weiss-Greiler P, Wolschann P. Solubility enhancement of low soluble 
biologically active compounds--temperature and cosolvent dependent inclusion 
complexation. Int J Pharm. 2003;256(1-2):85-94. 
188. Rungnim C, Phunpee S, Kunaseth M, et al. Co-solvation effect on the binding mode of 
the α-mangostin/β-cyclodextrin inclusion complex. Beilstein journal of organic 
chemistry. 2015;11(1):2306-2317. 
189. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin 
Drug Deliv. 2005;2(2):335-351. 
190. Doliwa A, Santoyo S, Ygartua P. Influence of piroxicam: hydroxypropyl-beta-
cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam. 
Skin Pharmacol Appl Skin Physiol. 2001;14(2):97-107. 
191. Boonyarattanakalin KS, Wolschann P, Lawtrakul L. Molecular dynamics of β-CD in 
water/co-solvent mixtures. Journal of Inclusion Phenomena and Macrocyclic 
Chemistry. 2011;70(3):279-290. 
192. Boonyarattanakalin K, Viernstein H, Wolschann P, Lawtrakul L. Influence of Ethanol as 
a Co-Solvent in Cyclodextrin Inclusion Complexation: A Molecular Dynamics Study. Sci 
Pharm. 2015;83(2):387-399. 
193. Okubo T, Kitano H, Ise N. Conductometric studies on association of cyclodextrin with 
colloidal electrolytes. The Journal of Physical Chemistry. 1976;80(24):2661-2664. 
194. Martin JV, Turmine M, Letellier P, Hemery P. Study of β-
cyclodextrin/dodecyltrimethylammonium bromide complex into water-isopropanol 
mixtures. Electrochimica Acta. 1995;40(17):2749-2753. 
195. Smithrud DB, Diederich F. Strength of molecular complexation of apolar solutes in 
water and in organic solvents is predictable by linear free energy relationships: a 
general model for solvation effects on apolar binding. Journal of the American 
Chemical Society. 1990;112(1):339-343. 
196. Nakai Y, Yamamoto K, Terada K, Horibe H. Interaction of Tri-O-methyl-[beta]-
cyclodextrin with Drugs. I. Effect of Tri-O-methyl-[beta]-cyclodextrin on the Partition 
Coefficients of Drugs. Chemical & Pharmaceutical Bulletin. 1982;30(5):1796. 
197. Mizutani T, Wada K, Kitagawa S. Molecular recognition of amines and amino esters by 
zinc porphyrin receptors: binding mechanisms and solvent effects. The Journal of 
organic chemistry. 2000;65(19):6097-6106. 
198. Maitra U, Rao P, Vijay KP, Balasubramanian R, Mathew L. Solvent effect in molecular 
recognition: Determining binding constants in different solvents following an 
extraction based protocol. Tetrahedron Letters. 1998;39(20):3255-3258. 
 219 
 
199. Pai N, Patil SS. Development and validation of RP-HPLC method for estimation of 
formoterol fumarate and budesonide in pressurised meter dose inhaler form. Der 
Pharmacia Sinica. 2013;4(4):15-25. 
200. Veiga FJB, Fernandes CM, Carvalho RA, Geraldes CFGC. Molecular Modelling and 1H-
NMR: Ultimate Tools for the Investigation of Tolbutamide: .BETA.-Cyclodextrin and 
Tolbutamide: Hydroxypropyl-.BETA.-Cyclodextrin Complexes. Chemical and 
Pharmaceutical Bulletin. 2001;49(10):1251-1256. 
201. Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJB. Multicomponent complex formation 
between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers 
monitored by NMR and solubility studies. European Journal of Pharmaceutical 
Sciences. 2005;24(1):1-13. 
202. Larsen KL, Aachmann FL, Wimmer R, Stella VJ, Kjolner UM. Phase solubility and 
structure of the inclusion complexes of prednisolone and 6 alpha-methyl prednisolone 
with various cyclodextrins. Journal of pharmaceutical sciences. 2005;94(3):507-515. 
203. Uekama K, Sakai A, Arimori K, Otagiri M, Saito H. Different mode of prednisolone 
within alpha-, beta-, and gamma-cyclodextrins in aqueous solution and in solid state. 
Pharm Acta Helv. 1985;60(4):117-121. 
204. Charumanee S, Okonogi S, Sirithunyalug J, Wolschann P, Viernstein H. Effect of 
Cyclodextrin Types and Co-Solvent on Solubility of a Poorly Water Soluble Drug. Sci 
Pharm. 2016;84(4):694-704. 
205. Green AR, Guillory JK. Heptakis(2,6-di-O-methyl)-β-cyclodextrin Complexation with the 
Antitumor Agent Chlorambucil. Journal of Pharmaceutical Sciences. 1989;78(5):427-
431. 
206. Cruickshank DL, Rougier NM, Vico RV, et al. Inclusion of the insecticide fenitrothion in 
dimethylated-β-cyclodextrin: unusual guest disorder in the solid state and efficient 
retardation of the hydrolysis rate of the complexed guest in alkaline solution. Beilstein 
journal of organic chemistry. 2013;9(1):106-117. 
207. Wenz G. Influence of intramolecular hydrogen bonds on the binding potential of 
methylated beta-cyclodextrin derivatives. Beilstein J Org Chem. 2012;8:1890-1895. 
208. Iijima T, Karube Y. The interaction of acid azo dyes with chemically modified β-
cyclodextrins. Elsevier Science Ltd. 1998;36(4):305-311. 
209. Bardelang D, Rockenbauer A, Jicsinszky L, et al. Nitroxide bound beta-cyclodextrin: is 
there an inclusion complex? The Journal of organic chemistry. 2006;71(20):7657-7667. 
210. Iijima T, Karube Y. The interaction of acid azo dyes with chemically modified β-
cyclodextrins. Dyes and Pigments. 1998;36(4):305-311. 
211. Letort S, Balieu S, Erb W, Gouhier G, Estour F. Interactions of cyclodextrins and their 
derivatives with toxic organophosphorus compounds. Beilstein journal of organic 
chemistry. 2016;12(1):204-228. 
212. Miranda JC, Martins TE, Veiga F, Ferraz HG. Cyclodextrins and ternary complexes: 
technology to improve solubility of poorly soluble drugs. Brazilian Journal of 
Pharmaceutical Sciences. 2011;47(4):665-681. 
213. Ventura CA, Giannone I, Paolino D, Pistarà V, Corsaro A, Puglisi G. Preparation of 
celecoxib-dimethyl-β-cyclodextrin inclusion complex: characterization and in vitro 
permeation study. European Journal of Medicinal Chemistry. 2005;40(7):624-631. 
214. Djedaïni F, Lin SZ, Perly B, Wouessidjewe D. High-Field Nuclear Magnetic Resonance 
Techniques for the Investigation of a β-Cyclodextrin:Indomethacin Inclusion Complex. 
Journal of Pharmaceutical Sciences. 1990;79(7):643-646. 
215. Mic M, Prnu A, Bogdan M, Turcu I. Inclusion complex of benzocaine and -cyclodextrin: 
1 H NMR and isothermal titration calorimetry studies. Paper presented at: Processes in 
Isotopes and Molecules2013. 
216. Pinto LM, Fraceto LF, Santana MH, Pertinhez TA, Junior SO, de Paula E. Physico-
chemical characterization of benzocaine-beta-cyclodextrin inclusion complexes. 
Journal of pharmaceutical and biomedical analysis. 2005;39(5):956-963. 
 220 
 
217. Foe K, Cheung HT, Tattam BN, Brown KF, Seale JP. Degradation products of 
beclomethasone dipropionate in human plasma. Drug Metab Dispos. 1998;26(2):132-
137. 
218. Sahasranaman S, Issar M, Toth G, Horvath G, Hochhaus G. Characterization of 
degradation products of mometasone furoate. Pharmazie. 2004;59(5):367-373. 
219. Bardsley B, Smith MS, Gibbon BH. Structure elucidation and spectroscopic analysis of 
photodegradants of the anti-rhinitis drug fluticasone furoate. Org Biomol Chem. 
2010;8(8):1876-1880. 
220. Zoppi A, Delrivo A, Aiassa V, Longhi MR. Binding of sulfamethazine to beta-cyclodextrin 
and methyl-beta-cyclodextrin. AAPS PharmSciTech. 2013;14(2):727-735. 
221. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochemistry. 
2004;39(9):1033-1046. 
222. Puentes CM, Wenzel TJ. Phosphated cyclodextrins as water-soluble chiral NMR 
solvating agents for cationic compounds. Beilstein Journal of Organic Chemistry. 
2017;13(1):43-53. 
223. Provencher KA, Weber MA, Randall LA, Cunningham PR, Dignam CF, Wenzel TJ. 
Carboxymethylated cyclodextrins and their complexes with Pr(III) and Yb(III) as water-
soluble chiral NMR solvating agents for cationic compounds. Chirality. 2010;22(3):336-
NA. 
224. Aussenegg F, Ditlbacher H. Plasmonen als Lichttransporter: Nanooptik. Physik in 
unserer Zeit. 2006;37(5):220-226. 
225. Kelly KL, Coronado E, Zhao LL, Schatz GC. The Optical Properties of Metal 
Nanoparticles:  The Influence of Size, Shape, and Dielectric Environment. The Journal 
of Physical Chemistry B. 2003;107(3):668-677. 
226. Mishra A, Tripathy P, Ram S, Fecht HJ. Optical properties in nanofluids of gold 
nanoparticles in poly(vinylpyrrolidone). J Nanosci Nanotechnol. 2009;9(7):4342-4347. 
227. Ahmad MB, Tay MY, Shameli K, Hussein MZ, Lim JJ. Green synthesis and 
characterization of silver/chitosan/polyethylene glycol nanocomposites without any 
reducing agent. International journal of molecular sciences. 2011;12(8):4872-4884. 
228. Bac LH, Kim JS, Kim JC. Size, optical and stability properties of gold nanoparticles 
synthesized by electrical explosion of wire in different aqueous media. Reviews on 
advanced materials science. 2011;28(2):117-121. 
229. Kaszuba M, McKnight D, Connah MT, McNeil-Watson FK, Nobbmann U. Measuring sub 
nanometre sizes using dynamic light scattering. Journal of Nanoparticle Research. 
2008;10(5):823-829. 
230. Khlebtsov BN, Khlebtsov NG. On the measurement of gold nanoparticle sizes by the 
dynamic light scattering method. Colloid Journal. 2011;73(1):118-127. 
231. Andrade PF, de Faria AF, da Silva DS, Bonacin JA, Goncalves Mdo C. Structural and 
morphological investigations of beta-cyclodextrin-coated silver nanoparticles. Colloids 
Surf B Biointerfaces. 2014;118:289-297. 
232. Ali HRH, Edwards HGM, Kendrick J, Munshi T, Scowen IJ. Vibrational spectroscopic 
study of budesonide. Journal of Raman Spectroscopy. 2007;38(7):903-908. 
233. Ali HR, Edwards HG, Kendrick J, Scowen IJ. Vibrational spectroscopic study of 
fluticasone propionate. Spectrochim Acta A Mol Biomol Spectrosc. 2009;72(2):244-247. 
234. Infrared and Raman Characteristic Group Frequencies:  Tables and Charts. 3rd ed By 
George Socrates (The University of West London, Middlesex, U.K.). J. Wiley and Sons:  
Chichester. 2001. xviii + 348 pp. $185.00. ISBN:  0-471-85298-8. Journal of the 
American Chemical Society. 2002;124(8):1830-1830. 
235. Kim T, Assary RS, Curtiss LA, Marshall CL, Stair PC. Vibrational properties of levulinic 
acid and furan derivatives: Raman spectroscopy and theoretical calculations. Journal of 
Raman Spectroscopy. 2011;42(12):2069-2076. 
236. Egyed O. Spectroscopic studies on β-cyclodextrin. Vibrational Spectroscopy. 
1990;1(2):225-227. 
 221 
 
237. Hill W, Fallourd V, Klockow D. Investigation of the Adsorption of Gaseous Aromatic 
Compounds at Surfaces Coated with Heptakis(6-thio-6-deoxy)-β-cyclodextrin by 
Surface-Enhanced Raman Scattering. The Journal of Physical Chemistry B. 
1999;103(22):4707-4713. 
238. Gimenez IF, Anazetti MC, Melo PS, et al. Cytotoxicity on V79 and HL60 cell lines by 
Thiolated-beta-Cyclodextrin-Au/Violacein Nanoparticles. J Biomed Nanotech. 
2005;1(3):1-7. 
239. Bryant MA, Pemberton JE. Surface Raman scattering of self-assembled monolayers 
formed from 1-alkanethiols at silver [electrodes]. Journal of the American Chemical 
Society. 1991;113(10):3629-3637. 
240. Joo TH, Kim MS, Kim K. Surface‐enhanced Raman scattering of benzenethiol in silver 
sol. Journal of Raman Spectroscopy. 1987;18(1):57-60. 
241. Varnholt B, Oulevey P, Luber S, Kumara C, Dass A, Bürgi T. Structural Information on 
the Au–S Interface of Thiolate-Protected Gold Clusters: A Raman Spectroscopy Study. 
The Journal of Physical Chemistry C. 2014;118(18):9604-9611. 
242. Willets KA. Super-resolution imaging of SERS hot spots. Chemical Society reviews. 
2014;43(11):3854-3864. 
243. Xie Y, Wang X, Han X, et al. Selective SERS detection of each polycyclic aromatic 
hydrocarbon (PAH) in a mixture of five kinds of PAHs. Journal of Raman Spectroscopy. 
2011;42(5):945-950. 
244. Lee K-S, El-Sayed MA. Gold and silver nanoparticles in sensing and imaging: Sensitivity 
of plasmon response to size, shape, and metal composition. Journal of Physical 
Chemistry B. 2006;110(39):19220-19225. 
 
 
 
 
  
 222 
 
Appendix A1 
 
a) The average number of Ag or Au atoms per nanoparticles may be calculated 
based on the determination of the average core diameters of the particles (D, 
nm) using TEM analysis. Assuming a spherical and a uniform fcc (face 
centered, cubic) shape of the nanoparticle, the average number of Ag or Au 
atoms (N) per nanoparticle be calculated by the following equation: 
N= 
πρD
3
6M
NA 
Where N is the average number of Ag or Au atoms per nanoparticle, ρ is the 
density of fcc of Ag (10.5 g/cm3) or Au (19.3 g/cm3), D is the average diameter 
of the nanoparticles, M is the atomic mass of Ag (107.86 g) or Au (196.96 g), NA 
is the Avogadro’s number (the number of atoms per mole = 6.023 × 1023 
atoms/gram-mole). 
As the π, NA, ρ and M are constant; therefore the equation is calculated to be  
N = 30.88 D3 for Au, N = 30.68 D3 for Ag. 
The number of the Ag or Au atoms per nanoparticles can be calculated by 
another method, assuming a spherical shape of the Ag/Au NPs and considering 
the volume ratio of Ag/Au atoms to the Ag/Au-NPs is 74.1% with the cubic 
structure. For Ag atom, the radius of the atom is 0.144 nm and its volume can 
be calculated by the following equation 
𝑉 =  
4
3 
𝜋𝑟3 
Where the r is the radius of the Ag atom and therefore its volume is 0.0125 nm3. 
The volume of Ag NPs with diameter (D) in nm is  
π
6
D
3 . Thus, the number of the 
Ag atoms in one nanoparticle is  
74.1
100
×
π
6
D
3
×
1
0.0125
 , which is can be calculated to 
be 31 D3 
b) The molar concentration of the Ag or Au-NPs is calculated by dividing the 
total number of the Ag or Au atoms (which is equal to the initial amount of the 
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silver or gold salt used in the first reaction) over the average number of the Ag 
or Au atoms per nanoparticle according to the following equation 
C= 
NTotal
NVNA
 
Where NTotal is the total number of Ag or Au atoms added in the first reaction, N 
is the average number of Ag or Au atoms per nanoparticle, V is the volume of 
the reaction solution in litre and NA is the Avogadro’s number. 
c) The concentration of the Ag-NPs is calculated by using the N = 30.68 D3 for 
the calculation of the average number of Ag atoms per nanoparticle and the D 
was found to be 21 nm from the TEM analysis. Therefore N was equal to 2.84 x 
105 nm3.  
The molarity of the Ag salt in the first reaction was 1 mM (0.001 M) and its 
volume was 10 mL (0.01 L) whereas the total volume of the reaction solution 
was 40 mL (0.04 L). Therefore, the concentration of the Ag-NPs was: 
 
C= 
NTotal
NVNA
 
C = 
0.001 ×0.01 ×6.023 ×10
23
2.84 x 105 ×0.04 ×6.023 × 1023
 = 8.8 × 10-10M = 0.88 nM 
The initial Ag concentration in ppm is: 
8.8 × 10-10 × 1000 ×  2.84 x 105  × 107.86 = 26.97 ppm 
d) The final Ag concentration in the uncentrifuged and centrifuged Ag-NPs 
solutions were 10.61 and 8.68 ppm respectively and because they had been 
diluted to half by nitric acid, then the concentration would be 21.22 and 17.36 
ppm respectively. As the initial Ag concentration was 26.97 ppm, then, the 
percentage of the synthesised Ag NPs was 78.7 and 64 % for uncentrifuged 
and centrifuged Ag-NPs solutions respectively. 
e) The seed Au-NPs concentration is calculated by using the N = 30.88 D3 for 
the calculation of the average number of Au atoms per nanoparticle and the D 
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was found to be 18 nm from the TEM analysis. Therefore N was equal to 1.80 x 
105 nm3.  
The molarity of the Gold(III) chloride trihydrate (HAuCl4) used in the first 
reaction to prepare the seed particles was 1 mM (0.001 M) and its volume was 
50 mL (0.05 L) whereas the total volume of the reaction solution was 55 mL 
(0.055 L). Therefore, the concentration of the seed Au NPs was: 
C = 
0.001 ×0.05 ×6.023 ×10
23
1.80 x 105  ×0.055 ×6.023 × 1023 
 = 5.05 × 10-9 M = 5 nM 
f) The final Au NPs concentration is calculated by using the N = 30.88 D3 for 
the calculation of the average number of Au atoms per nanoparticle and the D 
was found to be 36 nm from the TEM analysis. Therefore N was equal to 
14.40 x 105  nm3.  
The molarity of the HAuCl4 used in the second reaction to prepare the large 
particles was 11 mM (11 × 10-3 M) and its volume was 0.5 mL (5 × 10-4 L). Also, 
the seed particles was added to this reaction with a concentration 5.05 × 10
-9
M  
(previously determined) and at volume of 0.3 mL (3 × 10-4 L) and the total 
volume of the reaction solution was 32.97 mL (32.97 × 10-3 L). Therefore, the 
concentration of the large Au NPs was: 
C = 
[(5.05 × 10-9× 3 × 10-4 ×180 x 10
3
 ) +(11 × 10-3× 5 × 10-4)] ×6.023 ×1023
14.40 x 105× 32.97 × 10-3 × 6.023 × 1023
   
= 1.2 × 10-10 M 
 
The initial Au concentration in ppm is:  
1.2 × 10-10 × 1000 ×  14.40 x 105  × 196.96 = 34.47 ppm 
g) The final Au concentration in the uncentrifuged and centrifuged Au-NPs 
solutions were 29.55 and 26.90 ppm respectively. As the initial Au concentration 
was calculated and found to be 34.47 ppm, the percentage of the synthesised 
Au-NPs was 85.7 and 78 % for uncentrifuged and centrifuged Au-NPs solutions 
respectively. 
